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ABSTRACT 
African trypanosomosis is a parasitic disease in man and animals caused by protozoan 
parasites of the genus Trypanosoma. T. congolense, T. vivax and T. brucei brucei cause 
nagana in cattle. The variable nature of the parasite surface coat has hindered the 
development of an effective vaccine. An option for developing vaccines and 
chemotherapeutic agents against trypanosomosis is to target pathogenic factors released by 
the parasite during infection, namely an “anti-disease” approach. Two pathogenic factors 
released during infection are oligopeptidase B (OPB) and TcoCATL (congopain). TcoCATL, a 
major lysosomal cysteine peptidase, is a member of the papain family C1 cysteine 
peptidases. RNA interference (RNAi) was used to down-regulate the expression of TcoCATL 
in T. congolense IL3000 TRUM183:29-13 parasites in vivo during mouse infections. TcoCATL 
RNAi was monitored in infected mouse blood by comparing the hydrolysis of Z-Phe-Arg-AMC 
and parasitaemia between mice in which RNAi was induced and control mice. Mice infected 
with parasites induced for TcoCATL RNAi had lower parasitaemia when compared to control 
mice. An attempt was also made at deleting the entire CATL gene array in both T. 
congolense IL3000 and T. brucei 427 Lister strains. The second pathogenic factor studied, 
OPB, is a cytosolic trypanosomal peptidase that hydrolyses peptides smaller than 30 amino 
acid residues, C-terminal to basic residues. In order to evaluate the role that OPB play during 
disease, RNAi was also applied to knock-down the expression levels of OPB in T. brucei T7T 
and T. congolense IL3000 TRUM183:29-13 strains (TbOPB and TcoOPB respectively). 
Oligopeptidase B null mutant strains (∆opb) were also generated in T. brucei brucei Lister 
427. An attempt was also made to generate OPB null mutants in T. congolense IL3000 
parasites. Western blot analysis of the knock-down experiments using chicken anti-TcoOPB 
peptide IgY showed that only TbOPB levels were reduced in T. brucei T7T parasites induced 
for RNAi when compared to TcoOPB RNAi induced cultures. Quantitative assessment of a 
fourteen day induction experiment for OPB RNAi in T. brucei showed an 87% reduction in 
TbOPB levels when compared to levels on day one. There was no growth effect observed in 
T. brucei parasites cultured in vitro and induced for TbOPB RNAi. It was concluded that 
TbOPB is not necessary for the in vitro survival of T. brucei parasites, thus making the 
generation of OPB null mutants possible. ∆opb T. brucei parasites were successfully 
generated and grew normally in vitro and were as virulent as wild type strains during infection 
in mice. Immunohistopatholgy of infected mouse testes revealed ∆opb parasites in extra 
vascular regions showing that T. brucei OPB (TbOPB) is not involved in assisting T. brucei 
parasites to cross microvascular endothelial cells. Gelatin gel analysis of ∆opb null mutants 
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and wild type strains showed an increase in cysteine peptidase activity. Enzymatic activity 
assays were carried out to identify how closely related oligopeptidases are affected by 
knocking out TbOPB, and a significant increase of T. brucei prolyl oligopeptidase (TbPOP) 
activity was observed. However, western blot analysis did not show any increase of TbPOP 
protein levels in ∆opb parasites, suggesting that either TbOPB is responsible for generating 
an endogenous inhibitor for TbPOP or that another POP-like enzyme might compensate for a 
loss in OPB activity in ∆opb null mutants. This study made a significant contribution to an 
understanding of the interplay between different trypanosomal peptidases that are important 
pathogenic factors in trypanosomosis. It highlights the need to simultaneously target several 
trypanosomal peptidases to develop an effective vaccine or chemotherapeutic agents for 
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CHAPTER 1  
INTRODUCTION 
1.1 GENERAL OVERVIEW 
African trypanosomosis is a parasitic disease in man and animals caused by protozoan 
parasites of the genus Trypanosoma. On the African continent, these parasites are mainly 
transmitted by the tsetse fly (Glossina spp.). This disease presents a major obstacle to 
development in sub-Saharan Africa and is responsible for the loss of human life, depletion of 
livestock and underutilisation of arable land (Swallow, 2000; McDermott and Coleman, 2001; 
Antoine-Moussiaux et al., 2009). The disease occurs as far south as the northern part of 
KwaZulu-Natal (Kappmeier et al., 1998), and recent studies identifying infections in cattle 
makes a study of the disease particularly relevant in the local context (Mamabolo et al., 
2009). In cattle, the disease is mainly caused by T. congolense and T. vivax, while T. b. 
brucei is less pathogenic. Various approaches have been used to manage the spread of the 
disease in livestock, mainly through vector control (Brown, 2008) and chemotherapy 
(Delespaux and de Koning, 2007), with various degrees of success and at a very high 
financial cost. Vaccine development presents an attractive alternative for the control of this 
disease in cattle. Initial vaccine targets included surface antigens of the parasite (Taylor and 
Mertens, 1999). However, the life cycle of African trypanosomes is exclusively extracellular 
and parasites survive mammalian host immune responses by constantly changing their 
surface antigens through a mechanism known as antigenic variation (Taylor and Rudenko, 
2006), thereby hindering the development of vaccine formulations (Magez and Radwanska, 
2009). More recently, an “anti-disease” vaccine approach has been pursued targeting the 
invariant disease-causing factors released by the parasite rather than the infecting parasite 
itself (Schofield et al., 1993; Authié et al., 2001; Schofield, 2007). Particularly relevant are 
trypanosome proteolytic enzymes such as proteinases and peptidases e.g. congopain or 
TcoCATL (Authié et al., 1992) and oligopeptidase B or OPB (Coetzer et al., 2008). These 
peptidases provide a more attractive target than surface antigens as they are invariant. In 
addition, they can also be chemotherapeutic targets and pave the way for the development of 
new drugs.  
 
The inclusion of pathogenic factors in an effective sub-unit vaccine or as drug targets requires 
studies that elucidate their function in parasite physiology and the role that they may play 
during infection. Reverse genetics is the tool of choice for this type of study. Reverse genetics 
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is a technology that enables researchers to study the function of a gene by either down-
regulating its messenger RNA (Ullu et al., 2002), or by deleting it completely from the genome 
of the organism under study (Xu et al., 2009). The elimination of mRNA can be achieved by 
inducible RNA interference (RNAi), whereas the deletion of a gene is effected by gene knock-
down experiments. RNAi has been used as a tool in a variety of organisms including 
trypanosomes (Ullu et al., 2004). The RNAi phenomenon exists naturally in several 
eukaryotes and plays a role in defence against viral infections and in the regulation of gene 
expression. It is defined as the mechanism through which gene-specific, double stranded 
RNA (dsRNA) triggers the degradation of homologous transcripts (Fire et al., 1998). This 
process is mediated by a natural biological system that transforms the dsRNA into shorter 
versions called small interfering RNAs (siRNA) (Shi et al., 2006a). The siRNAs then drive 
gene silencing by sequence specific messenger RNA (mRNA) degradation thereby leading to 
a reduction in protein synthesis from the targeted gene. Gene knock-out experiments involve 
the complete deletion of a gene from an organism by homologous recombination events (Xu 
et al., 2009). This involves constructing DNA vectors that carry sequences homologous to the 
regions flanking the gene to be studied that will excise the gene from the genome of the 
organism by replacing it with a drug resistance gene. This then allows for selection of clones 
that do not carry the gene of interest any longer by their ability to grow in media containing 
the drug (Ommen et al., 2009).  
 
This study used RNAi and gene deletion to investigate the function of two trypanosome 
peptidases with documented pathogenic effects during infection, namely TcoCATL and OPB. 
Inducible gene silencing using RNAi and the deletion of genes allows access to two types of 
information. Firstly, whether the targeted genes are necessary for the survival of the 
parasites, and if the gene product can therefore be targeted for chemotherapy and secondly, 
whether the targeted genes are indeed important pathogenic factors, by in vivo infection 
studies comparing the effect of gene knock-out clones versus wild type parasites. 
 
1.2 TRYPANOSOMES AND TRYPANOSOMOSIS 
African trypanosomosis is a mammalian parasitic disease caused by protozoans of the genus 
Trypanosoma, which are transmitted by the tsetse fly (Glossina spp.). On the African 
continent, tsetse flies are distributed over a land mass area of approximately 10 million km2 
and present a major obstacle to human and livestock development, and the utilisation of 
 2
 3
arable land (Kuzoe, 1993). There are several species of trypanosomes that affect both 
humans and animals. In humans, the most important is T. brucei which has two sub species 
that are the main cause of sleeping sickness i.e. T. brucei rhodesiense and T. brucei 
gambiense (El-Sayed et al., 2000). African trypanosomes implicated in cattle disease are T. 
congolense and T. vivax and to a lesser extent T. b. brucei. Trypanosomosis in cattle is also 
referred to as nagana (Taylor, 1998). There are about 172 million head of cattle kept in the 37 
countries in sub-Saharan Africa that have tsetse infestation, covering an area of 
approximately 8.7 million km2 (Swallow, 2000). Annual losses due to the disease are 
estimated to be around 1.3 to 5 billion US$ (Kristjanson et al., 1999; McDermott and 
Coleman, 2001). In South Africa, trypanosomosis in cattle was identified in the late 1800s 
(Taylor, 1998; Brown, 2008). In 1894 while working in Zululand, Sir David Bruce 
demonstrated the transmission of a protozoan parasite which was later named T. b. brucei, 
by tsetse flies in cattle. He was also able to show that wild herbivores were asymptomatic 
following trypanosome infections and were likely reservoirs for the disease in livestock 
(Brown, 2008). Reports of trypanosome infections in South African cattle have been as recent 
as 2009 in Northern parts of KwaZulu-Natal close to the Hluhluwe-Umfolozi game reserve 
(Mamabolo et al., 2009). The cattle were found to be infected with T. congolense and T. 
vivax. 
 
1.2.1 Classification of Trypanosomes 
The genus Trypanosoma falls under the class Zoomastigophora where members of the class 
are classified by the number of flagellar they possess (Vickerman, 1982; Vickerman, 2000).  
Members of the order Kinetoplastida possess one or two flagellar with trypanosomes well 
represented due to their economic importance. Leishmania and Trypanosoma are the two 
economically most important genera in this order. Members of the genus Trypanosoma are 
divided into two sections, stercoraria and salivaria, depending on the position of their infective 
forms in the vector host gut during development. Members of the section stercoraria e.g. T. 
cruzi, develop into metacyclics at the posterior end of the digestive tract of the vector. By 
contrast, members of section salivaria e.g. T. brucei, develop at the anterior end and are 
transmitted to the mammalian host via saliva. Fig.1.1 gives a comprehensive classification of 
the Trypanosoma genus.  
 
Figure 1.1 Classification of trypanosomes. [Adapted from Vickerman (2000)]
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1.2.2 Biology and life cycle of trypanosomes 
Trypanosomes infect many different hosts (Table 1.1) and use a variety of vectors to transmit 
the disease between the primary hosts. For example, T. brucei is transmitted between 
mammalian hosts through a tsetse fly vector. In contrast, T. equiperdum is sexually 
transmitted between horses and spends no life cycle stage in insects. T. rangeli and T. cruzi 
are transmitted between hosts through triatomine vectors such as the bed bug. 
Trypanosomes are mononuclear and possess a large mitochondrion that contains a 
kinetoplast (Fig.1.2). The kinetoplast contains both maxicircles and minicircles of DNA, where 
mRNA transcribed in the maxi-circles is modified by guide-RNA from the minicircles (Ryan 
and Englund, 1989).  This is thought to regulate gene expression and play a role in 
mitochondrial metabolism at different stages in the life cycle of a trypanosome (Simpson, 
1987). Trypanosomes have a single flagellum that arises at the posterior end from the basal 
body in the floor of the flagellar pocket, with an extending paraxial rod (Noble and Noble, 
1982). Flagellar functions involve motility, attachment to host surfaces, and a role in 
morphogenesis and cell division (Kohl and Bastin, 2005). The flagellum emerges from the 
flagellar pocket, which is an important component involved in immune evasion by the 
internalisation of VSG-antibody complexes through the action of phospholipase-C (Field et 
al., 2009). The flagellar pocket is also the principal site at which host macromolecules are 
internalised.     
 
The entire life cycle of African trypanosomes is extracellular (Fig.1.3). In T. brucei, metacyclic 
trypomastigotes are introduced to the mammalian host by the tsetse fly while taking a blood 
meal where they rapidly transform into antigenically variable bloodstream forms and divide by 
binary fission causing a build-up of metabolic and cell waste that forms a chancre at the site 
of the bite (Baral, 2010). From the chancre, bloodstream trypomastigotes enter the lymphatic 
system and pass into the bloodstream where they are carried to other sites throughout the 
body, reaching other blood fluids (e.g. lymph and spinal fluid). Bloodstream parasites 
continue to replicate transforming from long slender forms to intermediate and eventually into 
non-dividing short stumpy forms that are once again taken up by the tsetse fly during a 
bloodmeal on an infected host (Vickerman, 1985). In the fly's midgut, the parasites transform 
into procyclic trypomastigotes. Fourteen to 21 days later, the procyclic forms migrate into the 
proventricular region of the gut and multiply asexually into epimastigotes. The epimastigotes 
then reach the fly's salivary glands where they continue dividing into metacyclics, ready to 
infect another host. The whole cycle in the fly takes approximately three weeks to progress 
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(Noble and Noble, 1982). In T. congolense, metacyclic forms develop in the mouth parts as 
opposed to the salivary glands in T. brucei, whereas in T. vivax, the entire insect stage occurs 
exclusively in the mouth parts from epimastigotes to metacyclics (Fig.1.3). 
 
Table 1.1: Different trypanosome species and their corresponding hosts and diseases 
 Trypanosoma species Host and disease where named 
T. avium Birdsa 
T. boissoni Elasmobranchs e.g. sharks and raysb 
T. brucei Sleeping sickness in humans and nagana in 
cattlec 
T. carassii Freshwater fish (teleosts)d 
T. cruzi Chaga’s disease in humansc 
T. congolense Nagana in cattle, horses, and camelsc 
T.  equinum Horsese 
T. equiperdium Dourine or covering sickness in horsese 
T. evansi Surra in cattle, camels and horsesf 
T.  lewisi Ratsg 
T.  melophagium Sheeph 
T.  percae Fishi 
T. rangeli Human and cattlej  
T. rotatorium Amphibiansk 
T. simiae Nagana in pigs, cattle, horses, camels and 
warthogsl 
T. suis Surra in cattlef 
T. theileri Ruminantsi 
T. triglae Fishb 
T. vivax Nagana in cattlec 
aGutierrez (1989), bJirku et al. (1995), cBarrett et al. (2003), dOverath et al. (1998), eVickerman et al. 
(1993), fHoare (1972), gSturtevant and Balber (1983), hBüscher and Friedhoff (1984), iGibson et al. 
(2005), jGrisard (2002), kHysek and Zizka (1976), iVan Den Berghe and Zaghi (1963)
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Figure 1.2 General structure of T. congolense. (Noble and Noble, 1982) 
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Figure 1.3 Life cycles of T. b. brucei, T. congolense and T. vivax. Parasites in mammalian 
bloodstream and tissues possess surface coats consisting of variable glycoprotein antigens, whereas 
those in insect stages have procyclin on the surface and are non-infective to mammals until the 
metacyclic stage found in the mouth parts of insects which are infective to mammals. T. b. brucei 
develops in the tsetse midgut, proventriculus and salivary glands, where metacyclic forms occur. T. 
congolense develops in the tsetse midgut, proventriculus and mouth parts, where metacyclic forms are 
produced. T. vivax develops only in the tsetse mouthparts. (http://www.ilri.org accessed on 15-02-
2010). 
 8
1.2.3 Antigenic variation in trypanosomes. 
During the bloodstream stage of the trypanosome life cycle, the parasite is covered with a 
monolayer of approximately 107 copies of a 60 kDa glycosyl-phosphatidyl inositol (GPI) 
anchored glycoprotein termed the variant surface glycoprotein (VSG) (Pays, 2006). VSG 
expression commences in the tsetse fly vector’s salivary glands, at the metacyclic stage. This 
process is initiated just as division of parasites comes to an end resulting in metacyclics with 
a heterogeneous variable antigen type  (VAT) referred to as metacyclic VAT (M-VAT) (Tetley 
et al., 1987). Once in the mammalian host, the trypanosomes continue to express M-VAT and 
rapidly change from one VAT to another. Bloodstream form VATs are then expressed with 
one major VAT for each different peak of parasitaemia during infection (Hajduk and 
Vickerman, 1981). Only one predominant VSG antigen type is expressed on the surface of 
most parasites at any given time during an infection. VSG is a major parasite product that 
induces a strong immune response in the host which kills off most of the infecting parasites 
but a small number survive this challenge due to the different VSG they acquire using a 
process known as VSG switching (Pays et al., 2004). This allows the parasites to escape 
antibody-mediated killing and multiply causing the next wave of parasitaemia and thus 
prolonging the infection. Antigenic variation is possible in infections initiated by a single 
trypanosome (Vickerman et al., 1993).  
 
The expression of different VSG types in a trypanosome population is controlled post-
transcriptionally after polycistronic RNA is transcribed from a pool of approximately 1500 VSG 
genes and pseudo-genes (Taylor and Rudenko, 2006). Most of these genes are silent and 
only become active when they are linked to specialised VSG expression sites (VSG-ES). 
Expression sites are associated with several genes that are also expressed on the parasite 
surface such as the transferrin receptor and the serum resistance-associated gene in T. b. 
rhodesiense (Pays, 2006). VSG switching is facilitated by either in situ switching which shifts 
VSG-ES from one VSG gene to another, or through the homologous recombination between 
different VSG genes and pseudo-genes (Taylor and Rudenko, 2006). Most of the invariable 
stable antigens found in trypanosomes are not located on the parasite surface and consist of 
structural proteins and enzymes that are found at all stages of the trypanosome life cycle. 
Although they are not exposed to the host immune system, they can be highly immunogenic 
and important in immunopathology of the infection (Vickerman et al., 1993) or for potential 
use in serodiagnosis. Examples include hsp-70 and TcoCATL (Authié et al., 1993a). The 
procyclic form of T. brucei bears a dominant glycoprotein surface antigen called procyclin 
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which is synthesised and transported to the trypanosome surface before the VSG is lost 
during transformation of bloodstream forms to procyclics (Richardson et al., 1988). 
 
1.2.4 Immune mechanisms against trypanosomes and immunopathology 
Mammalian immune reactions to trypanosome infection is mediated by both the low 
specificity pro-inflammatory innate response and the antigen specific adaptive immune 
response (Stijlemans et al., 2007a). A tsetse bite transferring infective metacyclics into the 
host causes the classical activation of macrophages by trypanosomal DNA and the GPI 
anchor of the VSG leading to the release of pro-inflammatory cytokines like TNF, IL-12 and 
nitric oxide around the bite region and the formation of a chancre (Stijlemans et al., 2007a; 
Baral, 2010). This results in an acute pro-inflammatory reaction by the host also known as a 
type I immune response which is responsible for the control of the first wave of parasitaemia. 
Because prolonged inflammation is pathological to the host, a type II anti-inflammatory 
immune response mediated by the production of type II cytokines such as IL-4, IL-10 and IL-
13 follows the initial innate response (Baral, 2010). These molecules down-regulate 
classically activated macrophages and modulate them to become alternatively activated 
macrophages which are anti-inflammatory. 
 
A strong proliferative response of B lymphocytes, first in the lymphoid system, and later in the 
central nervous system follows the initial chancre stage (Taylor, 1998). B-cell proliferation 
accounts for the destruction and clearance of parasites in successive waves of parasitaemia 
that follow the initial wave with high IgG and IgM titres observed that are involved in 
prolonging host survival during a chronic infection (Magez et al., 2008). Along with the 
increase in B cell numbers is an accompanying decline in T cell populations and subsequent 
depression of the host’s T cell-dependent responses (Taylor, 1998). Later during infection, as 
the disease becomes chronic, B lymphocytes become exhausted resulting in the absence of 
circulating IgG and reduced IgM levels leading to the suppression of host immune responses 
(Baral, 2010). Immunosuppression is responsible for the frequent incidence of concurrent 
viral, bacterial and parasitic infections found in trypanosome infected hosts (Askonas, 1985; 
Magez et al., 2010). In addition, memory B-cell activation is permanently lost during infection 
when host B-cell compartments are irreversibly destroyed leading to failures in vaccination 
programmes against trypanosomosis and other diseases (Radwanska et al., 2008; Magez et 
al., 2010).  
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A notable pathological effect of trypanosome infections is anaemia (Taylor and Authié, 2004). 
Extravascular erythrocyte destruction is as a result of phagocytosis by the phagocytic 
mononuclear system which targets red blood cells with trypanosome antigen-antibody 
complexes on their surfaces. Phagocytosis is also thought to be mediated by trypanosome 
enzymes (Taylor and Authié, 2004). Immune complex formation and the release of active 
amines, peptides and lipids (collectively known as ‘autocoids’), also play a major role in 
pathogenesis (Antoine-Moussiaux et al., 2009). These are produced during the repeated 
destruction of trypanosome populations by host antibody, and by the shedding of antigens 
from trypanosomes into antibody-laden surroundings. The activation of the complement 
system by immune complexes on the surface of various cell types leads to the lysis or 
opsonisation of these cells and in the case of red blood cells leads to severe anaemia 
(Taylor, 1998). Autoantibodies against a wide variety of host tissue and cells is thought to be 
responsible for tissue lesions in the host, and the vast variety of VSG epitopes cross-react 
with host components leading to further tissue damage (Vickerman et al., 1993).  
  
1.2.4.1 Trypanotolerance 
Trypanotolerance is the term used to describe animals that are resistant to the development 
of trypanosomosis after infection with trypanosomes (Murray et al., 1982). Features 
describing trypanotolerance are the ability to control parasite proliferation, limit pathogenic 
effects of parasitaemia and the control of anaemia (Murray et al., 2004). Trypanotolerance is 
common amongst game animals that in Africa act as reservoirs of the disease (Brown, 2008). 
Cape buffalo infected with trypanosomes develop lower levels of parasitaemia when 
compared to similarly-infected cattle with the action of xanthine oxidase and trypanosome 
specific IgG implicated in parasite control (Black et al., 2001). West and Central African 
breeds of domestic cattle such as the N’Dama longhorn and West African shorthorn are 
resistant to trypanosome infection when compared to other breeds such as Zebu and 
European cattle (Tabel et al., 2000). Resistant breeds of cattle are referred to as 
‘trypanotolerant, whereas breeds that succumb quickly to infection are referred to as 
‘trypanosusceptible’. Trypanotolerant cattle have lower parasitaemia and less anaemia than 
trypanosusceptible breeds (Murray et al., 1982). Furthermore, there are differences in the 
immune response between the two breeds where studies have shown that N’Dama cattle 
have a greater ability to control the initial wave of parasitaemia than Zebu cattle and have 
more IgM secreting B-cells, proliferating CD8+- and gamma-delta T-cells during a T. 
congolense infection (Taylor et al., 1996; Tabel et al., 2000). Studies have since shown that 
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the role of circulating IgM is limited in controlling successive waves of parasitaemia in a 
chronic infection and that trypanotolerance in cattle is associated with the secretion of IFNγ 
and TNF, the activation of macrophages and the production of nitric oxide; all hallmarks of an 
innate immune response during the initial phase of trypanosome infection (Magez et al., 
2008)   
 
 Experiments with bovine cross-breeds between resistant and susceptible cattle breeds 
showed that N’Dama and Boran cross-breeds were able to limit parasitaemia development 
(Naessens et al., 2003). These results suggest that trypanotolerance arises as a result of two 
mechanisms: one which is an innate process independent of genetic origin that helps control 
parasite levels in the host and the other dependent on genetic origin and helps reduce 
anaemia and the death of white blood cells (Naessens et al., 2003). Because trypanotolerant 
breeds of cattle have the ability to control parasitaemia and development of anaemia, their 
presence has been exploited in the humid and sub-humid zones of West and Central Africa. 
In areas of high trypanosome challenge, nearly all the cattle are of trypanotolerant breeds. 
Although smaller in size, trypanotolerant breeds are considered to be as productive as other 
breeds that are more susceptible to trypanosomes (Naessens, 2006).   
 
1.3 CONTROL OF TRYPANOSOMOSIS  
1.3.1 Chemotherapy 
With the lack of surveillance and adequate veterinary structures in areas affected by 
trypanosomosis, disease control has been at best sporadic and inefficient. In sub Saharan 
Africa, individual farmers mainly use chemotherapy to manage the disease in livestock 
(McDermott and Coleman, 2001; Delespaux and de Koning, 2007). The use of drugs has 
been difficult to estimate, with many generic brands been sold unofficially rather than by 
monitored official routes (Geerts et al., 2001). Three trypanocidal compounds have been 
used to treat veterinary trypanosomosis for over 50 years: diminazene aceturate, homidium 
and isometamidium. Isometamidium is synthesized by coupling homidium with a part of the 
diminazene molecule (Fig.1.4). Diminazene resistance is prevalent in areas where there is a 
high incidence of trypanosomosis and drug usage (Delespaux and de Koning, 2007). 
Resistance is associated with the P2 aminopurine transporter though other membrane 
transporter proteins are also implicated (Matovu et al., 2003). Cross resistance between 
homidium and isometamidium has been reported (Delespaux and de Koning, 2007) and 
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occurs when large populations of infected cattle are repeatedly treated with isometamidium. 
The development of newer drugs that do not result in resistance include modifications of 
diminazene that contains furan linkers and aromatic diamidines (Delespaux and de Koning, 
2007) and drugs that target unique glycosomal enzymes e.g. peroxins, not found in the 






Figure 1.4 Chemical structures of the three primary drugs used to treat African animal 
trypanosomosis. (Delespaux and de Koning, 2007). 
 
1.3.2 Vector control 
Early attempts targeting the tsetse fly vector used a combination of traps, bush clearance and 
arial spraying with dicholoro-diphenyl-trichloroethane (DDT) and benzene hexachloride (BHC) 
(Brown, 2008). This proved to be successful with the elimination of trypanosomosis in South 
Africa in 1953. Tsetse control using these methods is however not long-term as new cases of 
trypanosomosis have been identified in northern KwaZulu-Natal in the 1990s and as recently 
as 2009 (Kappmeier et al., 1998; Mamabolo et al., 2009). Methods for vector control such as 
aerial and ground spraying has been replaced by stationary odour-baited traps, pesticide 
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treated targets and cattle dip insecticides referred to as ‘pour-ons’ as a multifaceted approach 
to vector control (Brown, 2008).  
 
Another suggestion for vector control is ‘transgenesis’ which is a method that reduces the 
ability of the insect to transmit trypanosomes and the development of vectors that interfere 
with the procyclic stage in the tsetse midgut (Aksoy, 2003; Magez et al., 2010). Transgenesis 
also aims to reduce survival of the tsetse fly vector itself (Magez et al., 2010). The 
development of transmission blocking vaccines (TBVs) is based on the idea that targeted 
antigens are less variable as they have not been under evolutionary pressure by the host 
immune system (Magez et al., 2010). Tsetse flies fed on goats immunised with in vitro lysates 
from T. brucei, T. congolense and T. vivax were all able to control the development of 
respective parasites in their mid-guts (Murray et al., 1985). A similar study reduced T. b. 
rhodesiense infection rates in flies fed on rabbits immunised with G. pallidipes midgut 
proteins (Kinyua et al., 2005).  
  
 The dissemination of sterile males in tsetse infested areas have also been applied in 
controlling tsetse populations (Aksoy et al., 2001; Hao et al., 2001; Schofield and Maudlin, 
2001; Aksoy, 2003). Using transgenic and sterile males is expensive and requires regular 
release of the flies. This method has proved to be successful in eradicating tsetse flies on the 
island of Zanzibar (Msangi et al., 2000; Vreysen et al., 2000). Long term eradication of the 
trypanosome vector has, however, been under evaluation as there is a possibility of re-
infestation by new tsetse populations (Aksoy, 2003).  Rolling out this scheme to mainland 
Africa or over a large land area greater than 10 million km2 is not considered to be cost 
effective or sustainable (Rogers and Randolph, 2002).    
 
1.3.3 Vaccine development 
An area that has been explored for the control of trypanosomosis, but has borne numerous 
frustrations, is the development of vaccines (Radwanska et al., 2008; Baral, 2010; Magez et 
al., 2010). Cattle immunised with irradiated trypanosomes or purified VSG are immune to a 
homologous infection but are not protected from a heterologous challenge (Taylor and 
Mertens, 1999). Because trypanosomes have a very efficient method of switching GPI-
anchored surface VSGs that are coded for by a wide array of genes and pseudo genes, it 
makes it difficult to use a VSG based vaccine against trypanosomosis (McCulloch and Horn, 
2009). A more effective vaccine would be one that targets invariant antigens in the parasite 
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that do not change across infections (Authié et al., 1993b; Taylor, 1998). Invariant antigens 
investigated as vaccine and chemotherapeutic targets include structural and surface parasite 
proteins and pathogenic trypanosome products released during infection.   
 
1.3.3.1   Trypanosomal structural antigens  
Trypanosomal structural proteins have been used as vaccine targets with varying success. 
Mice immunised with native tubulin from T. brucei conferred 60-80% protection against T. 
brucei, T. congolense and T. rhodesiense infections (Lubega et al., 2002). This was 
confirmed in experiments using recombinant T. evansi beta-tubulin that partially protected 
against infections by T. evansi, T. equiperdium and T. b. brucei (Li et al., 2007). Experiments 
using recombinant T. brucei actin showed similar degrees of protection against the same 
infecting strains as those used for recombinant beta-tubulin (Li et al., 2009). Despite these 
promising results, further investigations are required to assess whether the immunity 
conferred by both beta-tubulin and actin is antigen-specific as a parallel control using other 
similarly recombinantly expressed trypanosomal proteins were not included in all three 
experiments (Magez et al., 2010). Mice immunised subcutaneously with paraflagellar rod 
protein purified from T. cruzi epimastigotes were able to survive a challenge with 103 T. cruzi 
parasites (Wrightsman et al., 1995). Interestingly, mice immunised intraperitoneally with 
purified paraflagellar rod protein succumbed to a challenge with an equal number of T. cruzi 
parasites (Wrightsman et al., 1995). It was also noted that mice that received subcutaneous 
injections had a much lower anti-paraflagellar rod protein antibody titre when compared to 
those that were immunised intraperitoneally. These results suggested that protection was 
conferred by cell mediated, rather than antibody mediated immunity (Wrightsman et al., 
1995). Further experiments that measured the proliferation of splenocyte T cells and 
immunisation with recombinant paraflagellar rod protein revealed that protection is conferred 
by a Th-1-type cellular response (Miller et al., 1996; Luhrs et al., 2003).  
 
1.3.3.2   Invariant surface antigens  
Trypanosomal invariant surface antigens have also been assessed for suitability as vaccine 
targets. An initial study of the flagellar pocket membrane from different T. b. rhodesiense 
variable antigen types was able to localise flagellar pocket antigens on the surface of 
trypanosomes (Olenick et al., 1988). This demonstrated that invariant surface proteins can be 
recognised by the infected host immune system. Immunisation of mice with preparations of 
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the flagellar pocket membranes conferred 60-40% protection for two of the three variable 
antigen types used for infection during the experiment (Olenick et al., 1988). Further 
experiments using the flagellar pocket from T. rhodesiense as an antigen also provided 
partial protection to T. congolense and T. vivax infections in cattle (Mkunza et al., 1995). Anti-
flagellar pocket membrane antibodies raised in mice were used to screen a cDNA expression 
library of T. brucei bloodstream form parasites and predominantly identified heat shock 
protein 60 (HSP60) and the invariant surface glycoprotein 75 (ISG75) (Radwanska et al., 
2000a). Mice infected with T. brucei revealed that an anti-HSP60 response is induced when 
parasites switched into stumpy forms, whereas a weak antibody response was detected for 
ISG70 (Radwanska et al., 2000b).  
 
Based on these observations, ISG75 recombinantly expressed in E. coli was used to 
immunise rabbits and the serum collected was able to detect all of the different species in the 
Trypanozoon subgenus, proving that ISG75 is conserved across the genus (Tran et al., 
2008). However, ISG75 immunised mice were unable to survive an infection with T. brucei 
parasites (Magez et al., 2010).  In experiments using mice immunised with the flagellar 
pocket membrane, partial protection was only observed in mice challenged with less than 103 
parasites. An infection with more than 103 parasites suppressed specific antibody responses 
to ISG70 with antibody titres dropping rapidly after two weeks of infection (Radwanska et al., 
2000b). Furthermore, although immunisation with invariant surface antigens resulted in the 
production of antigen specific memory B-cells, a subsequent infection with trypanosomes 
seemed to abolish this memory in addition to other B-cell compartments leaving the host 
susceptible not only to trypanosomosis but also to other livestock diseases such as foot and 
mouth disease, anthrax and swine fever (Radwanska et al., 2008; Magez et al., 2010).     
 
1.3.3.3   Pathogenic products from trypanosomes 
Because of antigenic variation, the host immune system is constantly producing antibodies to 
different antigen types in one infection clearing most parasites but in the process releasing 
many trypanosome products into the host circulatory system (Antoine-Moussiaux et al., 
2009). These products include lipids degraded by trypanosome phoslipase A1 generating free 
fatty acids that disrupt cell membranes (Wainszelbaum et al., 2001), hemolysins that assist T. 
cruzi invade cells (Andrews and Whitlow, 1989) and mitogens that enhance non-specific 
polyclonal B cell proliferation enabling parasites evade a specific immune response  (Reina-
San-Martin et al., 2000). Other factors are also responsible for inflammation and toxicity 
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include peptidases such as CATLs and oligopeptidases (Authié et al., 1993a; Coetzer et al., 
2008). This has led to exploring the development of vaccines that target products released 
during an infection in a strategy referred to as an ‘anti-disease’ approach (Authié et al., 2001). 
A trypanosomal anti-disease vaccine is formulated to alleviate the symptoms associated with 
the disease rather than attempting to eradicate the infecting parasite itself.  
 
Early during infection as parasites divide in the host, trypanosomes rapidly switch their VSG 
coat and in the process release large amounts of GPI-anchored VSG, through the action of 
trypanosomal phospholipase C (Pays et al., 2004). The glycosyl-inositol-phosphate (GIP) 
moiety of the GPI anchor which is attached to soluble VSG is in itself a strong activator of 
macrophages that produce TNF (Magez et al., 2002). TNF is responsible for the pro-
inflammatory response observed in a type I immune response during infection and excessive 
amounts circulating in the host lead to TNF-mediated trypanosomosis associated 
immunopathology (Magez et al., 2002). Immunisation of mice with native GPI from T. brucei 
was able to reduce pathology associated with trypanosome infection in mice by reducing 
TNF-associated symptoms, reduce anaemia and increase the lifespan of immunised mice by 
approximately 10 days when compared to non-immunised mice (Stijlemans et al., 2007b). 
Because phospholipase C is responsible for the shedding of parasite VSG, mice infected with 
phospholipase C null mutant parasites were more resistant to disease, had lower 
parasitaemia and increased survival when compared to wild type infections (Baetselier et al., 
2001). Disease resistance in null mutant infections is attributed to mice been able to switch 
from a classical type I macrophage activation reaction to the alternative type II reaction that 
does not involve overproduction of TNF observed in wild type infected mice (Namangala et 
al., 2001). Phospholipase A1 in T. brucei and T. cruzi infections is responsible for the 
breakdown of phospholipids into free fatty acids and lysophospholipids (Opperdoes and van 
Roy, 1982; Wainszelbaum et al., 2001). The release of free fatty acids and lysophospholipids 
leads to the degradation of phospholipid bilayers in surrounding cells and cause inflammation 
that is associated with lesions observed in trypanosomosis. 
 
During T. congolense, T. vivax and T. evansi infections, sialidases have been implicated in 
causing anaemia (Nok and Balogun, 2003; Nok et al., 2003; Antoine-Moussiaux et al., 2009). 
Sialidases are responsible for the removal of sialic acid from cell surfaces and in T. 
congolense infections, an increase in parasitaemia is associated with an increase in serum 
free sialic acid that is released from the surface of erythrocytes (Murray et al., 1985). Red 
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blood cells without sialic acid on their surfaces are targeted for erythrophagocytosis by 
macrophages leading to late stage anaemia in T. congolense  infections (Antoine-Moussiaux 
et al., 2009). The down-regulation of sialidases in T. congolense resulted in reduced rates of 
infectivity with a longer pre-patent periods, lower parasitaemia and less disease associated 
pathogenesis in mice infected with parasites targeted for sialidase RNAi in vivo and knock-out 
(Coustou et al., 2011). Mice immunised with recombinant sialidases from T. congolense are 
also able to survive longer than non-immunised mice when challenged with either T. 
congolense IL1180 or IL3000 (Coustou et al., 2011).  
 
Experiments using trypanotolerant and trypanosusceptible cattle challenged with T. 
congolense revealed a 69 kDa antigen which elicited an IgM response from both breeds of 
cattle and an IgG response from trypanotolerant cattle against a 33 kDa antigen (Authié et al., 
1993a; Authié et al., 1993b). This 33 kDa antigen was identified as a cysteine peptidase 
referred to as TcoCATL (Authié et al., 1992). Cattle immunised with TcoCATL recovered 
faster and showed a higher IgG response to T. congolense challenge than non-immunised 
cattle. Another peptidase that has been implicated in host pathology is the serine peptidase 
oligopeptidase B (OPB) which is released by dead and dying parasites and found to be active 
in the plasma of rats with an acute infection of T. b. brucei (Morty et al., 2001). The role that 
these two peptidases play during trypanosome infections is discussed further in Section 1.4 
 
1.4 PROTEOLYTIC ENZYMES IN TRYPANOSOMES 
Enzymes that catalyse the hydrolysis of peptide bonds are collectively referred to as 
proteolytic enzymes (proteases) or peptidases (Barrett and Rawlings, 2004; Rawlings et al., 
2010). With the discovery of a seventh catalytic type of proteolytic enzyme, the asparagine 
peptide lyases (Rawlings et al., 2011), the terms peptidase and proteolytic enzyme are no 
longer synonymous because they do not use hydrolysis to cleave peptide bonds. These self-
cleaving enzymes use asparagine as the nucleophile in the lyase reaction (Rawlings et al., 
2011). Peptidases are further classified as exopeptidases that cleave proteins at the N- or C- 
termini (aminopeptidases and carboxypeptidases respectively) or endopeptidases that 
hydrolyse internal peptide bonds (Barrett and Rawlings, 2004). Endopeptidases have also 
been referred to as proteinases (Barrett and McDonald, 1986). Seven classes of proteolytic 
enzymes are distinguished according to their respective reactive groups that catalyse the 
cleavage of peptide bonds (Table 1.2). The first letter of the reactive group is used for the 
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name of proteolytic enzyme families and clans (Rawlings et al., 2008). A family is a group of 
proteolytic enzymes that share significant amino acid identity to a representative proteolytic 
enzyme e.g. prolyl oligopeptidase in the case of the prolyl oligopeptidase family of serine 
peptidases, (Barrett and Rawlings, 2004; Rawlings et al., 2008). Members of the same family 
possess the same catalytic group as the representative proteolytic enzyme. A clan on the 
other hand, can have more than one family and members have similar tertiary structures and 
arrangement of reactive groups (Barrett and Rawlings, 2004).  
 
Table 1.2: The seven different classes of proteolytic enzymes (Rawlings et al., 2010). 
Class  Reactive group Example Inhibitors 
Serine  Hydroxyl group 
of serine 
Oligopeptidase Ba,b,c 3,4-dichloroisocoumarina,b,c 
peptidyl-
chloromethylketonesd, 
protaminee   













Aspartic acid  Carboxyl group 
of aspartic acid 
Pepsinm   Pepstatin Am 
Metallo Zn2+/  Ca2+ Matrix metallopeptidases 
(MMPs)n, 
E. coli aminopeptidase No 
T. congolense aminopeptidasesp 
T. cruzi aminopeptidaseq 
Bestatinr 
Doxycyclines 
tissue inhibitors of 
metalloproteinases (TIMPs)t 
Glutamic acid Carboxyl group 
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Proteolytic enzymes show a preference for particular amino acid residues adjacent to the 
peptide bond they cleave (Berger and Schechter, 1970; Barrett and Rawlings, 2004). The 
substrate residue immediately or terminal to the scissile bond is called P1 with subsequent 
residues labelled P2, P3….Pn towards the N-terminus and P2’, P3’….Pn’ towards the C-terminus 
of the scissile bond. The corresponding sub-sites on the proteolytic enzyme are labelled S1 
with subsequent sub-sites towards the N-terminus of the proteolytic enzyme labelled as S2, 
S3….Sn (Fig. 1.5). Sub-sites binding to the prime residues of the substrate are labelled S1’, 
S2’…Sn’. 
 
Figure 1.5 Berger and Schechter model for substrate specificity. The scissile bond is the site of 
cleavage with S3 - S3’ the peptidase sub-sites and P3 - P3’ the corresponding substrate amino acid 
residues with R1-R6 side chain groups that fit into the proteolytic enzyme sub-sites. (Smooker et al., 
2010) 
 
1.4.1 Cysteine peptidases 
Cysteine peptidases possess a cysteine residue in their active site. There are 35 known 
families in this class of peptidase (Rawlings et al., 1994; Rawlings et al., 2008), all with 
cysteine and histidine residues in their catalytic site. The order of cysteine and histidine 
residues in the primary structure differs between different families (Barrett and Rawlings, 
2004). Cysteine peptidases are divided into several clans. Clans CD and CC are comprised 
of viral peptidases and clan CB contains legumain-like cysteine peptidases e.g. T. brucei 
GPI-transamidase (Nagamune et al., 2003). Clan CA is the largest group of cysteine 
peptidases containing the papain family C1, with papain as the representative peptidase and 
family C2 of calpain-like cysteine peptidases which possess a calcium binding regulatory 
domain (Sajid and McKerrow, 2002). The papain-like family C1 is further divided into two 
major sub-families: cathepsin-B like peptidases which possess an occluding loop (Mendoza-
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Palomares et al., 2008) and cathepsin-L like peptidases which bear a unique ‘ERFNIN’ amino 
acid residue sequence (Sajid and McKerrow, 2002).  
 
T. congolense cysteine peptidase, TcoCATL, is a member of the cathepsin-L like cysteine 
peptidase family (Lecaille et al., 2002). Papain-like cysteine peptidases possess a highly 
conserved catalytic site formed by three catalytic residues: Cys25, His159 and Asn175 (papain 
numbering) (Rawlings et al., 2008; Caffrey and Steverding, 2009). Cys25 and His159 form an 
ion pair stabilised by Asn175 via a hydrogen bond. During peptide hydrolysis, the nucleophilic 
cysteine attacks the carbonyl carbon of the scissile bond forming a tetrahedral intermediate 
(Fig 1.6). The tetrahedral intermediate transforms into an acyl enzyme releasing the C-
terminal portion of the peptide. The acyl enzyme is hydrolysed by water and forms another 
tetrahedral intermediate that dissociates into the free enzyme and releases the N- terminal 
portion of the peptide (Lecaille et al., 2002; Barrett and Rawlings, 2004) .          
 
Figure 1.6 Proposed reaction mechanism for cysteine peptidases. (Lecaille et al., 2002). 
 
1.4.1.1 The major cysteine peptidase in T. congolense (TcoCATL) 
So far, two closely related cysteine peptidase families have been identified in T. congolense, 
CP1 (Fish et al., 1995) and CP2 (Jaye et al., 1994) with both families sharing 90% sequence 
identity (Boulangé et al., 2001). Congopain or TcoCATL, using a more recent nomenclature 
proposed by Caffery and Steverding (2009), is a 33 kDa CP2- type lysosomal peptidase that 
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has been isolated from T. congolense bloodstream forms (Authié et al., 1992; Mbawa et al., 
1992). In contrast to its T. cruzi homologue, cruzipain (TcrCATL), that retains activity below 
pH 4 (Chagas et al., 1997), TcoCATL shows maximum activity at pH 6.4 which rapidly 
decreases at a lower pH. This difference in activity is attributed to the presence of Leu 
(TcoCATL) in place of Glu (TcrCATL) at position 205 (papain numbering) at the S2 subsite 
(Chagas et al., 1997). TcoCATL is expressed as a 444 amino acid pre-pro-peptide composed 
of a signal peptide (20 amino acids long), a pro-peptide region (105 amino acids long 
containing a 56 amino acid inhibitor domain), and a catalytic domain that is 319 amino acid 
residues long (Fig.1.7) (Lecaille et al., 2002). The pro-peptide, that contains a 56 amino acid 
residue long inhibitory domain, is necessary for the production of mature TcoCATL as it 
blocks the active site during protein folding to prevent proteolytic activity (Lalmanach et al., 
1998). Also present is a 130 amino acid long C-terminal extension linked to the catalytic 
domain by a polyproline hinge, a feature also present in cruzipain (Cazzulo and Frasch, 1992; 
Boulangé et al., 2001) but absent in mammalian cathepsins. The C-terminal region is thought 
to be highly immunogenic and is similar to the C-terminal domain found in cruzipain which is 
released from the rest of the mature protein during infection (Martinez et al., 1991). Due to its 
catalytic action, mature TcoCATL is found in the lysosomes of living parasites and is only 
released after the host immune system lyses the parasite (Mbawa et al., 1991b).  
 
TcoCATL is a highly immunogenic antigen of T. congolense and induces both humoral and 
cellular responses in cattle (Authié et al., 1993a). Because of its immunogenicity, TcoCATL 
has been identified as a pathogenic factor during trypanosomosis (Authié et al., 2001). 
Truncated CP1 and CP2 lacking the C-terminus (due to its highly immunogenic nature) were 
used to immunise cattle in order to assess whether antibodies against the catalytic domain 
could inhibit trypanosome CPs during infection (Authié et al., 2001). Immunised cattle 
subsequently challenged with T. congolense were assessed for anaemia and antibody 
responses. Although the onset of anaemia was the same in all infected animals, immunised 
cattle were able to recover from anaemia and regain normal leukocyte counts 2-3 months 
after challenge. Immunised cattle did not suffer from severe weight loss observed in non-
immunised controls (Authié et al., 2001). This demonstrated that both CP1 and CP2 have a 
role to play in anaemia and more so for CP2 in immunosuppression. Immunised cattle were 
also able to mount a high IgG response against native CP and VSG antigens during infection, 
which seemed to protect them from pathology associated with the disease (Lalmanach et al., 
2002). It has also been shown that anti-CP antibody titres are more specific to native CP 
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when TcoCATL is complexed with α2-macroglobulin as an adjuvant (Huson et al., 2009). This 
is because TcoCATL retains its 3-dimensional conformation inside the α2-macroglobulin 
cage-like structure thus increasing the efficiency of delivery to antigen presenting cells 
(Huson et al., 2009). TcoCATL has some unique characteristics when compared to other 
trypanosomal cathepsin-L like cysteine peptidases. Recombinant TcoCATL expressed in P. 
pastoris forms a dimer at neutral pH but remains as a monomer at acidic pH (Boulangé et al., 
2011). Also, several other TcoCATL-like peptidases with non-classical active site motifs have 
been identified by comparative genomics and were shown to be active at physiological pH 
(Pillay et al., 2010). Both these factors are important when considering the development of an 
anti-disease vaccine as cognisance needs to be taken of dimer-specific epitopes that are 
recognised by trypanotolerant cattle and the activity of TcoCATL-like peptidases that may not 
be inhibited in cattle only immunised against classical TcoCATL. 
 2.2 kDa               11.9 kDa  33.9 kDa     
Signal           Pro-region Catalytic domain (+ C-terminal extension)    
peptide     (+ inhibitor domain) 319aa
20 aa       105 aa (+ 56 aa) 189 aa                              (+130 aa)
 
Figure 1.7 Structural domains of TcoCATL. TcoCATL is expressed as a 48 kDa, 444 amino acid 
long pre-pro-enzyme with a signal peptide, a pro-region containing an inhibitor sequence and a 
catalytic domain with a C-terminal extension linked by a polyproline hinge.   
1.4.2 Serine Peptidases 
Serine peptidases are a class of peptidases that possess a serine residue in their active site. 
Over a third of all known proteolytic enzymes are serine peptidases which have been 
identified across different species and are divided into 50 clans and 184 families (Rawlings et 
al., 2008). The clans are grouped according to the protein fold surrounding the catalytic site 
e.g. clan PA peptidases possess Greek-key β-barrel protein folds, clan SB consists of a 3-
layer sandwich fold and clan SC an α/β hydrolase fold around the active site (Page and Di 
Cera, 2008). In many serine peptidases, the catalytic action of the serine hydroxyl group is 
improved by the presence of a histidine residue and a stabilising aspartate residue, with the 
side chains of serine, histidine and aspartate building the catalytic triad (Barrett and Rawlings, 
2004). During hydrolysis, the nucleophilic hydroxyl group of serine attacks the carbonyl 
carbon of the peptide bond under hydrolysis and forms a tetrahedral intermediate that 
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dissociates into an acyl-enzyme intermediate and releases the N-terminal portion of the 
cleaved peptide (product 1, Fig. 1.8). Addition of water generates a second tetrahedral 
intermediate that regenerates the original catalytic triad releasing the C- terminal portion of 
the cleaved peptide (product 2, Fig. 1.8) (Rea and Fülöp, 2006). Members of clan SC are α/β 
hydrolase-fold enzymes consisting of parallel β-strands surrounded by α-helices (Page and Di 
Cera, 2008). Both endo- and exo- peptidases are represented in this clan such as members 
of family S33 that hydrolyse N-terminal proline (exo-peptidase) and those in family S9 that 
cleave peptide bonds within peptides (endo-peptidase) (Rea and Fülöp, 2006). Family S9 is 
represented by prolyl oligopeptidase (EC 3.4.21.26) with various other members including 
dipeptidyl peptidase IV (EC 3.4.14.5), acylaminoacid releasing enzyme (EC 3.4.19.1) and 











Figure 1.8 Mechanism of action for serine peptidases. (Voet et al., 2006).  
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1.4.2.1 Oligopeptidase B 
Oligopeptidase B (OPB) is a serine peptidase from the prolyl oligopeptidase family that 
hydrolyses peptide bonds of low molecular mass peptides smaller than 30 amino acids long 
(Barrett and Rawlings, 2004). The representative peptidase, prolyl oligopeptidase, cleaves 
peptides on the carboxy end of proline residues, whereas OPB only hydrolyses peptides on 
the carboxy end of basic residues, preferring arginine over lysine (Kanatani et al., 1991; 
Morty et al., 1999a; Coetzer et al., 2008). The structure of oligopeptidase B has been 
described in E. coli (Gerczei et al., 2000) through homology modelling using prolyl 
oligopeptidase as a template. The crystal structure of OPB from L. major (LmOPB) has also 
recently been described in complex with antipain, an OPB inhibitor (McLuskey et al., 2010). 
LmOPB is a two-domain structure with a C-terminal catalytic domain and an N-terminal β-
propeller domain linked by a hinge region (Fig. 1.9) (McLuskey et al., 2010). The C-terminal 
catalytic domain contains the catalytic triad Ser577, Asp662 and His697 located on loops 
between β-strands facing the propeller creating a cavity where antipain is bound (McLuskey 
et al., 2010). The N-terminal regulatory domain is made up of a seven bladed β-propeller that 
lies over the catalytic triad allowing only short peptides access to the active site and 
consequently endogenous serine peptidase inhibitors (serpins) do not inhibit prolyl 







Figure 1.9 The structure of LmOPB crystallised with antipain. General loop regions are shown in 
yellow, α-helices in red, β-strands in blue, and 310 helices in green. ← shows the position of antipain in 
cyan as a stick model bound to the catalytic domain. [Adapted from McLuskey et al. (2010)].  
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Trypanosomal oligopeptidase B efficiently hydrolyses peptides that contain basic amino acid 
residues (Arg or Lys) in P1 with a preference for arginine residues in both P1 and P2, favouring 
basic residues over Gly, Phe, Leu, Thr and Pro (Morty et al., 1999a; Morty et al., 1999b; 
Coetzer et al., 2008). Natural peptides such as host peptide hormones and peptides with a 
high number of basic residues are efficiently hydrolysed by OPB (Troeberg et al., 1996b; 
Morty et al., 2005a). In vitro, OPB hydrolyses the peptide hormone atrial natriuretic factor 
(ANF), at four sites, thereby reducing ANF smooth muscle relaxant and hypertensive 
properties (Morty et al., 2005a). Other hormones hydrolysed by OPB include 
adrenocorticotropic hormone (ACTH) (Tsuji et al., 2004), neurotensin and reduced 
vasopressin (Troeberg et al., 1996a). Oligopeptidase B is found in the cytoplasm and has 
been isolated from several species of trypanosomes, i.e. T. b. brucei (Troeberg et al., 1996a), 
T. congolense (Morty et al., 1999a), T. evansi (Morty et al., 2005a) and T. vivax (Huson, 
2006). Oligopeptidase B is released by dead or dying parasites into the host circulation where 
it retains full catalytic activity (Morty et al., 2001). This is significant in host pathology since 
the degradation of peptide hormones could damage physiological homeostasis and 
subsequently cause several symptoms associated with infection (Troeberg et al., 1996a; 
Morty et al., 2005a). The trypanocidal agents suramin, diminazene and pentamidine inhibit 
OPB activity (Morty et al., 1998; Coetzer et al., 2008). Pentamidine inhibited OPB in a 
competitive manner whereas suramin inhibition was non-competitive in a fluorescent peptide 
substrate assay using native OPB. Inhibition of OPB by suramin and its analogues showed a 
relationship with trypanosome death in culture. This strongly suggests that OPB is one of the 
targets of suramin activity in trypanosomes (Morty et al., 2005c). Inhibiting OPB with peptidyl-
chloromethylketones and peptidyl-phosphonate diphenyl esters killed in-vitro cultures of T. b. 
brucei. A peptidyl-phosphonate diphenyl ester also cured mice after infection with 
trypanosomes (Morty et al., 2000). In T. cruzi, oligopeptidase B has been implicated in the 
invasion of mammalian cells during infection (Burleigh et al., 1997; Caler et al., 1998). It was 
found that T. cruzi OPB was involved in the recruitment of host lysosomes by Ca2+-signalling 
activity (Burleigh et al., 1997). Deletion of the gene coding for OPB in T. cruzi affected the 
ability of null-mutant T. cruzi parasites to invade host cells in vitro and establish an infection in 
mice (Caler et al., 1998). The addition of recombinant OPB to null mutant parasite extracts 
restored Ca2+-signalling activity, proving that OPB has a central role to play in T. cruzi 
infections (Caler et al., 1998).  
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Gene knock-out studies in Leishmania major and L. donovani showed that the loss of OPB 
resulted in delayed foot pad lesion formation in mice but no difference was observed in 
virulence during infection (Munday et al., 2011; Swenerton et al., 2011). Knock-out parasites 
were also less able to infect and survive within macrophages in vitro and a prominent up-
regulation of enzymatically inactive membrane associated enolase was detected in L. 
donovani parasites without OPB (Swenerton et al., 2011). Macrophages infected with OPB 
knock-out parasites when compared to wild type parasites showed significant up-regulation of 
different families of proteins including those involved in cytokine secretion, signal 
transduction, and the inflammatory response. The absence of enolase on Leishmania 
membrane surfaces enables the parasite to bypass macrophage activation during early 
stages of infection and knock-out parasites proved that OPB has a role to play in clearing 
membrane bound enolase (Swenerton et al., 2011).   
 
To study the roles that trypanosome peptidases play in parasite survival and infection, it is 
necessary to employ techniques that either down-regulate or completely remove their 
occurrence in the parasite. Down-regulation of a gene can be achieved at the transcription 
level by targeting RNA which is used as a template during translation whereas deletion of the 
gene is carried out at DNA level. These techniques used to identify gene function fall under 
the broad area of reverse genetics.  
 
1.5 ELUCIDATION OF GENE FUNCTION IN PROTOZOAN PARASITES USING 
REVERSE GENETICS 
Traditional genetics (also called forward genetics) has relied on the identification of genes 
based on a phenotype that has been previously described e.g. as a disease or mutation. 
Following advances in gene sequencing, the sequences of several genes have been 
elucidated but their functions are yet to be understood (Baumeister, 2002). The function of 
genes in protozoa, and their importance in pathology in relation to the host have been studied 
using several techniques collectively referred to as reverse genetics (Fig.1.10) (Clayton, 
1999). Experiments targeting gene function include transposon mutagenesis that creates 
mutant genes (Leal et al., 2004; Damasceno et al., 2010), and the transfection of parasites 
with transient plasmids which is useful for post transcriptional analysis of genes (Clayton, 
1999). The ultimate validation of gene function is achieved by either partial or complete 
disruption of the gene of interest using gene knock-out experiments or by RNA interference 
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(RNAi) (Clayton, 1999; Baumeister, 2002; Ullu et al., 2002; Militello et al., 2008). Genes of 
interest can also be overexpressed (gene knock-in) to study their functions in regulatory 
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Figure 1.10 Different techniques used to study the function of genes using reverse genetics. 
Definitive function of a gene is achieved by either partial knock-down of transcribed RNA (RNAi) or 
complete deletion of DNA (gene knock-out). Overexpression of a gene in a regulatory pathway can 
also result in a new phenotype. 
 
1.5.1  RNAi in kinetoplastid protozoa  
The RNAi mechanism does not exist in all pathogenic parasites (Table 1.3). The first reports 
of RNAi in protozoa was described in Trypanosoma spp. with clear bioinformatic and 
functional evidence of the pathway in T. b. brucei (Ngo et al., 1998; Ullu et al., 2004). These 
experiments were initially used to characterise structural proteins such as α- and β- tubulin, 
the silencing of which resulted in the appearance of fat multinucleated cells referred to as 
 28
FAT cells (Ngo et al., 1998). This phenotype was attributed to α-tubulin short interfering RNA 
(siRNA) that disrupted cytokinesis and cytoskeletal organisation of trypanosome cells. Other 
structural proteins targeted in early experiments were paraflagellar rod protein 2 (PFR2), 
flagellum attachment protein (FLA) and actin (Ngo et al., 1998; Rusconi et al., 2005). PFR2 
was used in studies demonstrating that RNAi in trypanosomes targets specific sequences 
responsible for the phenotype observed without affecting other genes (Rusconi et al., 2005).  
 
Studies have also explored other targets with less obvious phenotypes than structural 
proteins. The majority of these are enzymes responsible for various pathways in 
trypanosomes. In T. brucei, enzymes targeted for RNAi include argonaute protein that is 
involved in processing siRNA during degradation of targeted transcripts (Ngo et al., 1998; 
Rusconi et al., 2005). Experiments in T. brucei targeting acetyl:succinate CoA-transferase 
(ASCT) was used to confirm the link between the ASCT gene sequence and mitochondrial 
ASCT activity (Riviere et al., 2004). ASCT is, however, not an essential enzyme as it is not 
the only acetate producing enzyme in trypanosomes. Other metabolic enzymes that have 
been characterised using RNAi are iron superoxide dismutase (SOD) (Wilkinson et al., 2006) 
and trypanothione synthetase (TryS) (Ariyanayagam et al., 2005). Mitochondrial SOD was 
found to be essential for parasite survival only after RNAi induced parasites were exposed to 
paraquat, a superoxide generating agent (Wilkinson et al., 2006). A similar trend was 
observed targeting TryS for RNAi where TryS deficient parasites where sensitive to arsenical 
drugs indicating a role for trypanothione metabolism in their mode of action (Ariyanayagam et 
al., 2005).  
 
Several peptidases have also been targeted for RNAi in T. brucei parasites. Silencing the 
major surface peptidase (MSP) in T. brucei procyclics decreased the amount of transgenic 
surface glycoprotein released with a associated increase in cell associated glycoprotein 
(LaCount et al., 2003). Silencing MSP in bloodstream forms is toxic to the parasite making 
MSP a valid drug target (LaCount et al., 2003). Cathepsin B-like peptidase, rather than 
TbCATL (brucipain) was confirmed as the major target in T. brucei for the diazomethane 
inhibitor Z-Phe-Ala-CHN2 using RNAi (Mackey et al., 2004). RNAi against TbCATL did not 
result in any obvious phenotype in cultured trypanosomes, whereas silencing the cathepsin B 
gene led to an enlargement of the endosome, defective cytokinesis and ultimately induced 
the death of cultured parasites (Mackey et al., 2004). These results were confirmed in a 
mammalian model where RNAi was induced during infection in mice using doxycycline 
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(Lecordier et al., 2005). RNAi against cathepsin B in mice infected with parasites bearing 
cathepsin B gene silencing constructs led to parasite clearance and prevented a lethal 
infection (Mackey et al., 2004). Silencing TbCATL expression during infection did not cure the 
mice but reduced parasite virulence with 50% of mice infected with trypanosomes containing 
TbCATL gene silencing constructs surviving for 60 more days than wild type infections 
(Abdulla et al., 2008). TbCATL was implicated in lower virulence because of its involvement 
in parasites’ ability to cross the blood-brain barrier, thereby confirming previous results using 
cysteine peptidase inhibitors (Nikolskaia et al., 2006a). 
 
A lysosomal associated membrane protein (LAMP) – like protein 67 (p67) in T. brucei was 
induced for RNAi to assess what role it plays in trafficking TbCATL and human trypanolytic 
factor (TLF) (Peck et al., 2008). Depletion of RNA transcribing for p67 had no effect on 
TbCATL trafficking to lysosomes, and endocytosis was unaffected although lysosomes 
became enlarged after 24 hours of RNAi induction. On the other hand, parasites that were 
previously sensitive to TLF became resistant to lysis indicating that p67 was essential for TLF 
activity in lysosomes although a specific role was not established (Peck et al., 2008). 
Experiments on T. congolense showed that the RNAi pathway exists in the parasite. Genes 
coding for the argonaute and dicer proteins that are involved in the RNAi mechanism have 
been identified in T. congolense (Shi et al., 2006a). Experiments targeting tubulin and 
luciferase reporter genes for RNAi in T. congolense have been successful (Inoue et al., 2002; 
Coustou et al., 2010). Parasites from the genus stercoraria lack the genes coding for proteins 
involved in RNAi and experiments in T. cruzi do not give expected phenotypes (DaRocha et 
al., 2004). Other protozoan parasites that lack the RNAi pathway include Theileria and 
Babesia spp. and some Leishmania spp. (Militello et al., 2008). Leishmania spp. in the 
subgenus Viannia have an RNAi pathway. This has been proved with RNAi experiments on 
L. braziliensis targeting green fluorescent protein reporter genes and the argonaute protein 
(Lye et al., 2010). Proving RNAi in the Plasmodium spp. has so far yielded controversial 
results (Blackman, 2003). Experiments on falcipain-1 and 2, the major cysteine peptidases in 
P. falciparum, using dsRNA demonstrated nuclease activity that led to the fragmentation of 
RNA (Malhotra et al., 2002). Phenotypes mimicking the addition of the cysteine peptidase 
inhibitor E-64 were also observed. Recent literature on these studies attributes the results to 
mechanisms other than RNAi such as general toxicity of exogenous RNA added in the 
experiment and specific antisense effects that physically obstruct transcription (Baum et al., 
2009).    
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Table 1.3: RNAi experiments conducted in different protozoan parasites [Adapted from Militello et 
al. (2008)] 







T. brucei + + + + 
T. congolense + + + - 
L. braziliensis + - - - 
Giardia intestinalis + - - - 
Entamoeba histolytica + - - - 
Trichomonas vaginalis + - - - 
Toxoplasma gondii + - - - 
Plasmodium spp. - - + + 
T. cruzi + - - - 
L. major - - - - 
L. infantum - - - - 
Cryptosporidium spp. - - - - 
Theileria spp. - - - - 
Babesia bovis - - - - 
Eimeriia tenella - - - - 
 
RNAi has also been useful when performing high-throughput studies on genes whose 
functions have not been elucidated, especially with the completion of the T. brucei genome 
sequencing (Berriman et al., 2005). RNAi target sequencing (RIT-seq) uses a plasmid library 
containing randomly sheared genomic DNA fragments that have been cloned into RNAi 
vectors (Alsford et al., 2011). Recombinant vectors were then used to transform blood-stream 
form and insect form parasites and clones that showed a growth defect after three and six 
days were selected for genomic DNA extraction and sequencing using vector primers. A 
differentiation defect was also assessed by adding cis-aconitate to transformed bloodstream 
form parasites and selecting those that had a defect in differentiating to procyclics (Overath et 
al., 1986). Data acquired from sequencing was mapped using the T. brucei genome to 
identify coding sequences. A total of 1908 and 2724 coding sequences were identified as 
significant to parasite survival after 3 and 6 days respectively of RNAi induction in the 
bloodstream form; 1972 and 2677 coding sequences were identified for procyclics and 
differentiating cells respectively  (Alsford et al., 2011). Inducible RNAi libraries have also been 
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used to identify drug transporters in T. brucei bloodstream forms and RNA recognition motifs 
involved in RNA processing (Wurst et al., 2009; Pillay, 2011). 
 
1.5.1.2   Mechanism of RNA interference  
RNA interference (RNAi) has been used as a tool to study gene function and identify possible 
drug and vaccine targets in trypanosomes (Clayton, 1999). RNAi was first described in 
Caernohabditis elegans when experiments carried out to analyse gene function using 
antisense approaches produced the same phenotype as the sense control (Guo and 
Kemphues, 1995). The term ‘RNA interference’ was described after experiments using 
double stranded RNA (dsRNA) to silence the unc2 gene in nematodes were carried out (Fire 
et al., 1998). It is defined as the mechanism through which gene-specific dsRNA triggers the 
degradation of homologous transcripts and is a natural phenomenon found in nearly all 
eukaryotic organisms (Fire et al., 1998; Montgomery et al., 1998; Ullu et al., 2002; Ullu et al., 
2004) 
 
There are several natural endogenous roles for RNAi in trypanosomes. This pathway has 
been implicated in several gene silencing functions such as heterochromatin assembly and 
maintenance, DNA and histone methylation, DNA elimination, promoter silencing and 
developmental control (Ullu et al., 2004). T. brucei parasites deficient in RNAi have high 
levels of retrotransposons, indicating that RNAi protects an organism’s genome by targeting 
mobile elements (transposons) (Shi et al., 2004b). RNAi has also been suggested as a 
natural antiviral defence mechanism since several double stranded viruses that infect 
protozoa have been identified (Militello et al., 2008). Another possible function for RNAi is its 
role in regulating gene expression through the action of microRNAs (miRNAs) that inhibit 
translation by binding to the 3’UTR region of target mRNAs (Sharp, 2001; Ullu et al., 2004; 
Shi et al., 2004b). miRNAs differ from siRNA in that siRNA are generated from the cleavage 
of long endogenous or exogenous dsRNA whereas miRNA are naturally occurring regulatory 
RNAs (Ullu et al., 2004).  
 
RNAi in T. brucei relies on the introduction of double-stranded RNA molecules into cells to 
block the translation of messenger RNA into protein (Fig.1.11). The double-stranded RNA, 
which must be partly identical in sequence to the gene to be inhibited, is cleaved into shorter 
fragments called siRNA (25 nt long) by an enzyme called dicer (Shi et al., 2006a) (Fig.1.11). 
Experiments have shown that there are two forms of dicer in T. brucei (TbDCL): cytoplasmic 
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TbDCL1 that silences potentially harmful viruses in the cytoplasm and nuclear TbDCL2 that is 
responsible for the T. brucei nuclear RNAi pathway (Durand-Dubief and Bastin, 2003). Dicer 
is a multi-protein comprising of one PAZ domain [named after three proteins containing this 
domain: Piwi, Argo and Zwille (Cerutti et al., 2000)] that binds RNA and two adjacent RNAse 
III domains at the N terminal half of the protein (RNAse IIIa and RNAse IIIb) (Fig.1.12). The 
PAZ domain and the RNAse III domains are 65 angstroms apart and because of this 
distance, the siRNAs produced in T. brucei are 25 nucleotides (nt) long (Shi et al., 2006a).  
 
The siRNA generated by dicer are then split into ‘antisense’ and ‘sense’ strands by the 
argonaute protein, AGO1, which is the catalytic component of the RNA-induced silencing 
complex. The RNA sense strand is complementary to the DNA template used for transcription 
and is used as a template for translation and protein synthesis. RNA that is complementary to 
sense RNA is referred to as antisense RNA. The sense strand is degraded by AGO1 and the 
remaining antisense strand is incorporated into a protein complex called the RNA-induced 
silencing complex (RISC) and acts as a guide for the degradation of complementary mRNAs 
transcribed within the parasite (Shi et al., 2004a; Shi et al., 2006b). The RISC complex is also 
referred to as slicer (Fig.1.11). Slicer is a member of the argonaute (AGO) family containing 
an RNAse H motif that cleaves mRNA. T. brucei AGO protein (TbAGO1) contains two 
domains, a PAZ domain similar to the one found in dicer, and a Piwi domain which contains 
RNAse H-type activity that acts as the active site for slicer (Fig.1.12) (Shi et al., 2004a). In 
addition to these two domains, TbAGO1 has an N-terminal domain with a high abundance of 
RGG repeats (Shi et al., 2004a). The PAZ domain functions as an anchoring site for the two-
nucleotide 3’-overhang of siRNAs (Shi et al., 2004a). The activity of slicer is directed by the 
antisense RNA towards the target mRNA, which is degraded, thus effectively 'silencing' the 
gene from which it was transcribed (Novina and Sharp, 2004).  
 
Initial experiments using dsRNA in T. brucei involved the transient transfer of synthetically 
synthesised dsRNA (Ngo et al., 1998). RNA interference induced in this manner was 
temporary and not transferable to the next generation. Methods were adapted from work in C. 
elegans that involved soaking worms in dsRNA solution instead of injecting them to induce 
RNAi (Tabara et al., 1998). This method proved to be inefficient due to its transient nature 
and alternatives were developed. Heritable and inducible vectors for RNAi provide a more 
stable option because they are integrated into the parasite genome and can be transferred 
from one generation to the next. They also contain a tetracycline repressor which enables 
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RNAi to be induced by the addition of tetracycline to the growth medium of transfected 

















Figure 1.11 Schematic representation of the RNAi system in trypanosomes. Dicer cleaves 
exogenous dsRNA into 25 nt long siRNA which is separated by AGO1 protein into sense and 
antisense strands. The antisense strand then guides the AGO1-siRNA complex to degrade 
complementary mRNAs causing silencing of RNA from which the original dsRNA was transcribed 
(Balaña-Fouce and Reguera, 2007). 
 
Dicer




PAZ ~ 110 aa RNAse IIIa RNAse IIIb
65
angstroms
Piwi ~ 300 aa
 
Figure 1.12 Structures of dicer and slicer proteins. Both proteins possess a PAZ RNA binding 
domain of approximately 110 amino acids in size that is responsible for anchoring dsRNA for 
processing. Slicer also possesses a Piwi domain with RNAse H activity for degrading complementary 
mRNA. The distance between the PAZ domain and RNAse III domains in dicer is 65 angstroms 
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functional RNAi silencing in T. congolense (Inoue et al., 2002). Integration of a stem and loop 
vector into T. cruzi was successful but failed to induce RNAi due to the absence of an RNAi 
mechanism in the parasites (DaRocha et al., 2004). 
 
1.5.2 Gene knock-out studies in kinetoplastid protozoa 
Gene knock-out techniques involve the deletion of DNA coding for the gene under study. This 
requires the transfection of parasites with replacement plasmid vectors that target the gene of 
interest for deletion (Clayton, 1999). Because kinetoplastid parasites are diploid, two rounds 
of transfection are required to delete both copies of the targeted gene. Drug markers that 
confer resistance are used to select for recombinant heterozygotes (with one copy of the 
gene deleted) and null mutants (with both copies of the gene deleted). Antibiotic resistance 
markers routinely used when transforming trypanosomes and Leishmania include puromycin 
acetyltransferase, neomycin phosphotransferase, hygromycin phosphotransferase and 
bleomycin resistance protein (Table 1.4) (Clayton, 1999; Ommen et al., 2009). 
 
In kinetoplastid parasites where the RNAi mechanism is absent or ineffective (Leishmania 
spp. and T. cruzi), gene deletion studies have taken precedence over other reverse genetics 
techniques (Xu et al., 2009). The first study on gene deletion in Leishmania was the knock-
out of the gene coding for dihydrofolate reductase-thymidylate synthase (DHFR-TS) in L. 
major (Cruz et al., 1991). The replacement strategy used was sequential with the 
replacement of one gene to create a heterozygote, followed by the generation of null mutants 
(Fig.1.13). DHFR-TS null mutants grew only in the presence of thymidine, suggesting that the 
sole role of DHFR-TS was the provision of thymidine in L. major (Cruz et al., 1991). Early 
experiments on transformation of DNA in T. brucei evaluated the viability of inserting DNA 
plasmids into intergenic regions of the αβ-tubulin gene and ribosomal RNA (rRNA) (Lee and 
Van der Ploeg, 1990; Carruthers et al., 1993). The highest transformation efficiencies were 
observed when targeting rRNA and using Zimmerman post-fusion medium with glucose 
(ZPFMG) (Carruthers et al., 1993). Knocking-out the thioredoxin gene in T. b. brucei 
bloodstream and procyclic parasites had no effect on their viability (Schmidt et al., 2002). A 
possible explanation for the lack of a phenotype was the abundance of tryparedoxin, an 





Table 1.4: Markers available for selecting permanently transformed trypanosomes and 
Leishmania. 




G418 Ribosome Enzymatic inactivation of druga,b 
Blasticidin S deaminase 
(BLA) 
 




Hygromycin Ribosome translocation 
Enzymatic inactivation 
of druge,f 










Puromycin acetyltransferase  
(PAC) 
Puromycin Protein synthesis Enzymatic inactivation of drugh,i 
Streptothricin acetyltransferase 
(SAT1) 
Nouseothricin Ribosome Enzymatic inactivation of drugj,k 
aLaban et al. (1990), bten Asbroek et al. (1990), cKobayashi et al. (1991), dMcCulloch and Barry (1999), 
eCruz et al. (1993), fLee and van der Ploeg (1991), gJefferies et al. (1993), hFreedman and Beverley 
(1993), iLorenz et al. (1998), jRuepp et al. (1997), kJoshi et al. (1995). 
 
Knocking-out the same gene in two different, but related parasites can lead to different 
phenotypes observed. GPI: protein transamidase complex null mutants (∆GP18) in T. brucei 
were unable to establish infections in the tsetse midgut (Lillico et al., 2003). Knocking out the 
same gene in L. mexicana did not change the virulence and survival of ∆GP18 null mutant 
parasites in the mammalian host (Hilley et al., 2000). It is also possible to knock-out several 
gene repeats in one reaction. Leishmanolysin, a surface metallopeptidase of 63 kDa (gp63), 
is found in a gene array with seven repeats that spans a 20 kb region (Joshi et al., 2002). 
∆gp63 mutants were generated by deleting this entire region and results showed that gp63 
was a virulence factor in L. major. Cysteine peptidases in L. mexicana are encoded by a 
tandem array of 19 genes in the lmcpb locus and two single copy genes, lmcpa that is 
cathepsin L-like, and lmcpc that is cathepsin B-like (Mottram et al., 1996). The disruption of 
the entire lmcpb gene array along with the lmcpa single copy cathepsin L-like genes was 
successfully achieved using gene knock-out techniques with null mutant parasites showing 
reduced virulence in Balb/c mice (Mottram et al., 1996). The reinsertion of amastigote-specific 
and metacyclic-specific cysteine peptidase genes into lmcpb null mutant parasites did not 
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improve virulence which was only restored with the re-expression of the multiple lmcpb genes 
(Mottram et al., 2004). 
 
It is not possible to obtain null mutant clones when targeting genes that are essential to the 
parasite under study. Amastigote specific cysteine peptidase in L. chagasi is encoded by a 
single copy gene (Mundodi et al., 2002). Knock-out studies were only able to achieve 
heterozygotes with the reduced ability to infect macrophage cells (Mundodi et al., 2005). 
Gene deletion does not always result in an observable phenotype (Estevez et al., 1999; 
Schmidt et al., 2002). Deleting the gene coding for glutamate dehydrogenase (GDH) did not 
affect the abundance of edited RNAs, a function that has been attributed to GDH (Estevez et 
al., 1999). It is also important to observe how other genes in the parasite are affected by the 
deletion of one gene (Deutscher et al., 2008; Swenerton et al., 2011). Deletion of 
oligopeptidase B in L. donovani led to a large up-regulation of enzymatically inactive 
membrane associated enolase. It could be inferred that OPB clears membrane associated 
enolase in the parasite to help evade macrophage activation during early stages of infection 
(Swenerton et al., 2011). 
 
The common method used to delete the two alleles of a gene in trypanomastids is to flank an 
antibiotic resistance marker gene with the 5’- and 3’- intergenic regions of the target gene 
(Fig.1.13) (Ommen et al., 2009). For specific and efficient gene targeting, up to 1000 base 
pairs of both flanking regions can be cloned into the knock-out vector (Fig.1.14). 
Recombinant vectors are then transfected into parasites where homologous recombination is 
responsible for replacing the targeted gene with a selection marker. One step gene 
replacement has been suggested in Leishmania spp. (Ommen et al., 2009). In this 
experiment, both genes are replaced in one reaction making it a viable alternative to first 
creating heterozygotes. A polymerase chain reaction-based strategy has been used in T. 
brucei (Gaud et al., 1997). This involves generating a knock-out vector using the 5’ and 3’ 
DNA regions flanking the gene of interest and drug resistance genes as templates in one 
PCR reaction thereby drastically reducing the amount of work required for cloning (Gaud et 
al., 1997; Xu et al., 2009). The multi-site gateway system is even more efficient than the PCR 
based system and involves using commercial vectors that have homologous recombination 
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1.5.2.1   Mechanism of homologous recombination  
Homologous recombination is the process in which nucleotide sequences are exchanged 
between two identical sequences of DNA and is used to repair double stranded DNA breaks 
and ensuring the completion of DNA replication (Kanti Bhattacharyya et al., 2004; Sung and 
Klein, 2006). Although double stranded DNA breaks are considered to be dangerous to the 
cell, they can be introduced intentionally, the best example being during meiosis to facilitate 
genetic exchange (Proudfoot and McCulloch, 2006). In trypanosomes, homologous 
recombination is one of the mechanisms involved in antigenic variation during telomere 
exchange that switches a silent VSG site with an active VSG expression site (Taylor and 
Rudenko, 2006). Homologous recombination was first described in E. coli  where the RecA 
protein was found to be central to the process (Cox, 2003). Rad51 and Dmc1 (disrupted 
meiotic cDNA) proteins are the eukaryotic homologs of RecA and are responsible for binding 
to DNA, searching for homologous DNA molecules and subsequently exchanging counterpart 
DNA strands (Fig. 1.15) (Kanti Bhattacharyya et al., 2004). Rad51 is responsible for 
recombination events during mitosis between sister chromatids and requires the involvement 
of Dmc1 for recombination between two different parental chromosomes during meiosis 
(Masson and West, 2001). Dmc1 is therefore meiosis specific and although single copy 
genes have been identified in T. brucei, T. cruzi and L. major, Dmc1 mutation does not result 
in any alterations to DNA repair and recombination (Proudfoot and McCulloch, 2006).  
 
Rad51 has been identified in both T. brucei and L. major (McCulloch and Barry, 1999; 
McKean et al., 2001). Disruption of the Rad51 gene in T. brucei down-regulates DNA 
recombination and VSG switching (McCulloch and Barry, 1999), and exposure of L. major 
parasites to phleomycin (Table 1.4) up-regulates its expression (McKean et al., 2001). Five 
Rad51-related genes have been identified in T. brucei and mutations in two of them, Rad51-3 
and Rad51-5, resulted in reduced DNA recombination and rendered parasites sensitive to 
DNA damage by methyl methanesulfonate (Proudfoot and McCulloch, 2005). Rad51-3 was 
also found to contribute to VSG- switching (Proudfoot and McCulloch, 2005). Another gene 
product that has been found to be associated with Rad51 in T. brucei is BRAC2 (breast 
cancer susceptibility gene) (Hartley and McCulloch, 2008). BRAC2 regulates homologous 
recombination by binding to Rad51 and blocking its activity until it is needed for repair 
(Hartley and McCulloch, 2008). Although the Rad51 pathway (Fig. 1.15) is dominant during 
the repair of double stranded breaks in trypanosomes, other mechanisms that have been 
implicated in DNA repair are the involvement of the Mre11 complex (Robinson et al., 2002; 
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Tan et al., 2002) and mismatch repair (Barnes and McCulloch, 2007). Rad51 mediated 
homologous recombination begins with the binding of single stranded DNA to single strand 
binding protein that is followed by replacement with Rad52 (Fig. 1.15) (Kanti Bhattacharyya et 
al., 2004). Rad52 directs Rad51 to bind to the single stranded DNA forming a nucleoprotein 
filament. Each molecule of Rad51 binds to three nucleotides of single stranded DNA forming 
a right handed helix. Rad54 then associates with Rad51 in the helix and is responsible for 









Figure 1.15 The Rad51 pathway for homologous recombination. Single strand binding protein 
(RPA) binds single stranded DNA (ssDNA) and is replaced by Rad52 that directs the attachment of 
Rad51 to ssDNA. Rad54 associates with Rad51-ssDNA helix and provides ATPase activity that is 
required for strand exchange with double stranded DNA (dsDNA) [Adapted from Kanti Bhattacharyya 





1.6 OBJECTIVES AND OUTLINE OF THE PRESENT STUDY 
The main aim of this study was to investigate the function of two trypanosome peptidases that 
have been identified as pathogenic factors during infection, namely TcoCATL and 
oligopeptidase B (Authié, 1994; Coetzer et al., 2008).  
 
The objectives identified to achieve the main aim of the study were: 
- The induction of RNAi targeting TcoCATL in T. congolense parasites using the p2T7Ti 
vector in order to assess the in vitro functions of the peptidase  
- To generate TcoCATL gene array knockout T. congolense parasites that would be 
used for mouse infections so as to study what role TcoCATL plays during infection 
and its function as a pathogenic factor 
- The induction of RNAi targeting OPB in T. congolense and T. brucei parasites using 
the p2T7Ti vector for analytical in vitro studies that would assess the importance of the 
peptidase for parasite division 
- The generation of OPB null mutants in T. congolense and T. brucei for in vivo studies 
in mice that would confirm previous in vitro studies used to define the role of OPB 
during infection as a pathogenic factor.  
 
Functional analysis of these two enzymes was achieved using RNAi that down-regulates 
mRNA transcribing for the genes of interest and gene knock-out that deletes the genes at 
DNA level. Oligopeptidase B was studied in the T. congolense procyclic forms using RNAi 
and in T. brucei bloodstream and procyclic forms using both RNAi and gene knock-out. 
TcoCATL was studied in the T. congolense bloodstream form in mice following a model that 
has been performed using TbCATL, the major cysteine peptidase in T. brucei (Abdulla et al., 
2008).  
  
The in vivo down regulation of TcoCATL using RNAi is described in Chapter 2. This required 
the identification of regions in the gene that are conserved across different trypanosome 
species and amplification of selected regions from genomic DNA. TbCATL from T. brucei was 
also included in the experiment as a positive control. PCR products obtained were cloned into 
the p2T7TI RNAi vector and recombinant plasmids used to transform a procyclic T. 
congolense inducible strain. A recombinant RNAi vector containing tubulin was used as a 
positive control for transformation (Inoue et al., 2002). Because TcoCATL expression is very 
low during the procyclic stage, selected clones targeted for TcoCATL RNAi were 
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differentiated into bloodstream forms and used to infect mice where RNAi was induced. 
Down-regulation was assessed using activity assays specific for TcoCATL. The generation of 
TcoCATL knock-outs in T. congolense was also attempted and regions flanking the TcoCATL 
gene array were successfully identified using Southern blot and sequencing. 
 
The in vitro down regulation of oligopeptidase B in T. congolense and T. brucei using RNA 
interference and generation of chicken anti-oligopeptidase B antibodies used to analyse the 
down-regulation of OPB is described in Chapter 3. Conserved regions in the gene were 
identified, cloned and transformed into respective parasite strains as described for TcoCATL 
in Chapter 2. Because oligopeptidase B is expressed at adequate levels in the procyclic form, 
it was not necessary to differentiate transformed parasites into bloodstream forms. RNAi was 
monitored using reverse transcription and quantitative PCR.  
 
The generation of oligopeptidase knock-outs in T. brucei bloodstream parasites is described 
in Chapter 4. Part of this work was carried out in the laboratory of Prof. Theo Baltz, 
Laboratoire de Microbiologie Cellulaire et Moléculaire et Pathogénicité, University Victor 
Segalen Bordeaux2, France as part of the South Africa (NRF) -France Scientific Cooperation 
research grant. Oligopeptidase B null mutants were confirmed using Southern and western 
blotting and in activity assays. Additional in vitro characterisation of null mutants was 
performed using microscopy and zymograms. In vivo characterisation of null mutants during 
mouse infections was also studied using activity assays and immunohistochemistry. Part of 
this work was accepted for publication (Kangethe et al., 2011).  
 
The results and conclusions pertaining to this study are discussed in Chapter 5.   
 
TcoCATL, TbCATL and OPB alignments are displayed in the appendix along with a 




IN VIVO DOWN-REGULATION USING RNA INTERFERENCE AND THE 
ATTEMPTED GENERATION OF KNOCK-OUTS OF TCOCATL, THE MAJOR 
CYSTEINE PEPTIDASE IN TRYPANOSOMA CONGOLENSE 
 
African bovine trypanosomosis, also referred to as nagana, is a parasitic disease that puts 
large numbers of cattle at risk in sub-Saharan Africa with estimated losses of up to five billion 
dollars annually (Swallow, 2000; Antoine-Moussiaux et al., 2009). Various methods have 
been employed to control the disease in cattle with chemotherapy the most commonly used 
mode of treatment (McDermott and Coleman, 2001). However, there has been a large 
increase in trypanosome resistance to most drugs (Delespaux and de Koning, 2007), and this 
has led to the exploration of other avenues for disease control, such as vaccine development 
(Antoine-Moussiaux et al., 2009). The first vaccines targeted the variable surface coat of the 
trypanosome parasite, but these only provide protection against homologous infections 
(Taylor and Mertens, 1999). There is therefore a need to target invariant antigens across 
heterologous infections when developing an effective vaccine (Authié et al., 1993b; Taylor, 
1998). Parasites lysed by the host immune system release a multitude of trypanosome 
products many of which are peptidases previously confined to the cytoplasm and lysosomes 
of live trypanosomes (Tizard et al., 1978). Trypanosome peptidases released during infection 
present an attractive target for the development of vaccines and chemotherapeutic agents as 
they are invariant (Taylor and Authié, 2004), and are also responsible for a variety of 
pathologies associated with the disease (McKerrow et al., 2006).  
Papain-family C1 cysteine peptidases, belonging to clan CA of cysteine peptidases, are 
released by trypanosomes during infection (Taylor and Authié, 2004; McKerrow et al., 2006; 
Antoine-Moussiaux et al., 2009). Family C1 is further divided into two major groups, cathepsin 
L (CATL)-like and cathepsin B (CATB)-like which in T. brucei are referred to as TbCATL and 
TbCATB respectively according to recently suggested nomenclature (Caffrey and Steverding, 
2009). CATL genes in kinetoplastid parasites occur in multiple copies with T. brucei CATL 
having more than 20 copies arranged in a long tandem array on the same chromosome 
(Mottram et al., 1989). T. cruzi CATL is encoded by more than 130 genes that are arranged in 
clusters found on two to four different chromosomes (Campetella et al., 1992; Caffrey and 
Steverding, 2009). L. chagasi and L. donovani both have five genes encoding CATL; also 
arranged in a tandem array with other Leishmania CATL (LmCATL) containing tandem arrays 
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of 8-20 genes (Caffrey and Steverding, 2009). In T. congolense, CATL genes (TcoCATL) 
exist as two kb gene units organised in a tandem array consisting of a 1332 bp pre-pro-
enzyme coding region, and a highly conserved intergenic region of approximately 660 bp 
(Kakundi, 2008). The sequence identity between these different copies of TcoCATL genes 
varies from 86% to 99% (Kakundi, 2008; Pillay et al., 2010). Multiple isoforms of CATL genes 
exist in L. mexicana (Mottram et al., 1997), T. cruzi (Lima et al., 2001) and T. congolense 
(Fish et al., 1995; Boulangé et al., 2001). LmCATL isoenzymes are expressed at different life 
cycle stages of the parasite, and have different substrate specificities (Mottram et al., 1997). 
TcoCATL gene expression is up-regulated at the bloodstream form stage of the parasite and 
although the TcoCATL isoenzymes CP1 and CP2 (congopain), have similar sequences (90% 
identical), they possess fundamental functional differences suggesting distinct roles for the 
enzymes in vivo (Boulangé et al., 2001).  
 
CATL and CATB have been implicated as virulence factors involved in parasite 
immunoevasion as well as cell and tissue invasion (Sajid and McKerrow, 2002) and have 
been evaluated as targets for various chemotherapeutic agents and inhibitors (Troeberg et 
al., 1999; Troeberg et al., 2000; Lecaille et al., 2002). In T. brucei infections in mice, CATB 
has been implicated in the degradation of host proteins and pathology (Mackey et al., 2004; 
Abdulla et al., 2008). Targeting TbCATB rather than TbCATL in vitro for RNAi led to 
endosome enlargement, defective cytokinesis after mitosis and death of parasites (Mackey et 
al., 2004). In vivo experiments targeting TbCATB and TbCATL using RNAi showed that the 
absence of TbCATB led to the clearance of parasites from the bloodstream when compared 
to controls which died within 13 days (Abdulla et al., 2008). Fifty per cent of the mice used in 
the experiment that targeted TbCATL for RNAi survived 60 days longer compared to controls 
(Abdulla et al., 2008). TbCATL was implicated in assisting parasite entry into the brain when 
using an in vitro model of the human blood-brain barrier (Abdulla et al., 2008).  
 
TcoCATL is the major cysteine peptidase in T. congolense bloodstream form parasites 
(Authié et al., 1992) and studies relating to its functions during infection have mainly 
concentrated on the role it plays in immunity (Authié et al., 1992; Authié et al., 1993a; Authié 
et al., 1993b; Authié, 1994; Authié et al., 2001). TbCATL has been implicated in assisting 
parasites cross the human blood-brain barrier (Abdulla et al., 2008), but assigning a similar 
function to TcoCATL in T. congolense  would be difficult given that T. congolense parasites 
are exclusively intravascular and do not leave the bloodstream of the host (Ojok et al., 2002). 
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To study what role TcoCATL plays in bloodstream form T. congolense physiology and host 
pathogenesis, RNAi knock-down parasites were generated and used in a mouse model to 
tract infection of parasites deficient in TcoCATL.  
 
For successful RNAi of CATL gene products in trypanosomes, it was necessary to induce 
RNAi during the bloodstream form stage of the parasite as opposed to the procyclic stage. 
This is because CATL activity is highest at the bloodstream stage of the lifecycle in both T. 
brucei and T. congolense parasites (Mbawa et al., 1991). For T. congolense, procyclic 
parasites were first transformed with the recombinant RNAi vector before converting the 
procyclic cultures into bloodstream parasites for infection of mice. This is because it is difficult 
to carry out the in vitro culture of T. congolense parasites and this technique has only recently 
been perfected (Coustou et al., 2010). TcoCATL RNAi transformed T. congolense 
bloodstream parasites were then used to infect mice and in vivo RNAi was induced using 
doxycycline as has been previously performed (Abdulla et al., 2008). An attempt was also 
made to knock-out the entire gene array of TcoCATL and TcoCATL-like genes. This required 
the identification of the regions flanking the TcoCATL tandem genes by Southern blot and 
sequencing and subsequently cloning these regions into knock-out vectors for transformation 
into T. congolense.   
 
2.1 MATERIALS AND METHODS 
2.1.1  Materials 
Molecular biology: ApaI, NotI, XbaI [reference for nomenclature see Roberts et al. (2003)], 
shrimp alkaline phosphatase (SAP), T4 DNA ligase and ligation buffer, 10 mM dNTP mix, X-
gal, IPTG, MassRuler™ DNA ladder mix, GeneJET™ plasmid miniprep kit, TransformAid™ 
bacterial transformation kit and Biotin DecaLabel™ DNA labeling kit were obtained from 
Fermentas (Vilnius, Lithuania). pGEM-T® vector was obtained from Promega (Madison, WI, 
USA). DNA clean and concentrator kit was obtained from ZymoResearch (Orange, CA, USA), 
E.Z.N.A® gel extraction kit from PEQlab (Erlangen, Germany) and Escherichia coli JM 109 
cells purchased from New England Biolabs (Ipawitch, MA, USA). FIREpol® Taq polymerase, 
10 x PCR reaction buffer and 25 mM MgCl2 were acquired from Solis Biodyne (Tartu, 
Estonia). Hybond™-N DNA binding membrane was obtained from Amersham 
(Buckinghamshire, UK). Molecular biology grade agarose was purchased from Conda 
laboratories (Madrid, Spain), ampicillin sodium salt from USB Corporation (Cleveland, OH, 
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USA), bacteriological agar and tryptone from Merck (Darmstadt, Germany). The yeast extract 
was purchased from Sigma (St. Louis, MO, USA). The recombinant p2T7Ti/BIP RNAi plasmid 
was a kind gift from Professor Theo Baltz (University of Victor-Segalen, Bordeaux 2, France). 
Recombinant cosmids containing T. congolense genomic DNA (strain IL3000) were provided 
by A. Boulangé (University of KwaZulu-Natal). 
 
Trypanosome culture: Minimum essential medium (MEM), Iscove’s Modified Dulbecco's 
Medium (IMDM), HEPES, sodium pyruvate, thymidine, adenosine, hypoxanthine, adenosine, 
bathocuprone sulfate acid, glutamine, 2-mercaptoethanol, hemin, proline, cis-aconitate, 
tetracycline, doxycycline hyclate and cyclophosphamide were obtained from Sigma (St. 
Louis, MO, USA). Heat inactivated goat serum and heat inactivated foetal calf serum (FCS) 
were obtained from Gibco (Paisley, UK). Filters (0.2 µm) were purchased from Pall (Ann 
Arbor, USA). Culture flasks (25 cm2) and 24-well plates were obtained from Corning (NY, 
USA). Amaxa Nucelofaction® transformation system and the Amaxa Basic Parasite 
Nucleofactor H solution 2 were obtained from Lonza (Levallois-Perret, France). T. congolense 
TRUM183:29-13 and T. brucei T7T-29 RNAi inducible parasite strains, and NOD/SCID mice 
were a gift from Professor Theo Baltz (University of Victor-Segalen, Bordeaux 2, France). 
Balb/C mice were obtained from the Bioresources Unit (BRU) Westville campus, University of 
KwaZulu-Natal (UKZN). Protocols using BALB/C mice were approved by the UKZN animal 
ethics committee (References 036/09/Animal and 069/10/Animal). Protocols using NOD/SCID 
mice were approved by the University of Bordeaux 2 animal care and use committee and the 
commission de genie genetique (Direction Generale de la Recherche et de l’Innovation).  
 
Peptide substrate: Benzyloxycarbonyl (Z)-Phe-Arg-7-amino-4-methylcoumarin (AMC) was 
obtained from Bachem (Torrance, CA, USA). Peptidase activity was measured using a 
FLUOstar optima spectrofluorometer (BMG Labtech, Offenburg, Germany).  
 
2.2.2 Methods 
2.2.2.1 Cloning conserved regions of TcoCATL and TbCATL genes for RNAi  
A pellet from 1 x 107 T. congolense (strain IL3000) or control T. b. brucei (strain Lister 427) 
parasites (Mackey et al., 2004; Abdulla et al., 2008), was used to extract genomic DNA as 
previously described (Medina-Acosta and Cross, 1993). Briefly, the pellet of parasites was 
resuspended in 1 ml of PBS (pH 7.2), centrifuged (1000 g, 10 min, RT), and the supernatant 
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removed. The pellet was dissolved in 150 µl TELT [50 mM Tris-HCl buffer, pH 8, 62.5 mM 
EDTA, pH9, 2.5 M LiCl, 4% (v/v) Triton X-100] and incubated for 5 min at RT. Phenol-
chloroform [150 µl; 1:1 (v/v)] was added and agitated for 5 min at RT. The aqueous and non-
aqueous phases were separated by centrifugation (13 000 g, 5 min, RT), and the upper 
phase added to 300 µl of absolute ethanol and centrifuged (13 000 g, 5 min RT) to precipitate 
genomic DNA. The supernatant was poured out and the DNA pellet washed with 1 ml of 
absolute ethanol before a last round of centrifugation (13 000 g, 5 min, RT). The ethanol was 
poured out and the pellet of genomic DNA incubated at 37ºC for 15 min to evaporate excess 
ethanol. The dry DNA pellet was dissolved in 100 µl of TE buffer [100 mM Tris-HCl buffer, pH 
7.5, 10 mM EDTA] containing 2 mg/ml RNAse and incubated at 37ºC for 45 min.  
 
DNA sequences coding for the CATL peptidase regions that are conserved between T. 
congolense [EMBL accession no. L25130, (Jaye et al., 1994)] and T. brucei [EMBL accession 
no. AJ297265, (Caffrey et al., 2001)] (see appendix 1) were selected to design primers that 
amplified a 320 bp fragment in T. congolense and a 300 bp fragment in T. brucei. The 
primers were designed to introduce an XbaI restriction site at each end of the PCR product 
for subcloning into the p2T7Ti RNAi plasmid. Primers for the 320 bp region in the TcoCATL 
region were: forward, (5’-GTGTCTAGAATGGCCGTTGCGG CGTGCTTT-3’) with an XbaI 
restriction site (underlined) and a start codon (bold); reverse, (5’-CTCTCTAGATTACCCAGT 
GGACACATTCAC-3’) with an XbaI restriction site (underlined) and a stop codon (bold). 
Primers for the 300 bp region in the TbCATL region were: forward, (5’-
GTGTCTAGAATGGCTATGGCAGCGTGCCTT-3’) with an XbaI restriction site (underlined) 
and a start codon (bold); reverse, (5’-CTCTCTAGATTAGCCAGTGGTTACGTTCAC-3’) with 
an XbaI restriction site (underlined) and a stop codon (bold). Extracted genomic DNA was 
used as a template for PCR. Briefly, the master mix for the PCR reaction contained sets of 
primers designed for TbCATL or TcoCATL (0.25 µM each) with T. brucei and T. congolense 
DNA respectively, 1 x PCR buffer, 2.5 mM MgCl2, 1 U Taq and 0.5 mM dNTPs in a total 
reaction volume of 25 µl. PCR amplification was started with a Taq polymerase activation 
step at 95ºC for 5 min, followed by 25 cycles of a DNA denaturing step at 95ºC for 30 s, a 
primer annealing step at 55ºC for 30 s, and an elongation step at 72ºC for 1 min. A final 
elongation step was added at the end of 25 cycles at 72ºC for 7 min. Each of the PCR 
products generated (5 µl) were analysed on a 1% (w/v) agarose gel in 1 x Tris-acetate-EDTA 
(TAE) buffer [40 mM Tris-HCl buffer pH 7.4, 20 mM glacial acetic acid and 0.1 mM EDTA] at 
80 V. The remaining 20 µl was purified using a DNA clean and concentrator kit before ligation 
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into the pGEM-T® vector (T-vector) using a ratio of 3:1 with 1 x ligation buffer and 1 U of T4 
DNA ligase at 4ºC overnight. 
 
The ligation mix was transformed into competent E. coli JM109 cells using the 
TransformAid™ bacterial transformation kit according to the manufacturer’s guide. E. coli 
JM109 cells (50 µl) from each transformation were plated on pre-warmed 2x YT plates [1.6% 
(w/v) tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl, 15 g/l bacteriological agar] containing 
100 µg/ml ampicillin, X-gal (20 µg/ml) and IPTG (10 µg/ml) before overnight incubation at 
37ºC. White colonies containing recombinant T-vector were selected for colony PCR using 
the respective CATL region primers described above and products analysed on a 1% (w/v) 
agarose gel in 1 x TAE buffer at 80 V. The positive clones were grown overnight in 5 ml of 2x 
YT medium before plasmid DNA extraction using the GeneJET™ plasmid miniprep kit 
according to the manufacturer’s specifications. Recombinant T-vector clones were 
sequenced [Segoli sequencing unit, International Livestock Research Institute (ILRI), Nairobi, 
Kenya].  
 
Recombinant Tco/TbCATL T-vector plasmid DNA was restricted using XbaI and the resulting 
320 bp (TcoCATL) and 300 bp (TbCATL) products were subcloned into XbaI linearised p2T7Ti 
RNAi vector (Fig. 2.1). Briefly, 50 µl of extracted plasmid DNA was restricted with XbaI to 
release T-vector cloned products and separated on a 1% (w/v) agarose gel in 1 x TAE buffer 
at 80 V. The 320 bp and 300 bp products were cut out of the gel and purified using the 
E.Z.N.A® gel extraction kit (PEQlab, Erlangen, Germany) according to the manufacturer’s 
manual and eluted in 30 µl of elution buffer. The p2T7Ti RNAi vector was also restricted with 
XbaI, purified and concentrated using the DNA clean and concentrator kit before treatment 
with 1 U of SAP for dephosphorylation to avoid the empty vector from re-ligating. The 
dephosphorylated vector and restricted fragments were then used in separate ligation 
reactions at a ratio of 1:3 (vector: insert) with 1 x ligation buffer and 1 U of T4 DNA ligase at 
4ºC overnight before transforming into E. coli JM109 cells and plating on 2x YT plates 
containing 100 µg/ml ampicillin. Positive clones were identified using colony PCR with insert 
primers and confirmed with restriction using XbaI. Recombinant p2T7Ti/TcoCATL (10 µg) was 
linearised with NotI in preparation for trypanosome transformation. 
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mixture electroporated using the Amaxa Nucelofaction® transformation system (program X-
100). The parasites were immediately transferred to 10 ml of pre-warmed complete MEM 
medium and grown for 24 h at 27ºC in a 25 cm2 flask. The 10 ml culture was added to 90 ml 
of selection medium containing bleomycin (2 µg/ml), neomycin (2.5 µg/ml) and hygromycin 
(6.25 µg/ml). Two ml per well of the diluted culture was dispensed in 24 well plates. Wells 
containing bleomycin/neomycin/hygromycin resistant parasites were expanded to 10 ml and 
selected for genomic DNA isolation and PCR using primers specific to bleomycin [forward, 
(5’-ATGGCCAAGTTGACCAGTGCC-3’) and reverse, (5’-TGCACGCAGTTGCCGGCCGGG-
3’)] to confirm integration of the p2T7Ti/TcoCATL plasmid. 
2.2.2.3 Assessment of infection and RNAi in mice using TcoCATL recombinant 
parasites 
Transformed procyclic clones positive for the bleomycin-resistance gene were converted into 
bloodstream form parasites as previously described (Coustou et al., 2010). Briefly, a 10 ml 
culture of procyclic parasites (107/ml) was pelleted by centrifugation (2000 g, 10 min, RT) and 
resuspended in incomplete MEM medium [MEM, Section 2.2.2 without foetal calf serum] for 2 
h or until epimastigotes could be observed adhering to the side of the flask. The incomplete 
MEM was supplemented with 10% (v/v) foetal calf serum and half the medium changed every 
two days. This was maintained until the epimastigote cultures were confluent on the inside 
surface of the flask. The supernatant (10 ml) containing a mix of metacyclic and epimastigote 
trypanosomes was pelleted (2000 g, 10 min, RT), resuspended in 100 µl of complete MEM 
and injected intraperitoneally into NOD/SCID (NOD.Cg-Prkdescid Il2rgtm1 Wjl/Szj) mice. 
Mice were monitored daily for parasitaemia and once parasites were observed, blood was 
drawn using cardiac puncture and used to infect two groups of 5 Balb/C mice [previously 
immune-suppressed with cyclophosphamide (200 mg/kg)]. When parasitaemia in both groups 
of mice reached an average level of between 5 x 106 and 1 x 107, one group was used to 
induce RNAi in vivo by the addition of doxycycline hyclate (1 mg/ml) to their drinking water as 
previously described (Abdulla et al., 2008). The mice were bled periodically from the tail to 
measure parasitaemia. An attempt to culture the bloodstream parasites in vitro in complete 
IMEM using bovine atrial endothelial (BAE) cells as feeder cells was made as previously 
described (Coustou et al., 2010).    
 
Blood samples were also collected and TcoCATL activity assayed by measuring the 
hydrolysis of Z-Phe-Arg-AMC. Briefly, a volume of mouse blood (determined by the level of 
parasitaemia in the different groups of mice) containing 1 x 105 parasites was diluted in 0.1% 
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(w/v) Brij-35 with 10 µg/ml SBTI, 1 µg/ml of pepstatin A, 1 mM AEBSF and 1 mM EDTA to 
make a total of 25 µl and incubated with 50 µl assay buffer [200 mM Tris-HCl buffer, pH 8, 10 
mM DTT and 0.02% (w/v) NaN3] for 10 min at 37°C. Aliquots were combined with substrate Z-
Phe-Arg-AMC (20 µM) and the fluorescence read (excitation at 360 nm and emission at 460 
nm) using a FLUOstar OPTIMA fluorescence microplate reader (BMG Labtech, Offenburg, 
Germany). For statistical analyses, values were expressed as means ± standard error of the 
mean (SEM). Significance levels were calculated by unpaired t tests and differences were 
considered significant at a *p value <0.001. 
 
2.2.2.4 Identification of TcoCATL and TbCATL 3’ and 5’ regions flanking the CATL 
tandem gene array 
The T. brucei tandem gene array was identified in the GeneDB database 
(http://www.genedb.org/genedb/tbrucei/, accessed 10-10-2007) and used to design primers 
that amplified regions flanking the 5’ and 3’ regions of the 19 kb TbCATL gene array (Table 
2.1) (see Appendix 1 for gene array). In T. congolense, selecting the flanking regions for 
TcoCATL was more difficult than in T. brucei because the T. congolense genome has not 
been fully sequenced. The gene that codes for TcoCATL is found in a multicopy array that is 
arranged in tandem repeats of more than 20 genes in units of ~2 kb when restricted with PstI 
(Fig. 2.2). A survey of TcoCATL genes in the GeneDB database 
(http://www.genedb.org/genedb/tcongolense/, accessed 10-10-2007) using the gene 
sequence for TcoCATL (congopain) [EMBL accession no. L25130, (Jaye et al., 1994)] 
revealed two contig sequences (0001218 and 0002521) that contained several TcoCATL 
regions (see Appendix 2 for alignment). The 0001218 contig contained a ~ 6.9 kb PstI 
fragment on the 5’ end of a TcoCATL gene (Fig. 2.2). This was taken as the 5’ flanking region 
of the gene array and two primers spanning a 997 bp section of the 5’ flanking region were 
designed (Table 2.1). In order to identify the 3’ flanking region of the TcoCATL array (Fig. 
2.2), a mix of cosmid vectors enriched for TcoCATL genes was restricted with PstI, separated 
on a 0.8% (w/v) agarose gel, transferred onto DNA binding nylon membrane using capillary 
action and cross-linked with UV before pre-hybridisation at 42 °C and subsequent 
hybridisation with biotin labelled probes generated from the TcoCATL ORF. Biontinylated 
probes were prepared by first perfoming a PCR using primers that amplified the pro-enzyme 
coding region at 1260 bp (Forward 5'-GCCGAATTCGCGTGCTCTGTTCCCGTGGCG-3’ and 
Reverse 5'-CAGGCG GCCGCCTCGTGCCGCACGAGCCGAGC-3'). The resulting 1260 bp 
TcoCATL product was labelled using the Biotin DecaLabel™ DNA labeling kit according to the 
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manufacturer’s instructions. Briefly, the PCR product was incubated with reaction buffer, 
biotin-labelled dNTPs from the kit and klenow fragment before incubation at 37°C overnight. 
The labelling mix was added to the nylon membrane, washed with stringency buffer [0.3 M 
NaCl, 30 mM sodium citrate, pH 7.0 containing 0.1% (v/v) SDS] and revealed using 0.06% 
(w/v) 4-chloro-1-naphthol, 0.0015% (v/v) H2O2 in Tris buffered saline (20 mM Tris–HCl, 
200 mM NaCl, pH 7.4).  A 2.3 kb region identified as the 3’ flanking region of the gene array 
and which did not correspond to 2 kb or multiples of 2 kb was cloned into a PstI restricted T-
vector and sequenced (Segoli sequencing unit, ILRI, Nairobi, Kenya). The resulting sequence 
was used to design primers that amplified a 600 bp region of the 3’ flanking region (Table 
2.1). 
Cp 1 Cp 2 Cp 3 Cp n
6.9 kb 2 kb 2 kb










Figure 2.2 Arrangement of TcoCATL genes within the TcoCATL gene array. Restriction of the 
array using a PstI site located on the 3’ end of each TcoCATL gene copy (indicated as Cp1, Cp2, 
Cp3...Cpn) gives a two kb fragment except for the two extreme ends of the array. The 5’ end gives a 
fragment of approximately 6.9 kb in size (GeneDB), and the 3’ end gives a fragment of approximately 
2.3 kb (Southern blot on Section 2.3.4).    
 
2.2.2.5 Cloning TcoCATL and TbCATL flanking regions into knock-out vectors  
T. congolense strain IL3000 and T. brucei 427 Lister  genomic DNA were extracted from in 
vitro cultures as previously described (Medina-Acosta and Cross, 1993) and used as a 
template for PCR with primers shown in Table 2.1. Products from the 3’ and 5’ flank sets 
were cloned into a T-vector as described in Section 2.2.2 and recombinant clones restricted 
with appropriate enzymes for which restriction sites had been incorporated into the primers in 
preparation for subcloning into knock-out vectors (Fig. 2.3). The fragments generated after 
using the primers shown in Table 2.1 were serially cloned into two different knock-out vectors 
pGLneo and pGLbla (Fig. 2.3). Briefly, recombinant 5’ and 3’ flank T-vector plasmid DNA was 
restricted using appropriate restriction sites that had been incorporated into the primers 
(Table 2.1), resulting in 3’ and 5’ flanking regions for both TbCATL and TcoCATL gene 
arrays. The resulting restriction products were serially subcloned into linearised pGLneo and 
pGLbla knock-out vectors (Fig. 2.3) as described in Section 2.2.2. Positive clones and the 
orientation of the flanks were confirmed using colony PCR with insert and vector primers 
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(Table 2.1). Ten µg from each of the four recombinant knock-out vectors was linearised with 
NotI in preparation for trypanosome transformation as described in Section 2.2.2. 
 
Table 2.1 Primer sequences designed to amplify the 5’ and 3’ flanking regions from T. 
congolense strain IL3000 and T. brucei 427 Lister for cloning into the knock-out vectors 
pGLneo and pGLbla. Each primer insert had either a NotI, XbaI or ApaI restriction site (underlined) for 
incorporation into the pGLneo or pGLbla knock-out plasmids. Neomycin and blasticidin resistance 
gene primers were used to confirm orientation of the 3’ flanking regions in the final recombinant 
plasmids. All primers were designed from database except for the TcoCATL 407 bp 3’ pair which was 
designed from sequencing data derived from a Southern blot (Section 2.3.4). 
Primer name and restriction site Sequence (5’→3’,restriction site underlined) 
TcoCATL 997 bp 5’ flank forward (NotI) CGGCGGCCGCCACGCGGGTGAAGGCCACACAACAG 
TcoCATL 997 bp 5’ flank reverse (XbaI)  CGTCTAGATATTCTTATTTTTAGCTCGTTCGTG 
TcoCATL 407 bp 3’ flank forward (ApaI) CGGGGCCCTTATTTTGTGTAAGCGTCTGGTGTA 
TcoCATL 407 bp 3’ flank reverse (ApaI) CGGGGCCCTTGGGCAGGCGTAAAAAGGGTACCC 
TbCATL 511 bp 5’ flank forward (NotI) CGGCGGCCGCATCGAGCCTGTACCGTCGTGAAGGT 
TbCATL 511 bp 5’ flank reverse (XbaI) CGTCTAGATTTTTTGTGTACAGCAGGAGTGACGG 
TbCATL 390 bp 3’ flank forward (ApaI) CGGGGCCCCTATTTTCTTTTTTCCTTTCC 
TbCATL 390 bp 3’ flank reverse (ApaI) CGGGGCCCGATATCAAAAGTAAGGTAAGCGC 
pGLbla forward primer (Bla Fw) TCAACAGCATCCCCATCTCT 

























Figure 2.3 Knock-out plasmids for deletion of the TcoCATL array in T. congolense strain IL3000. 
pGLbla provides blasticidin resistance to transformed parasites, whereas pGLneo confers neomycin 
resistance. The TcoCATL 3’ flank region in both plasmids uses an ApaI restriction site for sub-cloning 
and the 5’→3’ orientation of the insert is confirmed by using the 3’ reverse (Rv) insert primer with the 
Bla/Neo forward (Fw) vector primer. A single PCR product confirms that the orientation is correct. 
Inserts were also confirmed with PCR using 5’ flank and 3’ flank insert primers. 
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2.3  RESULTS 
2.3.1   Cloning conserved TcoCATL and TbCATL gene regions into the p2T7Ti RNAi 
vector  
Genomic DNA was isolated from T. brucei 427 Lister and T. congolense IL3000 strains (Fig. 
2.4, Panel A1, lanes 1 and 2) and used as a template for genomic DNA PCR with primers 
that had been designed to amplify conserved regions of the gene. A 300 bp product from T. 
brucei 427 Lister (TbCATL) and a 320 bp product from T. congolense IL3000 (TcoCATL) 
were successfully amplified (Fig. 2.4, A2, lanes 1 and 2) and ligated with the pGEM-T® vector 
(T-vector). Blue white screening and colony PCR (Fig. 2.4, B) revealed five T-vector 
recombinant clones each for TcoCATL (lanes 1-5) and TbCATL (lanes 6-10).  
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Figure 2.4 Amplification and T-vector cloning of CATL conserved gene regions from TbCATL 
and TcoCATL. M, MassRuler® DNA ladder mix / Middle Range® DNA ladder mix. A1: Genomic DNA 
isolated from 1, T. brucei 427 Lister; 2, T. congolense IL3000. A2: 1, 300 bp TbCATL PCR product 
using primers designed for T. brucei genomic DNA; 2, 320 bp TcoCATL PCR product using primers 
designed for T. congolense genomic DNA. B: Colony PCR for 1-5, TbCATL clones; 6-10, TcoCATL 
clones. C: T-vector miniprep 1, TbCATL; 2, TcoCATL; D: XbaI confirmatory restriction 1, 320 bp 
TcoCATL; 2, 300 bp TbCATL. All samples were analysed on a 1% (w/v) agarose gel and stained with 
ethidium bromide (3 µg/ml).  
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Plasmid minipreparations from each construct were prepared for TbCATL and TcoCATL (Fig. 
2.4, C, lanes 1 and 2) and confirmed using a restriction digest with XbaI giving a 320 bp for 
TcoCATL  and a 300 bp product for TbCATL (Fig. 2.4, D, lanes 1 and 2).  
 
Recombinant p2T7Ti/BIP was prepared for subcloning by releasing BIP (1000 bp) using XbaI 
(Fig. 2.5, A, lanes 1 and 2). XbaI linearised p2T7Ti vector (8000 bp) (Fig. 2.5, B1, lane 1 and 
C, lane 1) was ligated with 320 bp TcoCATL (Fig. 2.5, B2, lane 1) and 300 bp TbCATL (Fig. 
2.5, C, lane 2). 
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Figure 2.5 Subcloning of CATL conserved gene regions from TbCATL and TcoCATL into the 
p2T7Ti RNAi vector. M, MassRuler® DNA ladder mix. A: 1, Miniprep of recombinant p2T7Ti/BIP vector; 
2, XbaI restricted p2T7Ti releasing ~ 1000 bp BIP. B1: 1, gel purified XbaI restricted p2T7Ti vector. B2: 
1, 320 bp gel purified TcoCATL fragment from T-vector. C: 1, gel purified XbaI restricted p2T7Ti vector; 
2, 300 bp gel purified TbCATL fragment from T-vector. Products were analysed on a 1% (w/v) agarose 
gel and stained with ethidium bromide (3 µg/ml).  
 
Recombinant clones were selected for colony PCR using insert primers that amplified 320 bp 
products for recombinant p2T7Ti/TcoCATL (Fig. 2.6, A, lanes 1 -10) and 300 bp products for 
recombinant   p2T7Ti/TbCATL (Fig. 2.6, B, 1-3 and 5).  Successful subcloning into the p2T7Ti 
was confirmed using XbaI restriction for p2T7Ti/TbCATL showing a 300 bp band (Fig. 2.6, C1, 
lanes 1-3) and p2T7Ti/TcoCATL showing a 320 bp band (Fig. 2.6, C2, lane 1). Recombinant 
p2T7Ti/TcoCATL clones were selected for transformation into T. congolense TREU 183 29-13 
procyclic parasites and restricted with NotI (Fig. 2.6, D, lanes 1-4). Recombinant 
p2T7Ti/TbCATL clones were also selected for transformation into T. brucei T7T-29 
bloodstream form parasites and restricted with NotI (Fig. 2.6, D, lanes 5 - 8). Recombinant 
p2T7Ti/TcoCATL was successfully transformed into procyclic T. congolense TREU 183 29-13 
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clones. Several rounds of transformations using p2T7Ti/TbCATL and T. brucei T7T- 29 
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Figure 2.6 Subcloning of CATL conserved gene regions from TbCATL and TcoCATL into the 
p2T7Ti RNAi vector. M, MassRuler® DNA ladder mix in all gels. A: 1-10, Positive p2T7Ti/TcoCATL 
clones using 320 bp primers. B: 1-3 & 5, Positive p2T7Ti/TbCATL clones using 300 bp primers. C1: 1-
3, p2T7Ti/TcoCATL clones restricted with XbaI, releasing a 320 bp product (←). C2: 1, p2T7Ti/TbCATL 
clone restricted with XbaI, releasing a 300 bp product (←). D: 1-4, p2T7Ti/TcoCATL clones restricted 
with NotI; 5-8, p2T7Ti/TbCATL clones restricted with NotI in preparation for transformation. Products 
were analysed on a 1% (w/v) agarose gel and stained with ethidium bromide (3 µg/ml). 
 
T. congolense TREU 183 29-13 p2T7Ti/TcoCATL positive clones were expanded and 
genomic DNA isolated from cultures which was used in a PCR reaction with primers specific 
to bleomycin resistance. A 1000 bp product was detected in recombinant clones (Fig. 2.7, A, 
lanes 1 - 3) using the p2T7Ti plasmid as a positive control (Fig. 2.7, A, lane 4) and genomic 
DNA from untransformed T. congolense TREU 183:29-13 parasites as a negative control 
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Figure 2.7 Confirmation of p2T7Ti /TcoCATL insertion into T. congolense 29-13 strain IL3000 
procyclic parasites. M, MassRuler® DNA ladder mix. A: 1-3, 1000 bp PCR product amplified from 
phleomycin resistant clones using primers specific to phleomycin resistance; 4. p2T7Ti plasmid used as 
a positive control. B: 1, untransformed T. congolense 29-13 strain IL3000 procyclic parasites used as a 
negative control. Products were analysed on a 1% (w/v) agarose gel and stained with ethidium 
bromide (3 µg/ml). 
 
2.3.2  Conversion of T. congolense TREU 183 29-13 p2T7Ti/TcoCATL procyclic 
cultures into infective bloodstream forms 
Recombinant T. congolense procyclic cultures were converted to bloodstream form parasites 
because TcoCATL expression during the procyclic stage of the trypanosome life cycle is very 
low (Mbawa et al., 1991). Procyclic cultures were readily converted into epimastigote forms 
as evidenced by the presence of colonies of epimastigotes adhering to the tissue culture flask 
wall (Fig. 2.8, A). Metacyclic forms harvested from epimastigote cultures were then used to 
infect NOD mice and after several passages infected blood was used to infect Balb/C mice. 
Parasites were isolated from mouse blood and attempts to generate in vitro bloodstream form 
cultures did not result in long-term clones (Fig. 2.8, B). Bloodstream form parasites (T in Fig. 
2.8, B) were co-cultured with bovine aortic endothelial cells (E in Fig. 2.8, B) in IMEM which 
acted as feeder cells as has been previously described (Coustou et al., 2010). Cultures were 
passaged every 24 hours in an attempt to achieve stably dividing parasites. After 1 week of 
passages, most parasites would stop dividing and die (Fig. 2.8, B). The goat serum used to 
make complete IMEM was replaced with fresh goat serum as has been previously described 
(Coustou et al., 2010), but this did not change the outcome of the experiment. After several 
attempts, it was decided to induce RNAi in the mouse model as has been successfully done 























Figure 2.8 Conversion of recombinant p2T7Ti/TcoCATL T. congolense procyclic cultures into 
bloodstream forms (BSF). A: Generation of epimastigotes from procyclics P, procyclic T. congolense 
parasites; E, epimastigote T. congolense parasite colonies adherent to the flask wall; B. Establishment 
of BSF cultures from infected mouse blood; E, Bovine aortic endothelial cells (BAE); T, T. congolense 
BSF;  M, Residual mouse cells.    
 
2.3.3  RNAi induction in mice infected with T. congolense TREU183:29-13 
p2T7Ti/TcoCATL parasites 
When infection levels of T. congolense TREU 183 29-13 p2T7Ti/TcoCATL bloodstream form 
parasites in mice were at comparable levels, RNAi was induced in vivo by the addition of 
doxycycline in the drinking water of one group of mice (+Tet). The control group was provided 
with regular water (-Tet). Hydrolysis of Z-Phe-Arg-AMC by plasma samples was used to track 
the activity of TcoCATL in +Tet mice and -Tet mice (Fig. 2.9, A). TcoCATL activity in both 
groups of mice declined as time progressed (Fig. 2.9, A). Z-Phe-Arg-AMC hydrolysing activity 
in +Tet mice reduced at a faster rate than in -Tet mice (Fig. 2.9, A). Parasitaemia was also 
measured in both groups of mice. The +Tet mice had a higher parasitaemia peak on day 8 
but lower activity against Z-Phe-Arg-AMC than -Tet mice (Fig. 2.9, A and B). As the infection 
progressed in the two groups, parasitaemia in +Tet mice remained low but steadily increased 
in -Tet mice. Hydrolysis of Z-Phe-Arg-AMC in +Tet mice remained consistently lower than in  
-Tet mice. Parasitaemia on day 26 increased in both groups of mice and TcoCATL activity 
was almost as high as day one of induction. The experiment was stopped at this stage as the 
T. congolense TREU 183 29-13 p2T7Ti/TcoCATL parasites caused a chronic infection in the 
mice. Parasitaemia between day 9 and 20 was lower in +Tet mice when compared to -Tet 
mice with the most significant difference on day 18 (Fig. 2.9, B). The most significant 
difference in the hydrolysis of Z-Phe-Arg-AMC between the two groups of test mice was seen 

















































Figure 2.9 In vivo RNAi induction in mice infected with p2T7Ti/TcoCATL T. congolense 
bloodstream form parasites. Two groups of 5 mice each were infected with T. congolense strain 29-
13 parasites transformed with p2T7Ti/TcoCATL. RNAi targeting TcoCATL was induced in one group by 
providing 1 mg/ml of doxycycline in the drinking water (+Tet) and the other group was used as a 
control (-Tet). A: A volume of blood from different days of infection containing 1 x 105 parasites from 
RNAi induced mice (+Tet) and non-induced mice (-Tet) was resuspended in 0.1% (w/v) Brij-35 with 10 
µg/ml SBTI, 1 µg/ml of pepstatin A, 1 mM AEBSF and 1 mM EDTA to make a total of 25 µl and used in 
a fluorescence assay with Z-Phe-Arg-AMC. A mean of triplicate fluorescence readings was plotted 
relative to the highest reading as a percentage for each experiment ± SEM. B: Parasitaemia from RNAi 
induced mice (+Tet) was compared to non-induced control mice (-Tet). Each value is a mean of 5 mice 
± SEM. *p< 0.05 and **p<0.001 in comparison to the non-induced control mice. 
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2.3.4 Identification of sequences flanking the 3’ region of the TcoCATL gene array 
Selecting the flanking regions for TcoCATL was difficult as the gene that codes for this 
particular protein exists as a multicopy array that is arranged in tandem repeats of more than 
20 genes. A database search revealed a 6.9 kb fragment on the 5’ flank of the array with one 
PstI site on the 5’ end (Fig. 2.2). This fragment was used to design primers for the 5’ region 
flanking the TcoCATL gene array and used to amplify a 997 bp product from T. congolense 
IL300 genomic DNA (Fig. 2.12, A1). The 3’ region flanking the TcoCATL gene array could not 
be located in a database search, and required a different identification strategy. This involved 
restricting and probing recombinant cosmid vectors that have been enriched for TcoCATL 
genes (Boulangé et al., unpublished results). The TcoCATL recombinant cosmid vectors 
were restricted with PstI which targets the 3’ end of each TcoCATL gene in the array (Fig. 
2.2) 
Three recombinant cosmids enriched for TcoCATL genes were incompletely digested with 
PstI and separated on an agarose gel (Fig. 2.10, A) and a Southern blot performed (Fig. 2.10, 
B). Probing the Southern blot with biotin tagged full length TcoCATL revealed several bands 
that were 2 kb and multiples of 2 kb in size. A band at 2.3 kb was also identified (Fig. 2.10, 
B). The 2.3 kb band was cut out of the agarose gel (Fig. 2.10, C1, lane 2) and cloned into PstI 
restricted pGEM-T vector (Fig. 2.10, C1, lane 1). Recombinant 2.3 kb PstI fragment T-vector 
clones were identified using blue white screening and colony PCR with T7 and SP6 vector 
primers (Fig. 2.10, C2, lanes 1 and 2). A 1.9 kb insert previously cloned into the pGEM-T 
vector was used as a positive control (Fig. 2.10, C2, lane 3).  
 
A plasmid preparation of one of the recombinant clones (Fig. 2.10, C3, lane 1), was 
confirmed using PstI restriction (Fig. 2.10, C3, lane 2) releasing empty 3 kb pGEMT-vector 
and the 2.3 kb PstI fragment. The two recombinant clones (Fig. 2.10, C2, lanes 1 and 2), 
referred to as pstfrag3 and pstfrag4 respectively, were sequenced and results revealed a 
region of ~ 490 bp that did not align to the intergenic region in the TcoCATL gene array (Fig. 
2.11). This was expected as the both the 3’ and 5’ regions flanking the entire gene array are 
not expected to align with the TcoCATL intergenic region found within the array (as shown in 
Fig. 2.2). The region that did not align was identified as the 3’ region flanking the TcoCATL 




































Figure 2.10 Identification of the 3’ flanking region of the TcoCATL tandem gene array using Southern blotting. M, Middle Range® DNA 
ladder mix. A: 1-3, agarose (0.8%, w/v) gel electrophoresis of a mix of cosmid vectors enriched for TcoCATL genes restricted with PstI. Boxed 
area shows DNA that is not 2 kb or a multiple of 2 kb. B: 1 - 3, corresponding Southern blot of PstI restricted cosmid vectors enriched for 
TcoCATL genes developed with a biotinylated probe prepared from full length TcoCATL. Boxed area contains a 2.3 kb region identified as the 
3’ flank. C1: 1, PstI restricted gel purified pGEM T-vector prepared for ligation; 2, gel purified 2.3 kb PstI restricted fragment identified using 
Southern blotting. C2: 1-2, Positive 2.3 kb PstI fragment T-vector clones identified by colony PCR using vector primers; 3, 1.9 kb recombinant 
T-vector clone used as a positive control. C3: 1, Miniprep of positive 2.3 kb PstI T-vector clone; 2, confirmatory restriction of positive 2.3 kb PstI 
T-vector clone using PstI. Products were analysed on a 1% (w/v) agarose gel and stained with ethidium bromide (3 µg/ml). 
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TcoCATL      TTCCCAACGG GCAAGTGCGT GCAGTTCGGC GGCGCCGGTT CTGTCATCGC CTCGTGCGGC TCCAATAACC  1260 
pstfrag3_T7  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1    
pstfrag4_T7  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1    
 
TcoCATL      TCACACAGAT CGTCTAC--- ---CC-GTT- GAGCAG-C-T CCTGCAGCGG CTTCTCCATT CCGTTGACTG  1320 
pstfrag3_T7  ---CGGAGGG GGGGTGCGGG GGGATTCTTC TAGGAGTCGA CCTGCAGCGG CTTCTCCGTT CCGTTGACTG  67   
pstfrag4_T7  --------GG GGGGAAC--- ---CCTCCT- TAGAGGTCGA CCTGCAGCGG CTTCTCCGTT CCGTTGACTG  55   
 
TcoCATL      TGCCACTGGA CAAGTGCCTG CCCATCGTGG TTGGATCCGT GATGTATGAG TGCTCTGGCA AGGCTCCTAC  1390 
pstfrag3_T7  TGCCACTGGA CAAGTGCCTG CCCATTGTGA TTGGATCCGT GATGTACAAG TGCTCTGACA AGGCTCCTAC  137  
pstfrag4_T7  TGCCACTGGA CAAGTGCCTG CCCATTGTGA TTGGATCCGT GATGTATGAG TGCTCTGACA AGGCTCCTAC  125  
 
TcoCATL      GGAATCCGCC CGGCTCGTGC GGCACGAGTG AGGCTGCTGG CGGCGACTGC TTGCCGGCTT CACGTACCTC  1460 
pstfrag3_T7  GGAATCCGCC CGGCTCGTGC GGCACGAGTG AAGCTGCTGG CGGCGACTGC TTGCCGGCTT CACGTACCTC  207  
pstfrag4_T7  GGCATCCGCC CGGCTCGTGC GGCACGAGTG AGGCTGCTGG CGGCGACTGC TTGCCGGCTT CACGTACCTC  195  
 
TcoCATL      TCCCAAAACT CCAATTCTGT TTTGCTTTCA TGCACTGTTC CAGTGTATTT GCTTTCTCGG TGTGCGGCCA  1530 
pstfrag3_T7  TCCCGAAACT CCAATTCTGT TTTGCTTTCA TGCACTGTTC CAGTGTATTT GCTTTCTTGG TGTGCGGCCA  277  
pstfrag4_T7  TCCCGAAACT CCAATTCTGT TTTGCTTTCA TGCACTGTTC CAGTGTATTT GCTTTCTTGG TGTGCGGCCA  265  
 
TcoCATL      CACAATGCGG CTCTGAGGCG AGTGCGAGGG ACAC-GCGCC GCTCTGCCTC TCAGCACTTG CGGAGTGTGA  1599 
pstfrag3_T7  CACAATGCGG CTCTGAGGCG AGTGCGAGGG ACACCGCGCC GCTCTGCCTC TCAGCACTTG CGGAGTGTGA  347  
pstfrag4_T7  CACAATGCGG CTCTGAGGCG AGTGCGAGGG ACACCGCGCC GCTCTGCCTC TCAGCACTTG CGGAGTGTGA  335  
 
TcoCATL      GAAAGCTGCC CCAACCACGC GTGTGTCTTT CTATGCTTTT GCTTGTCCTT TTTCACCATT ACTTTTATTG  1669 
pstfrag3_T7  GAAAGCTGCC CCAACCACGC GTGTGTCTTT CTATGCTTTT ACTTGTCCTT TTTCTCCATT ACTTTTACTG  417  
pstfrag4_T7  GAAAGCTGCC CCAACCACGC GTGTGTCTTT CTATGCTTTT GCTTGTCCTT TTTCTCCATT ACTTTTACTG  405  
 
TcoCATL      GCTCACTGGC CACGGCCACA GTCGCTGCTG CCACTGACCC GCGAGGGGCG TCACACCCCG TCGGCCTTGT  1739 
pstfrag3_T7  GCTCACTGGC CACGGCAACA GTCGCTGCTG CCACTGACCC GCGAGGAGCG TCGCACCCCG TTGGCCTTGT  487  
pstfrag4_T7  GCTCACTGGC CGCGGCAACA GTCGCTGCTG CCACTGACCC GCGAGGAGCG TCGCACCCCG TTGGCCTTGT  475  
 
TcoCATL      TTTTTG---- ---------- ---------- ---------- ---------- ---------- ----------  1745 
pstfrag3_T7  TTTTTTTATT TTGTGTAAGC GTCTGGTATA AA-TTGTTTC GGACTTGCCC TCTCGTGACA AAGTTCTGTT  556  
pstfrag4_T7  TTTTTTTATT TTGTGTAAGC GTCTGGTGTA AAATTGTTTC GGACTTGCCC TCTCGTGAGA AAGTTCTGTT  545  
 
TcoCATL      ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745 
pstfrag3_T7  ATTCTCTTTC AGCTGTTTGG AAAACGTGTG CGTTTTT-GA AATGCAGGTT TATCTAAACA -GAGTTTATG  624  
pstfrag4_T7  ATTCTCTTTC AGCTGTTTGG AAAACGTGTG CGTTTTTTGA AATGCAGGTT TATCTAAACA AAAGTTTATG  615  
 
TcoCATL      ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745 
pstfrag3_T7  ATATCTACAC AGCCGTCCC- TCCCTCAGGT GGAATGGGCA ACGAGTTCCA TGG-CGTTTA TGGACTACTT  692  
pstfrag4_T7  ATATCTACAC AGCCGTCCCC TCCCTCAGGT GGAATGGGCA ACGAGTTCCA TGGGCGTTTA TGGATTACTT  685  
 
TcoCATL      ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745 
pstfrag3_T7  T-CGCTGATA TTA-GGGAA- CTTCCCTTTT TGTCGTGCTT TCGACC-GG- CAGA-GGACC TGAGAGTCA-  755  
pstfrag4_T7  TTCGCTGATA TTAAGGGAAA CTTCC-TTTT TGTCGTGCTT TCGACCCGGG CAGAAGGACC TGAGAGTCAA  754  
 
TcoCATL      ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745 
pstfrag3_T7  CGTATCATGT GGACGGGCTT C-TAACGATT GA-GG-GTGG AAACGTCATG G-TTAC-TTT GACCGCGGAC  820  
pstfrag4_T7  CGTATCATGT GGACGGGCTT CCTAACGATT GAAGGAATGG AAACGTCATG GCTTACCTTT GACCGCGGAC  824  
 
TcoCATL      ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745 
pstfrag3_T7  -ATAAAAATG GATTTCGTA- TCA-TTAAAG GCAGT--GAA TGGTAACCTT TT-ACGC-TG CC-A-GAA-T  880  
pstfrag4_T7  CATAAAA-TT GATTTCGTAA TCAATTAAGG GAAGTCCGAA GGGTACCCTT TTTACGCCTG CCCAAGAAAT  893  
 
TcoCATL      ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745 
pstfrag3_T7  C-TC-AGATT T--CTTTGAG TG-CTTG-AA GAAG-CCGAA GA-GAA-TCA C-TTC--GTG GCGGTATTGG  938  
pstfrag4_T7  CCTCCAAATT TTTCTTGGAG TGTTTTGGAG GAAGTCCGAA GAAGAACTCA CCTTCCCGTG GCGTAAATGG  963   
 
Figure 2.11 Sequence alignment of the two recombinant 2.3 kb PstI fragments pstfrag3 and 
pstfrag4 of the TcoCATL 3’ flanking region in a pGEM T-vector. Sequencing was performed using 
T7 and SP6 primers that are specific for the pGEM T-vector. Sequences in the dashed box show the 
alignment between the extreme 3’ end and the intergenic region of the T. congolense CATL array; 
sequences in the solid black box show the region downstream of the 3’ end of the TcoCATL array, 
which align in two different clones of the 2.3 fragment in the pGEM T-vector; sequences in the grey 
boxes show regions that were used to design forward and reverse primers for cloning into knock-out 
vectors. Sequences were aligned using Clustal W.  
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2.3.5  Cloning the 3’ and 5’ flanking regions from the TcoCATL gene array into knock-
out vectors pGLbla and pGLneo   
The 997 bp 5’-TcoCATL flanking region PCR product, 5’-TcoCATL (Fig. 2.12, A1, lane 1) and 
the 407 bp 3’-TcoCATL flanking region PCR product 3’-TcoCATL (Fig.2, 212, B1, lane 1) 
were both cloned into a pGEM T-vector. Blue white screening and colony PCR were used to 
identify recombinant clones of 997 bp for 5’-TcoCATL (Fig. 2.12, A2, lanes 1 - 4) and 407 bp 
3’ TcoCATL (Fig. 2.12, B2, lanes 1 - 10). Recombinant clones were confirmed with restriction 
using NotI and XbaI for 5’-TcoCATL giving a 997 bp fragment (Fig. 2.12, A3, lane 1) and ApaI 
for 3’-TcoCATL giving a 407 bp fragment (Fig. 2.12, B3, lane 1), in addition to empty pGEM 
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Figure 2.12 Amplification and T-vector cloning of 5’ and 3’ regions flanking the TcoCATL gene 
array. M, Middle Range® DNA ladder mix. A1: 1, 997 bp product flanking the 5’ region of the TcoCATL 
gene array. A2: 1 - 4, colony PCR identifying positive 5’ TcoCATL clones in T-vector. A3: 1, 
Confirmatory restriction of 997 bp 5’ TcoCATL fragment in T-vector with NotI and XbaI (←). B1: 1, 407 
bp product flanking the 3’ region of the TcoCATL gene array. B2: 1-10, colony PCR identifying positive 
3’ TcoCATL clones in T-vector. B3: 1, Confirmatory restriction of 407 bp 3’ TcoCATL fragment in T-
vector with ApaI (←). Products were analysed on a 1% (w/v) agarose gel and stained with ethidium 
bromide (3 µg/ml).  
 
 64
Vectors containing blasticidin resistance (pGLbla) and neomycin resistance (pGLneo) were 
prepared for ligation with 3’- and 5’- TcoCATL, or TbCATL (Section 2.3.6) (Fig. 2.13, A, lanes 
1 and 2). pGLbla (4566 bp) (Fig. 2.13, B, lane 1) and pGLneo (4995 bp) (Fig. 2.13, B, 2) were 
restricted with either NotI/XbaI or ApaI and before being serially ligated with the 997 bp 5’-
TcoCATL and 407 bp 3’-TcoCATL fragments (Fig. 2.12, A3, lane 1 and B3 lane 1). 
Recombinant clones were confirmed using insert primers for 997 bp 5’-TcoCATL (Fig. 2.13, C 
lane 3 for 5’-TcoCATL/pGLbla, and D lane 3 for 5’-TcoCATL/pGLneo) and 407 bp 3’-
TcoCATL (Fig. 2.13, C lane 2 for 3’-TcoCATL/pGLbla, and D lane 2 for 3’-TcoCATL/pGLneo).  
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Figure 2.13 Subcloning of 5’ and 3’ regions flanking the TcoCATL gene array. M, Middle Range™ 
DNA ladder mix. A: Vector preparation - 1, 4566 bp blasticidin resistance plasmid pGLbla (pGL1184); 
2, 4995 bp neomycin resistance plasmid pGLneo (pGL1217). B: Vector preparation - 1, NotI/XbaI or 
ApaI restricted pGLbla; 2, NotI/XbaI or ApaI restricted pGLneo. C: 1, 1074 bp product from 
recombinant pGLbla confirmed with PCR  using blasticidin forward primer with insert 3’ reverse primer; 
2, 407 bp product from recombinant pGLbla confirmed with PCR using 3’ insert primers; 3, 997 bp 
product from recombinant pGLbla confirmed with PCR using 5’ insert primers. D: 1, 1213 bp product 
from recombinant pGLneo confirmed with PCR  using blasticidin forward primer with insert 3’ reverse 
primer; 2, 407 bp product from recombinant pGLneo confirmed with PCR using 3’ insert primers; 3, 997 
bp product from recombinant pGLneo confirmed with PCR using 5’ insert primers. E: 1, 5970 bp NotI 
restricted recombinant TcoCATL/pGLbla; 2, 6399 bp NotI restricted recombinant TcoCATL/pGLneo. 
Products were analysed on a 1% (w/v) agarose gel and stained with ethidium bromide (3 µg/ml). 
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Orientation of the 3’-TcoCATL ApaI fragment in the 5’ → 3’ direction was confirmed using the 
3’-TcoCATL insert reverse primer and the vector primer resulting in a 1074 bp product for 3’-
TcoCATL/pGLbla (Fig. 2.13, C lane 1) and a 1213 bp product for 3’ TcoCATL/pGLneo (Fig. 
2.13, D, lane 1). Recombinant TcoCATL/pGLbla and TcoCATL/pGLneo clones were selected 
for transformation into T. congolense IL3000 procyclic parasites and restricted with NotI (Fig 
2.13, E, lanes 1 and 2), resulting in a 5970 bp fragment for TcoCATL/pGLbla and a 6399 bp 
fragment for TcoCATL/pGLneo. Several rounds of transformations using TcoCATL/pGLbla 
and TcoCATL/pGLneo with T. congolense IL3000 procyclic parasites did not yield any viable 
clones (results not shown). 
 
2.3.6 Cloning the 3’ and 5’ flanking regions from the TbCATL gene array into knock-
out vectors pGLbla and pGLneo   
Primers designed to amplify the 5’-TbCATL flanking region (5’-TbCATL) and the 3’ flanking 
region (3’-TbCATL) produced a 511 bp product for 5’-TbCATL (Fig. 2.14, A1, lane 1) and a 
390 bp product for 3’-TbCATL (Fig. 2.14, B1, lane 1), which were each cloned into a T-vector. 
Blue white screening and colony PCR were used to identify recombinant clones for 5’-
TbCATL at 511 bp (Fig. 2.14, A2, lanes 1 - 4) and 3’-TbCATL at 390 bp (Fig. 2.14, B2, lanes 
1 - 3). Recombinant clones were confirmed using NotI and XbaI restriction for 5’-TcoCATL 
giving 511 bp (Fig. 2.14, A3, lanes 1 - 4) and ApaI restriction for 3’-TcoCATL at 390 bp (Fig. 
2.14, B3, lanes 1 - 4).  
 
pGLbla and pGLneo prepared for ligation with 3’- and 5’- TbCATL (Section 2.3.5) and 
restricted with either NotI/XbaI or ApaI (Section 2.3.5), were serially ligated to the 511 bp 5’-
TbCATL fragment (Fig. 2.14, A3, lanes 1 - 4) and 390 bp 3’-TbCATL (Fig. 2.14, B3, lanes 1 - 
4) fragments. Recombinant clones were confirmed using insert primers for 511 bp 5’-TbCATL 
(Fig. 2.15, A1, lane 1 for 5’-TbCATL/pGLbla, and B, lane 3 for 5’-TbCATL/pGLneo) and 390 
bp 3’-TbCATL (Fig. 2.15, A1, lane 2 for 3’-TbCATL/pGLbla, and B, lane 2 for 3’-
TbCATL/pGLneo). Orientation of the 3’-TbCATL ApaI fragment in the 5’ → 3’ direction was 
confirmed using the 3’-TbCATL insert reverse primer and the vector primer resulting in a 
1057 bp product for 3’ TbCATL/pGLbla (Fig. 2.15, A2, lane 1) and a 1196 bp product for 3’-
TbCATL/pGLneo (Fig. 2.15, B, lane 1). Recombinant TbCATL/pGLbla (5467 bp) and 
TbCATL/pGLneo (5896 bp) clones were selected for transformation into T. brucei 427 Lister 
bloodstream form parasites and restricted with NotI (Fig 2.15, C, lanes 1 and 2).  Several 
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rounds of transformations using TcoCATL/pGLbla and TcoCATL/pGLneo with T. brucei 427 
Lister bloodstream form parasites did not yield any viable clones (results not shown). 
 








































Figure 2.14 Amplification and T-vector cloning of 5’ and 3’ regions flanking the TbCATL gene 
array. M, Middle Range™ DNA ladder mix. A1: 1, 511 bp product flanking the 5’ region of the TbCATL 
gene array. A2: 1-4, colony PCR identifying positive clones from A1 in T-vector. A3: 1 - 4, confirmatory 
restriction of clone from A2 with NotI and XbaI releasing a 511 bp product as indicated by the arrow 
(←). B1: 1, 390 bp product flanking the 3’ region of the TbCATL gene array. B2: 1-3, colony PCR 
identifying positive clones from B1 in T-vector. B3: 1, confirmatory restriction of clone from B2 with 
ApaI releasing a 390 bp product as indicated by the arrow (←). Products were analysed on a 1% (w/v) 
agarose gel and stained with ethidium bromide (3 µg/ml). 
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Figure 2.15 Subcloning of 5’ and 3’ regions flanking the TbCATL gene array. M, Middle Range® 
DNA ladder mix. A1: 1, 511 bp product from recombinant pGLbla confirmed with PCR using 5’ insert 
primers; 2, 390 bp product from recombinant pGLbla confirmed with PCR using 3’ insert primers. A2: 
1, 1057 bp product from recombinant pGLbla confirmed with PCR using blasticidin forward primer with 
insert 3’ reverse primer. B: 1, 1196 bp product from recombinant pGLneo confirmed with PCR using 
blasticidin forward primer with insert 3’ reverse primer; 2, 390 bp product from recombinant pGLneo 
confirmed with PCR using 3’ insert primers; 3, 511 bp product from recombinant pGLneo confirmed 
with PCR using 5’ insert primers. C: 1, 5467 bp NotI restricted recombinant TbCATL/pGLbla; 2, 5896 
bp NotI restricted recombinant TbCATL/pGLneo. Products were analysed on a 1% (w/v) agarose gel 
and stained with ethidium bromide (3 µg/ml). 
 
2.4 DISCUSSION 
Cysteine peptidases in Trypanosomes have been implicated in evading the host immune 
system, as well as cell and tissue invasion (Sajid and McKerrow, 2002). TcoCATL, the major 
cysteine peptidase in T. congolense, has been identified as an antigen during infection 
(Authié et al., 1992) and is one of the parasite products that is responsible for host 
pathologies associated with the disease (Authié et al., 2001). Experiments targeting the T. 
brucei cysteine peptidase brucipain (TbCATL), for RNAi revealed that mice infected with 
parasites that have down-regulated levels of TbCATL survived longer than mice infected with 
parasites that have regular levels of the peptidase (Abdulla et al., 2008). The same study 
demonstrated a role for TbCATL in helping T. brucei parasites cross the blood-brain barrier in 
an in vitro model (Abdulla et al., 2008). TbCATL targeted for RNAi as a control in the present 
study did not produce any transformed T. brucei T7T- 29 bloodstream parasites. Constructs 
targeting TcoCATL for RNAi on the other hand, were stably transformed into T. congolense 
TREU 183 29-13 procyclic cultures.  
 
TcoCATL is only expressed during the bloodstream stage of T. congolense parasites, 
(Boulangé et al., 2001), and it was therefore necessary to transform recombinant procyclic 
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cultures into bloodstream forms. This was successfully achieved using an approach that uses 
a transformation medium that converts T. congolense procyclic parasites into metacyclics 
(Coustou et al., 2010). The metacyclics were then used to infect SCID mice and after several 
passages were used to infect BALB/c mice. Mice infected with parasites and targeted for 
TcoCATL RNAi had lower numbers of parasites than mice that were non-induced for RNAi. 
This observation was consistent with experiments carried out for TbCATL RNAi (Abdulla et 
al., 2008). TcoCATL activity was assessed under RNAi induction using fluorescence readings 
generated by the hydrolysis of Z-Phe-Arg-AMC, the preferred substrate for cysteine 
peptidase activity in trypanosomes (Mbawa et al., 1991). Enzyme activity in mice where RNAi 
was induced with doxycycline was consistently lower compared to mice not supplied with 
doxycycline. This result indicated that the reduction in parasitaemia was as a direct result of 
the reduction of TcoCATL levels in RNAi induced parasites. It was noted that levels of activity 
in non-induced mice also declined. This was not surprising as the p2T7Ti vector used for RNAi 
has leaky T7 promoters that are still able to transcribe the double stranded silencing RNA as 
has been previously described (Inoue et al., 2002). This problem could have been alleviated 
by using a more stable RNAi vector such as pZJM used in RNAi experiments targeting 
TbCATL for RNAi (Abdulla et al., 2008). 
 
In addition, it was also noted that parasites escape downregulation between days 18-25 (Fig. 
2.9, panel B). This phenomenon has been described before where an essential genes 
targeted for RNAi can develop escape mutations as in the case of trypanothione in T. brucei 
(Ariyanayagam et al., 2005). Downregulation of trypanothione was associated with several 
fold increases in free glutathione and a decrease in growth rate, but parasites targeted for 
RNAi reverted to normal glutathione levels and regular growth rates after two weeks. This 
was attributed to point mutations within the gene coding for trypanothione, thus enabling 
parasites to escape downregulation (Ariyanayagam et al., 2005). Considering that TcoCATL 
is a gene coded for within an array of closely related variants (Pillay et al., 2010), it is quite 
possible that related TcoCATL variants are able to become active in the absence of the major 
cysteine peptidase. This anomally can be avoided by targeting multiple variants for RNAi 
when downregulating the activity of TcoCATL, or by knocking out the entire gene array as 
was attempted in this study. Survival data of mice could not be obtained as the T. congolense 
TREU 183 strain used for this experiment causes an infection with low virulence that does not 
kill the mice (Coustou et al., 2010).        
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Following successful down-regulation of TcoCATL using in vivo RNAi, an attempt was made 
to delete the TbCATL gene array in a T. brucei 427 Lister strain and the TcoCATL gene array 
in a T. congolense IL3000 strain. The 5’ and 3’ regions flanking the TbCATL gene array were 
readily identified on the GeneDB database where the full sequence of the T. brucei genome 
has been deposited (Berriman et al., 2005). The 5’ region flanking the TcoCATL gene array 
was also identified on the GeneDB database using contig 0001218 that contained a 6.9 kb 
PstI fragment bearing a TcoCATL gene copy on the 3’ end of the contig. The 3’ region 
flanking the TcoCATL gene array was unfortunately not available on the incomplete database 
and could only be identified using Southern blotting. Flanking regions for both gene arrays in 
T. brucei and T. congolense were successfully amplified and cloned into knock-out vectors. 
Attempts at transforming T. congolense and T. brucei parasites were, however, unsuccessful. 
This failure could be attributed to the size of the gene arrays in both parasites and several 
rounds of transformation would be required to get a successful clone. Because not all of the 
genes in the array code for active enzyme (Pillay et al., 2010), an alternative to knocking out 
all the genes in the array would be to delete smaller sections and targeting copies of the gene 
that code for the mature active enzyme.  
 
Cathepsin B (CATB) peptidases in trypanosomes belong to the same clan as CATL enzymes 
used in this study and are also inhibited by the diazomethane inhibitor Z-Phe-Ala-CHN2 
(Mackey et al., 2004). In vitro and in vivo treatment of parasites with Z-Phe-Ala-CHN2 was 
used to demonstrate the importance of cysteine peptidases for parasite survival (Scory et al., 
1999). Targeting TbCATB for RNAi rather than TbCATL in vitro validated the peptidase as a 
chemotherapeutic target resulting in endosome enlargement, defective cytokinesis and death 
of cultured parasites (Mackey et al., 2004). TbCATB is also necessary for degrading host 
proteins (Mackey et al., 2004). Targeting TbCATB for RNAi in vivo has a stronger phenotype 
than RNAi for TbCATL, and mice infected with parasites induced for TbCATB knockdown are 
able to survive and clear the infection (Abdulla et al., 2008). With RNAi absent in Leishmania, 
a closely related kinetoplastid, knockout experiments of the L. mexicana cysteine peptidase 
gene array (LmCPb) reduced macrophage infectivity by 80% indicating that LmCPb is 
important for virulence (Mottram et al., 1996).        
     
In conclusion, this work was able to confirm that TcoCATL is an essential peptidase in T. 
congolense parasites during infection by inducing RNAi in vivo in mice and indicated that 
reduction in expression of the gene resulted in lower numbers of parasites when compared to 
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mice infected with non-induced parasites. In T. brucei, targeting TbCATL negatively affects 
the ability of parasites to traverse the blood-brain barrier (Abdulla et al., 2008), thus reducing 
their virulence. Mice infected with parasites induced for TbCATL RNAi are therefore able to 
survive longer when compared to mice infected with parasites not induced for TbCATL RNAi 
(Abdulla et al., 2008). T. congolense, when compared to T. brucei, does not cross the blood-
brain barrier or traverse blood endothelial cells into tissue and is thus restricted to the 
vascular system (Ojok et al., 2002). Considering that TcoCATL is the major cysteine 
peptidase expressed during the bloodstream stage of the life cycle (Mbawa et al., 1992), it is 
very probable that it plays multiple roles and down-regulating its expression results in a 
reduction of parasite viability as shown here. To further develop this work, it would be ideal to 
attempt the infection of cattle or larger ruminants with parasites induced for TcoCATL RNAi to 
observe if this would affect the progression of the disease in a natural setting. A reduced 
amount of circulating TcoCATL may result in reduced pathology associated with invariant 
antigens released by infecting parasites as observed in trypanotolerant cattle. This could 
potentially lead to the development of a vaccine or drug that targets TcoCATL, and may be 
an important step in controlling the disease in Africa.  
 
It is difficult to generate TcoCATL null mutants for the sole reason that the gene exists in 
multiple copies. Fortunately this is not an obstacle in the case of OPB, another parasite 
peptidase that has been implicated as a pathogenic factor in trypanosomosis. TcoOPB and 
TbOPB occur as a single copy gene in the respective trypanosomes. Studies that employ 
gene disruption techniques targeting OPB are described in chapters 3 and 4.      
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CHAPTER 3  
IN VITRO DOWN REGULATION OF OLIGOPEPTIDASE B IN TRYPANOSOMA 
CONGOLENSE AND TRYPANOSOMA BRUCEI USING RNA INTERFERENCE 
 
The African trypanosome species T. congolense, T. vivax and T. b. brucei are responsible for 
trypanosomosis in cattle on the African continent with a 100-fold higher prevalence of the 
disease in livestock than in humans (Baral, 2010). The main immune response by the host 
towards infecting bloodstream form parasites is the production of antibodies against the 
variable glycoprotein coat (VSG) found on the surface of the parasite (Taylor and Rudenko, 
2006). Switching of VSG expression in a fraction of the infecting parasites occurs at genomic 
active expression sites as the host produces antibodies against the predominant VSG 
present in most of the circulating trypanosomes (Taylor and Rudenko, 2006). This ensures 
parasite survival and causes a new wave of parasitaemia that prolongs the disease (Pays et 
al., 2004). Trypanosomes are also able to evade the immune system by endocytosis of VSG-
antibody complexes, thereby protecting them from complement-mediated killing (Field et al., 
2009). Due to antigenic variation and immune evasion, it has been difficult to develop an 
effective vaccine that gives full protection. A more attractive option is to develop vaccines that 
target invariant antigens that do not change over the course of an infection (Antoine-
Moussiaux et al., 2009). When parasites undergo antibody mediated lysis, they release 
various compounds that could be responsible for pathogenesis in the mammalian host 
(Tizard et al., 1978). Trypanosome peptidases released during lysis present attractive 
vaccine targets as they are invariant and remain active in the host bloodstream (Tizard et al., 
1978; Antoine-Moussiaux et al., 2009). This has led to exploring the development of vaccines 
that target products released during an infection in a strategy referred to as an ‘anti-disease’ 
approach to reduce the symptoms of the disease rather than killing the parasite (Authié et al., 
2001; Schofield, 2007; Baral, 2010). 
 
Several pathogenic trypanosomal products such as cysteine peptidases (Authié et al., 1992; 
Boulangé et al., 2001; Pillay et al., 2010), paraglutamyl peptidases (Morty et al., 2006), 
aminopeptidases (Pillay, 2011) and oligopeptidases (Morty et al., 1999b; Morty et al., 2005a; 
Coetzer et al., 2008; Bastos et al., 2010) have been characterised following recombinant 
expression. The definitive in vitro functions of these peptidases have not been extensively 
studied and RNA interference (RNAi) provides a viable option to elucidate their functions in 
trypanosomes. RNAi is described as the targeted degradation of specific RNA transcripts by 
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homologous short interfering RNAs (siRNA) generated from longer exogenous RNA 
introduced into the parasite (Ullu et al., 2004; Balaña-Fouce and Reguera, 2007). Cysteine 
peptidases in T. brucei have been targeted for RNAi in vitro where the reduction of the 
cathepsin B-like peptidase (TbCATB) led to parasites having an enlarged endosome, 
impaired parasite division and ultimately death (Mackey et al., 2004). T. congolense parasites 
targeted for aminopeptidase RNAi in vitro displayed a growth defect in that they grew to a 
lower density when compared to parasites not targeted for aminopeptidase degradation 
(Pillay, 2011). Targeting the major surface peptidase in T. brucei procyclic parasites for RNAi 
led to a marked decrease in the release of transgenic variant surface glycoprotein 117 
(VSG117) (LaCount et al., 2003). T. brucei major surface peptidase mediated surface 
protease activity in T. brucei and inhibition of its activity with peptidomimetic collagenase 
inhibitors was toxic during the bloodstream stage of the life cycle (Bangs et al., 2001). 
Metacaspases are cysteine peptidases found in trypanosomes but absent in the mammalian 
host (Berg et al., 2010). This makes them attractive targets when designing drugs to combat 
trypanosomosis. T. brucei expresses five different metacaspases and experiments that target 
metacaspase 4 for RNAi and gene knockout showed that the peptidase is necessary for cell 
cycle  progression and virulence during infection in mice (Proto et al., 2011). It has also been 
shown that metacaspase 3 is responsible for processing metacaspase 4 once it is released 
by the parasite in a proteolytic cascade that generates a virulence factor necessary for 
establishing infections in the mammalian host (Proto et al., 2011).  
 
Oligopeptidase B (OPB) is a serine peptidase that has been identified as a possible 
pathogenic and virulence factor during infections caused by T. brucei (Morty et al., 1999b), T. 
congolense (Morty et al., 1999a), T. cruzi (Burleigh et al., 1997) and T. vivax (Coetzer et al., 
2008). In rats infected with trypanosomes, OPB has been shown to remain active in the host 
bloodstream where it has been implicated in the hydrolysis of peptide hormones such as 
atrial natriuretic factor (ANF) (Morty et al., 2005a) and gonadotropic releasing hormones 
(GnRH) (Tetaert et al., 1993). In order to study what role OPB plays in T. congolense 
(TcoOPB) and T. brucei (TbOPB) parasites in vitro, OPB knock-down parasites were 
generated using a tetracycline inducible RNAi vector (Inoue et al., 2002). RNAi was 
monitored using anti-TcoOPB antibodies raised in chickens, and by analysing the reduction of 




3.2   MATERIALS AND METHODS 
3.2.1 Materials 
Molecular biology: XbaI [for endonuclease nomenclature see, Roberts et al. (2003)], shrimp 
alkaline phosphatase (SAP), T4 DNA ligase, 10 mM dNTP mix, X-gal, IPTG, MassRuler® 
DNA ladder mix, Middle range® DNA ladder, GeneJET® plasmid miniprep kit, Transform Aid® 
bacterial transformation kit and RNase free DNAse were obtained from Fermentas (Vilnius, 
Lithuania). pGEM-T® vector was obtained from Promega (Madison, WI, USA). DNA clean and 
concentrator kit from ZymoResearch (Orange, CA, USA) and E.Z.N.A® gel extraction kit from 
PEQlab (Erlangen, Germany). Escherichia coli JM 109 and BL21 DE3 cells were purchased 
from New England Biolabs (Ipswich, MA, USA). FIREpol® Taq polymerase, 10 x PCR 
reaction buffer and 25 mM MgCl2 were acquired from Solis Biodyne (Tartu, Estonia). 
Molecular biology grade agarose was purchased from Conda laboratories (Madrid, Spain), 
Ampicillin sodium salt from USB Corporation (Cleveland, OH, USA), bacteriological agar and 
tryptone from Merck (Darmstadt, Germany) and kanamycin sulfate was obtained from Fluka 
(Buchs, Switzerland). The yeast extract was purchased from Sigma (St. Louis, MO, USA). 
The recombinant p2T7Ti/BIP RNAi plasmid was a kind gift from Professor Théo Baltz 
(University of Victor-Segalen, Bordeaux 2, France). Full length oligopeptidase B from T. 
congolense in pET28a was sourced from work previously done by Laura Huson and Lorelle 
Bizaaré in our laboratory (Huson, 2006; Bizaaré, 2008). 
 
Recombinant TcoOPB purification and peptide hydrolysis: Imidazole and His-select® 
nickel affinity column was purchased from Sigma (St. Louis, MO, USA). Amicon Centriprep® 
concentration filters were obtained from Millipore (Bedford, MA, USA) and the 2 mg albumin 
standard was obtained from Thermo Fisher scientific (Rockford, IL, USA). The peptide 
substrate benzyloxycarbonyl (Z)-Arg-Arg-7-amino-4-methylcoumarin (AMC) was obtained 
from Bachem (Torrance, CA, USA).  
 
Chicken IgY preparation and ELISA: Freund’s complete and incomplete adjuvants, rabbit 
anti-IgY coupled to HRPO and bovine serum albumin (BSA) were purchased from Sigma (St. 
Louis, MO, USA). Polyethylene glycol (PEG) 6000 was purchased from Merck (Darmstadt, 
Germany) and NuncMaxisorb® 96 well immuno plates were obtained from Thermo Fisher 
Scientific (Roskilde, Denmark). AminoLink® matrix was purchased from Pierce (Rockford, IL, 
USA). 2, 2’-Azinobis [3-ethyl-2, 3-dihydrobenzithiazole-6-sulfonate] (ABTS) was obtained 
from Roche (Mannheim, Germany).  
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Reverse transcription PCR and quantitative PCR (RT-qPCR): TriFast® reagent for RNA 
extraction was obtained from PEQlab (Erlangen, Germany), transcriptor high fidelity cDNA 
synthesis kit from Roche (Mannheim, Germany), and DNAse 1 from Fermentas (Vilnius, 
Lithuania). The 2x SensiMix SYBR® Green Kit for qPCR was obtained from Quantace 
(Watford, England). The Rotor-Gene® 6000 real time thermal cycler with Rotor-gene® 6000 
series software was from Corbett life science (Concorde, NSW, Australia).  
 
3.2.2 METHODS 
3.2.2.1 Recombinant expression and purification of full length TcoOPB 
Terrific broth [12 g/l tryptone, 24 g/l yeast extract, 0.4% (v/v) glycerol, 2.31 g/l KH2PO4 and 
12.54 g/l K2HPO4; 200 ml] (Tartof and Hobbs, 1987), containing 34 µg/ml of kanamycin was 
inoculated with a colony of recombinant E. coli BL21 DE3 cells containing the full length T. 
congolense oligopeptidase B gene (TcoOPB) in the pET28a expression vector and grown 
overnight at 37°C. Bacterial cells were harvested by centrifugation (5000 g, 15 min, RT) and 
resuspended in lysis buffer [PBS pH 7.4, Triton X-100 1% (v/v), 1 mg/ml lysozyme] at RT for 
10 min before freezing at -20°C. Frozen samples were thawed and sonicated 4 times for 10 s 
each and separated by centrifugation (3000 g, 15 min, RT). The supernatant containing the 
soluble fraction and the pellet containing the insoluble fraction were separated on a 10% 
SDS-PAGE gel to confirm expression alongside untransformed E. coli BL21 DE3 cells for 
comparison. His-select® nickel affinity resin (1 ml) was placed in a 10 ml chromatography 
column, washed with 2 column volumes of deionised water and equilibrated with 5 column 
volumes of equilibration buffer (50 mM NaH2PO4, 500 mM NaCl, 10 mM imidazole, pH 6.8). 
Bacterial lysate (10 ml) containing soluble recombinant TcoOPB was added to the 
equilibrated resin and mixed using an end-over-end rotator at 4°C overnight. The unbound 
fraction was collected and the resin allowed to settle before washing with equilibration buffer 
until an A280 reading of < 0.02 was obtained. The bound fraction was recovered using 10 ml of 
elution buffer (50 mM NaH2PO4, 500 mM NaCl, 250 mM imidazole, pH 8). The nickel resin 
column was regenerated using 2 column volumes of deionised water, 5 column volumes of 6 
M guanidine-HCl, another 3 column volumes of deionised water and a final 3-column volume 
wash with equilibration buffer before storage at 4°C in 30% (v/v) ethanol. The unbound 
fraction, washes and eluted fraction were analysed on a 10% SDS-PAGE gel for efficiency of 
purification and purity of recombinant TcoOPB. Purified recombinant TcoOPB fractions were 
pooled and concentrated using Amicon Centriprep® concentration filters according to the 
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manufacturers’ specifications. The final concentration of TcoOPB was determined using 
dilutions of an albumin standard (doubling dilutions from 1.5 to 0.125 mg/ml) separated on a 
10% SDS-PAGE gel alongside the purified protein sample. 
 
3.2.2.3 Z-Arg-Arg-AMC hydrolysis by recombinant T. congolense oligopeptidase B   
Serial dilutions of TcoOPB (0.5 to 0.0005 µg/ml) were made in 1 ml of 0.1% (w/v) Brij-35 and 
incubated with assay buffer [200 mM Tris-HCl buffer, pH 8, 10 mM DTT and 0.02% (w/v) 
NaN3] for 10 min at 37°C. Aliquots were combined in triplicate with the Z-Arg-Arg-AMC 
substrate (20 µM) and the fluorescence measured (excitation at 360 nm and emission at 460 
nm) using a FLUOstar OPTIMA fluorescence microplate reader (BMG Labtech, Offenburg, 
Germany). A sample comprising 0.1% (w/v) Brij-35 and assay buffer without enzyme was 
used as a negative control. 
 
3.2.2.4 Anti-TcoOPB antibody preparation and ELISA 
Anti-TcoOPB antibodies were raised in chickens. Briefly, four chickens were immunised 
intramuscularly at two different sites in the breast muscle at week 0 with 100 µg of 
recombinant TcoOPB emulsified with Freund’s complete adjuvant in a 1:1 (v/v) ratio. Booster 
immunisations were performed at weeks 2, 4, 6 and 10 with 100 µg with TcoOPB emulsified 
in Freund’s incomplete adjuvant in a 1:1 (v/v) ratio. Eggs were collected prior to the first 
immunisation to serve as pre-immune controls. Eggs were collected for a period of 14 weeks 
and stored at 4°C. Chicken immunoglobulin Y (IgY) was isolated from the eggs as previously 
described (Goldring and Coetzer, 2003). Briefly, the egg yolk was separated from the 
albumin, removed from the yolk sac and the yolk volume measured. Twice the yolk volume of 
isolation buffer [100 mM NaH2PO4, 0.02% (w/v) NaN3, pH 7.6] was added and 3.5% (w/v) of 
PEG 6000 dissolved by gentle stirring. The solution was centrifuged (4420 g, 30 min, RT) and 
filtered through absorbent cotton wool. The PEG 6000 concentration was increased to 12% 
(w/v) by the addition of 8.5% (w/v) of PEG, dissolved and centrifuged as before to pellet the 
IgY. The pellet was re-dissolved  in a volume of isolation buffer equal to the original yolk 
volume and 12% (w/v) PEG was added, dissolved and the final pellet collected by 
centrifugation (12 000 g, 10 min, RT). The final IgY pellet was dissolved in 1/6th of the original 
yolk volume using isolation buffer containing 0.1% (w/v) NaN3. The IgY concentration was 
determined by measuring the A280 of a 1:50 dilution of IgY and using an extinction coefficient 
of  E280 nm
1 mg/ml=1.25  (Goldring and Coetzer, 2003). 
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Recombinant TcoOPB was coupled to AminoLink® coupling gel for the affinity purification of 
antibodies produced against the protein. AminoLink® coupling gel was diluted 1:3 in coupling 
buffer [100 mM NaH2PO4, 0.05% (w/v) NaN3, pH 7.4] to a total of 4 ml, pipetted into a 
chromatography column, washed three times with 10 ml of coupling buffer and allowed to 
settle. Recombinant TcoOPB (3 mg, purified as described in Section 3.2.2) was added to the 
column with 50 µl of 1 M NaCNBH3, mixed on an end-over-end rotator (2 h, RT) and left to 
stand (4 h, RT). The gel was washed with one column volume of quenching buffer (1 M Tris-
HCl, pH 7.4) and incubated on an end-over-end rotator (30 min, RT) with one column volume 
of quenching buffer containing 50 mM NaCNBH3. The coupled gel was allowed to settle and 
washed with washing buffer (1 M NaCl) until an A280 reading of zero was obtained followed by 
a final wash with coupling buffer before storage at 4ºC. Isolated IgY was pooled into three 
fractions comprising of pool 1 (weeks 2 - 6 for all 4 immunised chickens), pool 2 (weeks 7 - 
12 for chickens 1 and 3) and pool 3 (weeks 7 -12 for chickens 2 and 4) and filtered through 
Whatman no. 1 filter paper. The TcoOPB affinity column was equilibrated with washing buffer 
[100 mM NaH2PO4, 0.05% (w/v) NaN3, pH 6.5] and each IgY pool cycled separately through 
the column overnight (10 ml/h, RT) to allow antibody binding to the immobilised recombinant 
protein. The column was washed with washing buffer until an A280 nm reading of ~ 0 was 
achieved to remove unbound IgY. Bound IgY was eluted with low pH elution buffer [100 mM 
glycine-HCl, 0.02% (w/v) NaN3, pH 2.8] in fractions of 900 µl in 1.5 ml tubes containing 100 µl 
of neutralisation buffer [1 M NaH2PO4, 0.02% (w/v) NaN3, pH 8.5]. Elution was monitored at 
A280 nm using 900 µl of elution buffer and 100 µl of neutralisation buffer as a blank. Fractions 
containing affinity purified IgY were pooled and 10% (w/v) NaN3 added to a final 
concentration of 0.1% (w/v) before storage at 4ºC. The affinity column was regenerated using 
12 column volumes of washing buffer. 
 
Antibody production in chickens immunised with TcoOPB was monitored using enzyme linked 
immunoadsorbent assays (ELISAs) as has been previously described (Huson et al., 2009). 
Recombinant TcoOPB in PBS (1 µg/ml) was used to coat the wells of a Nunc Maxisorb® 
microtitre plate (150 µl/well) and left overnight at 4°C. ELISA plates were patted dry on tissue 
paper to remove residual coating solution and 200 µl/well of blocking buffer [0.5% (w/v) BSA-
PBS] was added and incubated (1 h, 37°C) to prevent non-specific binding of antibodies. 
Plates were washed three times with 0.1% (v/v) Tween-20-PBS and patted dry again. IgY 
isolated from eggs collected weekly from all 4 chickens was serially diluted in blocking buffer 
from 100 µg/ml to 0.01 µg/ml and 100 µl/well of each dilution incubated in triplicate for 2h at 
 77
37°C. Affinity purified IgY from all three pools was also serially diluted in blocking buffer from 
100 µg/ml to 0.0001 µg/ml and 100 µl/well of each dilution incubated in triplicate for 2h at 
37°C. All plates were washed three times with 0.1% (v/v) Tween-20-PBS and patted dry 
before adding rabbit anti-chicken IgY-HRPO labelled secondary antibody diluted at 1: 20 000 
in blocking buffer and incubated (120 µl/well, 1 h, 37°C). The plates were given a final wash 
with 0.1% (v/v) Tween-20-PBS, patted dry and ABTS/H2O2 chromogen-substrate solution 
[0.05% (w/v) ABTS, 0.0015% (v/v) H2O2, 0.15 M citrate-phosphate buffer, pH 5] added and 
left to develop in the dark for 20 min before the absorbance was read at 405 nm using a 
FLUOstar OPTIMA microplate reader (BMG Labtech, Offenburg, Germany).  
.  
3.2.2.5 Cloning conserved gene regions of TcoOPB and TbOPB into the p2T7Ti RNAi 
plasmid vector and transformation of parasites 
Cloning was carried out as described before for TcoCATL and TbCATL in Section 2.2.2. 
Briefly, a pellet of parasites either from T. congolense (strain IL3000) or T. b. brucei (strain 
Lister 427) was resuspended in 1 ml of PBS (pH 7.2), centrifuged (1000 g, 10 min, RT), and 
the supernatant removed. The pellet was dissolved in 150 µl TELT [50 mM Tris-HCl buffer, 
pH 8, 62.5 mM EDTA, pH9, 2.5 M LiCl, 4% (v/v) Triton X-100] and incubated for 5 min at RT. 
Phenol-chloroform [1:1 (v/v); 150 µl] was added and the mixture placed on a rocker for 5 min 
at RT. The aqueous and non-aqueous phases were separated by centrifugation (13 000 g, 5 
min, RT), and the upper phase added to 300 µl of absolute ethanol and centrifuged (13 000 g, 
5 min RT) to precipitate genomic DNA. The supernatant was poured out and the DNA pellet 
washed with 1 ml of absolute ethanol before a last round of centrifugation (13 000 g, 5 min, 
RT). The ethanol was poured out and the pellet of genomic DNA incubated at 37ºC for 15 min 
to evaporate excess ethanol. The dry pellet of DNA was dissolved in 100 µl of TE buffer [100 
mM Tris-HCl buffer, pH 7.5, 10 mM EDTA] with RNase (2 mg/ml) and incubated at 37ºC for 
45 min.  
 
DNA sequences coding for OPB gene regions that are conserved between T. brucei [EMBL 
accession no. AF078916, (Morty et al., 1999b)] and T. congolense [Contig_0000238 GeneDB 
database [http://www.genedb.org/genedb/tcongolense/, accessed 10-10-2007, (Huson, 
2006)] (see Appendix 1) were selected to design primers that amplified a 489 bp fragment in 
T. congolense and a 492 bp fragment in T. brucei. The primers were designed to introduce an 
XbaI restriction site at each end of the PCR product for subcloning into the p2T7Ti RNAi 
plasmid. Primers for the 489 bp region in the TcoOPB gene were forward (5’-
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CTGTCTAGAATGTACGCCATTGCAGTGCGC-3’) with an XbaI restriction site (underlined) 
and a start codon (bold), and reverse (5’-CACTCTAGATTAGTCCGTCTTGAGCTCCCG-3’) 
with an XbaI restriction site (underlined) and a stop codon (bold). Primers for the 492 bp 
region in the TbOPB gene were forward (5’-GATTCTAGAATGATATATGCTATTGCGCAC-3’) 
with an XbaI restriction site (underlined) and a start codon (bold), and reverse (5’-
CACTCTAGATTAGTCTGTCTTGAGTTCACG-3’) with an XbaI restriction site (underlined) 
and a stop codon (bold). Extracted genomic DNA was used as a template for PCR as 
described in Section 2.2.2 and the resulting PCR products were ligated into the pGEM-T® 
vector (T-vector) using a ratio of 3:1 with 1 x ligation buffer and 1 U of T4 DNA ligase at 4ºC 
overnight. The ligation mix was transformed into competent E. coli JM109 cells using the 
Transform Aid™ bacterial transformation kit according to the manufacturer’s guide. 
Recombinant T-vector clones were selected as described in Section 2.2.2 and sequenced 
[Segoli sequencing unit, International Livestock Research Institute (ILRI), Nairobi, Kenya].  
 
Recombinant OPB T-vector plasmids were restricted using XbaI and the resulting 489 bp 
(TcoOPB) and 492 bp (TbOPB) products were subcloned into the XbaI linearised p2T7Ti 
RNAi vector. Briefly, 50 µl of extracted plasmid DNA was restricted with XbaI to release the T-
vector cloned products and separated on a 1% (w/v) agarose gel in 1 x TAE buffer at 80 V. 
The 320 bp and 300 bp products were cut out of the gel and purified using the E.Z.N.A® gel 
extraction kit according to the manufacturer’s manual and eluted in 30 µl of elution buffer. The 
p2T7Ti RNAi vector was also restricted with XbaI, cleaned and concentrated using the DNA 
clean and concentrator kit before treatment with 1 U of SAP for dephosphorylation to avoid 
the empty vector from re-ligating. The dephosphorylated vector and restricted fragments were 
used in separate ligation reactions at a ratio of 1:3 (vector: insert) with 1 x ligation buffer and 
1 U of T4 DNA ligase at 4ºC overnight before transforming into E. coli JM109 cells and plating 
on 2x YT plates containing 100 µg/ml ampicillin. Positive clones were identified using colony 
PCR with insert primers and confirmed with restriction using XbaI. Recombinant 
p2T7Ti/TbOPB, p2T7Ti/TcoOPB, and p2T7Ti/TcoTUB used as a positive control (10 µg each) 
were linearised with NotI and transformed into procyclic T. brucei T7T 29 and T. congolense 
TRUM 183 29-13 cultures respectively as previously described in Section 2.2.3. Positive 
trypanosome clones were selected for genomic DNA isolation and PCR using primers 
specific to bleomycin [forward (5’-ATGGCCAAGTTGACCAGTGCC-3’) and reverse (5’-
TGCACGCAGTTGCCGGCCGGG-3’)] to confirm integration of the p2T7Ti/TbOPB, 
p2T7Ti/TcoOPB and p2T7Ti/TcoTUB plasmids.  
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3.2.2.6 Western blot analysis of PCR positive clones 
A pellet of 2 x 106 parasites from each positively identified culture was washed twice with 
PBS (pH 7.2) and resuspended in 50 µl of lysis buffer [10 mM EDTA, 1% (v/v) Triton X-100, 
20 mM Tris-HCl buffer, pH 7.2, containing 10 µM L-trans-epoxysuccinyl-leucylamido(4-
guanidino)butane (E64)], an equal volume of reducing gel loading buffer was added and 
samples boiled for 10 min. Lysates generated  from ~ 5 x 105 parasites (25 µl) were 
separated per well on a 10% SDS-PAGE gel (Laemmli, 1970) at 18 mA per gel, blotted on 
nitrocellulose (Towbin et al., 1979) and probed with chicken anti-TcoOPB antibodies (50 
µg/ml dilution). Rabbit anti-chicken IgG-HRPO labelled secondary antibodies were used at 
1:10000. Blots were developed using 0.06% (w/v) 4-chloro-1-naphthol, 0.0015% (v/v) H2O2 in 
Tris buffered saline (20 mM Tris-HCl, 200 mM NaCl, pH 7.4). 
 
3.2.2.7  RNA analysis of PCR positive clones 
RNA was isolated from transformed trypanosome cultures using the TriFast™ reagent based 
on a method described by Chomczynski and Sacchi (1987). Briefly, 1 x 107 parasites were 
centrifuged (1000 g, 10 min, RT) and the pellet resuspended in 1 ml of TriFast® reagent after 
discarding the supernatant. Parasites were dissolved using a pipette and kept at room 
temperature for 5 min. Chloroform (0.2 ml) was mixed in for 15 s and incubated (10 min, RT). 
This was followed by centrifugation (12 000 g, 5 min, RT) to separate the mixture into a lower 
phenol-chloroform phase and an upper aqueous phase that contained the RNA. The upper 
aqueous phase was transferred into a new 1.5 ml RNase free tube and RNA precipitated by 
the addition of 0.5 ml isopropanol. The samples were kept on ice for 15 min before 
centrifugation (12 000 g, 10 min, 4ºC). An RNA pellet was observed at the bottom of the tube 
after the supernatant was removed and this was washed twice with 75% (v/v) ethanol 
followed by centrifugation (12 000g, 10 min, 4ºC). The ethanol was poured off, the pellet air 
dried and the RNA pellet dissolved in 100 µl of formamide before storage at -20ºC. 
 
Extracted RNA was quantified by measuring the absorbance at 260 nm and separated on a 
1.4% agarose gel as previously described (Pelle and Murphy, 1993). All RNA samples were 
treated with RNase free DNAse according to the manufacturers’ specifications and used for 
generating complementary DNA (cDNA), the first step in the RT-PCR reaction, by using the 
high fidelity cDNA synthesis kit. Briefly, 1 µg of RNA as determined by spectrophotometry 
was combined with 0.5 mM dNTPs, 0.25 µM oligo (dT)18, and DEPC (diethylpyrocarbonate) 
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treated water (0.1%, v/v) to a final volume of 10 µl and incubated at 65ºC for 10 min in a 
thermocycler. Samples were chilled on ice for 2 min before adding 4 µl of 5x reverse 
transcriptase buffer, 1 U of RNase inhibitor, 1 U of reverse transcriptase and DEPC treated 
water to a final volume of 20 µl and incubated at 40ºC for 50 min in a thermocycler before a 
final extension temperature at 70ºC for 15 min. cDNA generated was then used as a template 
for the second step of RT-PCR with gene specific primers for TbOPB and T. congolense 
tubulin (TcoTUB) (Table 3.1). A master mix for the reaction containing sets of primers 
designed for TbOPB or TcoTUB (0.25 µM each) and T. brucei and T. congolense cDNA 
respectively, 1 x PCR buffer, 2.5 mM MgCl2, 1 U Taq and 0.5 mM dNTPs in a total reaction 
volume of 25 µl was prepared. PCR amplification was started with an Taq polymerase 
activation step at 95ºCfor 5 min, followed by 25 cycles of a DNA denaturing step at 95ºC for 
30 s, a primer annealing step at 55ºC for 30 s, and an elongation step at 72ºC for 1 min. A 
final elongation step was added at the end of 25 cycles at 72ºC for 7 min. The resulting PCR 
products were separated on a 1% (w/v) agarose gel. 
 
Table 3.1 Primer sequences designed for quantitative PCR. Primers were used to analyse down-
regulation of TbOPB in T. brucei T7T parasites transformed with p2T7Ti/TbOPB. T. congolense TRUM 
183 29-13 parasites, transformed with p2T7Ti/TcoTUB, were used as a positive control for the 
experiment and actin as the reference gene for PCR. 
Primer name Sequence (5’→3’) 
TbOPB forward 5’-ATGATATATGCTATTGCGCAC-3’ 
TbOPB reverse 5’-GTCTGTCTTGAGTTCACG-3’ 
TbACT forward 5’-GACGAGGAACAAACTGCT-3’ 
TbACT reverse 5’-ACCGTCACCAGCGTCGAG-3’ 
TcoTUB forward 5’-ATGCGCGAGGCTATCTGCATC-3’ 
TcoTUB reverse 5’-GTAACTCCTCAACGTCCTCCTC-3’ 
 
T. brucei cDNA generated as described above was also used for quantitative PCR (qPCR). 
Briefly, primers for either TbOPB or T. brucei actin (TbACT) (0.25 µM each) were added to a 
master mix containing T. brucei cDNA template, 25 µl of 2x SensiMix dT [2x PCR buffer, 6 
mM MgCl2, 1 mM dNTPs and 2 U Taq], 1 µl of 50x SYBR® green solution and distilled water 
to a final volume of 50 µl. T. brucei cDNA generated from different concentrations of RNA 
ranging from 0 – 100 ng was used to measure the comparable cycling efficiency of TbACT 
and TbOPB primers to confirm using them together in one experiment as described by Livak 
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and Schmittgen (2001). Relative gene expression was calculated using the 2-∆∆CT method 
(Livak and Schmittgen, 2001). This method operates by comparing the cycle threshold values 
of different PCR reactions. Relative concentrations of cDNA present during the exponential 
phase of the reaction are determined by plotting fluorescence against cycle number on a 
logarithmic scale. A threshold for detection of fluorescence above background is determined 
and the cycle at which the fluorescence from a sample crosses the threshold is called the 
cycle threshold, CT. ∆CT was calculated by subtracting the TbACT primer CT values from 
TbOPB primer CT values obtained when using the same concentration of cDNA on different 
days of the experiment. ∆∆CT is obtained by deducting the average CT value of the whole 
experiment from each individual value to calculate the percent change in cDNA for each 
reaction. These values are then plotted as a percentage change over the time period of the 
experiment. Relative amounts of RNA for each clone in the subsequent days of the 
experiment were plotted in comparison to day one, which was taken at 100%. For statistical 
analyses, values were expressed as means ± standard error of the mean (SEM). Significance 
levels were calculated by unpaired t tests and differences were considered significant at a p 
value <0.001. 
 
3.3  RESULTS 
3.3.1   Recombinant expression and purification of TcoOPB 
Expression of the pET28a-TcoOPB clone in E. coli BL21 DE3 cells was successful as 
evidenced by the presence of a band at ~80 kDa in both the insoluble (Fig. 3.1 A, lanes 2-4) 
and soluble (Fig. 3.1 A, lanes 5-6) fractions of the bacterial lysate. The soluble fraction was 
used for His-tagged affinity purification where most of the recombinant protein was 
successfully separated from bacterial lysate and eluted with 250 mM imidazole (Fig.3.1 B, 
lane 5). His-tagged purified TcoOPB fractions were pooled (Fig. 3.1 C, lanes 1 & 2) and 
concentrated (Fig. 3.1 C, lane 3) before quantification by comparison with BSA standards 
(Fig. 3.1 D). The concentration of TcoOPB was estimated to be between 0.75 and 1 mg/ml. 
Dilutions of purified TcoOPB was used for an activity assay with Z-Arg-Arg-AMC, its preferred 



























Figure 3.1 SDS-PAGE analysis of recombinant expression and affinity purification of full length 
T. congolense OPB. Samples were analysed on 10% SDS-PAGE gels. M: molecular weight markers. 
A: lane 1, untransformed E. coli BL21 DE3 lysate; lanes 2-4, insoluble fraction of T. congolense OPB 
expression; lanes 5-7, soluble fraction of T. congolense OPB expression; expected size of 
recombinant T. congolense OPB at ~ 80 kDa (←). B: lane 1, soluble fraction of T. congolense OPB 
expression loaded onto the HIS purification column; lane 2, unbound fraction; lane 3, first column 
wash; lane 4, second column wash; lane 5, eluted T. congolense OPB fraction. C: lanes 1 & 2, dilute 
T. congolense OPB fractions; lane 3, concentrated T. congolense OPB. D: BSA quantification of 
purified recombinant T. congolense OPB. By loading 10 μl/well of the following BSA dilutions; lane 1, 
1.5 mg/ml; lane 2, 1 mg/ml; lane 3, 0.75 mg/ml; lane 4, 0.5 mg/ml; lane 5, 0.25 mg/ml; lane 6, 0.125 
mg/ml; lane 7, purified and concentrated T. congolense OPB fraction estimated to be between 1 – 0.75 































Figure 3.2 Purified recombinant oligopeptidase B from T. congolense hydrolyses Z-Arg-Arg-
AMC. Different concentrations of recombinant TcoOPB were used in an activity assay with 0.1% (w/v) 
Brij-35. A mean of triplicate fluorescence values was plotted as arbitrary fluorescence units ± SEM.  
 
3.3.2 Production of anti-TcoOPB IgY antibodies 
Purified TcoOPB was used to raise antibodies in four chickens and the antibodies were 
isolated from the egg yolks. IgY antibodies from all four chickens were analysed over a 14-
week period using ELISA to determine when antibody production peaked (Fig. 3.3 A). 
Chicken 1 produced the highest titre antibodies in weeks 6 and 7 after the first immunisation 
(Fig. 3.3 B, TcoOPB 1), while chicken 2 produced antibodies with a lower titre that peaked at 
week 5 (Fig. 3.3 B, TcoOPB 2). The antibodies produced by chicken 3 also peaked at week 5 
(Fig. 3.3 B, TcoOPB 3) and those produced by chicken 4 at week 6 (Fig. 3.3 B, TcoOPB 4).  
 
IgY was pooled into three different groups comprising of pool 1 (weeks 2 - 6 for all immunised 
chickens), pool 2 (weeks 7 - 12 for chickens 1 and 3) and pool 3 (weeks 7 -12 for chickens 2 
and 4) and affinity purified using the recombinant TcoOPB affinity column (Fig. 3.4, A). 
ELISAs using recombinant OPB and affinity purified antibodies showed that pool 3 had the 































































































































































Figure 3.3 ELISAs showing antibody production in chickens following immunisation with 
recombinant T. congolense OPB. A: ELISA of IgY from chickens 1-4 showing antibody production 
over a 14-week period. B: TcoOPB 1, titration of antibodies produced by chicken 1; TcoOPB 2, 
titration of antibodies produced by chicken 2; TcoOPB 3, titration of antibodies produced by chicken 3; 
TcoOPB 4, titration of antibodies produced by chicken 4. ELISA plates were coated with 150 μl (1 
















































Figure 3.4 Affinity purification of anti-TcoOPB IgY and evaluation by ELISA. A: Elution profiles for 
affinity purification of anti-TcoOPB IgY. Pool 1, weeks 2 - 6 for all immunised chickens; pool 2, weeks 
7 - 12 for chickens 1 and 3; pool 3, weeks 7 -12 for chickens 2 and 4. Arrow indicates point at which 
elution with low pH glycine-HCl buffer was started. B: ELISA evaluation of anti-TcoOPB affinity purified 
antibody pools 1-3. NI, non-immune control IgY. The ELISA plate was coated with 150 μl (1 μg/ml) of 
recombinant TcoOPB per well. Each point plotted is the average of 3 replicates.  
 
Affinity purified chicken anti-TcoOPB IgY pools were characterised using a western blot with 
recombinant TcoOPB and lysates generated from T. congolense IL3000 and T. brucei 427 
Lister procyclic cultures (Fig. 3.5). Affinity purified pool 3 anti-TcoOPB antibodies recognised 
affinity purified recombinant TcoOPB (Fig. 3.5 A, lane 1) but did not recognise native OPB in 
lysates generated from T. congolense (Fig. 3.5 B, lane 1) or T. brucei (Fig. 3.5 B, lane 2).  
 
As an alternative to using IgY raised from full length recombinant TcoOPB, anti-TcoOPB 
peptide antibodies (chicken anti-TcoOPB peptide antibody, weeks 4 -7, 50 µg/ml) raised in a 
previous study (Huson, 2006) were used in a western blot. These antibodies recognised 
affinity purified recombinant TcoOPB (Fig. 3.5 C, lane 1) and OPB in both T. congolense and 
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Figure 3.5 Western blot analysis of recombinant TcoOPB and parasite lysates with affinity 
purified chicken anti-TcoOPB IgY antibodies. A: lane 1, recombinant TcoOPB probed with chicken 
anti-TcoOPB IgY (50 µg/ml); B: lane 1, T. congolense parasite lysate and lane 2, T. brucei parasite 
lysate, probed with chicken anti-TcoOPB IgY (50 µg/ml). C: lane 1, recombinant TcoOPB probed with 
anti-TcoOPB peptide IgY (50 µg/ml). D: lane 1, T. congolense parasite lysate and lane 2, T. brucei 
parasite lysate, probed with anti-TcoOPB peptide IgY (50 µg/ml). 
 
3.3.3 Cloning conserved gene regions of TcoOPB and TbOPB into the RNAi vector 
p2T7Ti 
Genomic DNA was isolated from T. brucei 427 Lister and T. congolense IL300 strains (Fig. 
3.6 A1, lanes 1 and 2 respectively) and used as a template for genomic DNA PCR with 
primers that had been designed to amplify conserved regions of the OPB gene (Fig.3.6 A2). 
A 489 bp product from T. congolense IL3000 (TcoOPB; lane 1) and a 492 bp product from T. 
brucei 427 Lister (TbOPB; lane 2) were amplified and ligated with the pGEM® T-vector. Blue- 
white screening and colony PCR revealed six T-vector recombinant clones for TcoOPB of 
489 bp (Fig. 3.6 B1, lanes 1-6) and ten for TbOPB of 492 bp (Fig.3.6 B1, lanes 1-10). Plasmid 
mini-preparations for TbOPB (Fig. 3.6 C, lane 1) and TcoOPB (Fig. 3.6 C, lane 2) in T-vector 
were prepared. The T-vector constructs for TcoOPB and TbOPB were confirmed using XbaI 
restriction releasing a 489 bp fragment for TcoOPB and 492 bp fragments from two clones of 
TbOPB (Fig. 3.6 D1, lane 1 and Fig. 3.6 D2, lanes 1 and 2 respectively).  
 
The XbaI linearised p2T7Ti RNAi vector of 5 kb (Fig. 3.7 A, lane 1) was ligated with the 489 bp 
TcoOPB and the 492 bp TbOPB (Fig. 3.7 A, lanes 2 and 3 respectively). Recombinant clones 
were selected for colony PCR using insert primers that amplified 489 bp products for 
recombinant p2T7Ti/TcoOPB (Fig. 3.7 B1, lanes 2, 3 and 9) and 492 bp products for 
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Figure 3.6 Amplification and T-vector cloning of conserved OPB gene regions from T. brucei 
and T. congolense. M, MassRuler® DNA ladder mix / Middle Range™ DNA ladder mix. A1: Genomic 
DNA isolation; lane 1, T. brucei 427 Lister; lane 2, T. congolense IL3000. A2: lane 1, 489 bp TcoOPB 
PCR product using primers designed for T. congolense genomic DNA; lane 2, 492 bp TbOPB PCR 
product using primers designed for T. brucei genomic DNA. B1: Colony PCR lanes 1-6, TcoOPB 
clones. B2: Colony PCR lanes 1-10, TbOPB clones. C: T-vector miniprep lane 1, TbOPB; lane 2, 
TcoOPB. D1: lane 1, XbaI restriction of TcoOPB in the T-vector. D2: lanes 1-2, XbaI restriction of 
TbOPB in the T-vector. All samples were separated on a 1% (w/v) agarose gel and stained with 
ethidium bromide (3 µg/ml). 
 
Successful subcloning into the p2T7Ti RNAi vector was confirmed using XbaI restriction for 
p2T7Ti/TcoOPB, releasing 489 bp products from three clones (Fig. 3.7 B2, lanes 1-3) and 
p2T7Ti/TcoOPB, releasing 492 bp products from six clones (Fig. 3.7 C2, lanes 1-6). 
Recombinant p2T7Ti/TcoOPB and p2T7Ti/TbOPB clones were prepared for transformation 
into T. congolense TREU 29-13 and T. brucei T7T-29 procyclic parasites by restriction with 
NotI giving ca. 5.4 kb fragments (Fig. 3.7 D, lanes 1 and 2 respectively). DNA isolated from a 
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Figure 3.7 Subcloning conserved gene regions from T. brucei OPB and T. congolense OPB into 
the p2T7Ti RNAi vector. M, MassRuler® DNA ladder mix in all gels. A: lane 1, gel purified XbaI 
restricted p2T7Ti vector; lane 2, XbaI restricted 489 bp gel purified TcoOPB fragment from T-vector; 
lane 3, XbaI restricted 492 bp gel purified TbOPB fragment from T-vector. B1: lanes 2, 3 and 9, 
positive p2T7Ti/TcoOPB clones using 489 bp primers; B2: lanes 1-3, p2T7Ti/OPB clones restricted with 
XbaI. C1: lanes 1, 2, 6 and 9-11, positive p2T7Ti/TbOPB clones using 492 bp primers. C2: lanes 1-6, 
p2T7Ti/TbOPB clones restricted with XbaI. D: lane 1, p2T7Ti/TcoOPB clone restricted with NotI; lane 2, 
p2T7Ti/TbOPB clone restricted with NotI; lane 3, p2T7Ti/TcoTUB clone restricted with NotI in 
preparation for transformation. Products were separated on a 1% (w/v) agarose gel and stained with 
ethidium bromide (3 µg/ml). 
 
3.3.4 Generation and characterisation of T. congolense and T. brucei p2T7Ti/OPB 
clones 
T. congolense p2T7Ti/TcoOPB, T. congolense p2T7Ti/TcoTUB and T. brucei p2T7Ti/TbOPB 
positive clones were expanded, used for genomic DNA isolation and analysed in a PCR 
reaction with bleomycin primers. The two sets of bleomycin primers used resulted in 
amplification of 350 bp (Fig. 3.8A, lanes 1-6) and 1000 bp (Fig. 3.8 A, lanes 7-12) products. 
Anti-TcoOPB peptide IgY was used in western blots to detect OPB in lysates from T. 
congolense p2T7Ti/TcoOPB and T. brucei p2T7Ti/TbOPB positive clones. A three-day RNAi 
induction experiment using 1 µg/ml of tetracycline in T. congolense p2T7Ti/TcoOPB cultures 
(Fig. 3.8 B, lanes 4-6) did not show any difference in OPB expression when compared to non-





M      1            2           3         4         5       6          7          8            9        10         11   12
A
-Tet            +Tet




- Tet            +Tet











Figure 3.8 Evaluation of clones transformed for RNAi using PCR and western blotting. A: 
Genomic DNA PCR on T. brucei T7T and T. congolense TRUM 183 clones transformed with 
p2T7Ti/OPB and p2T7Ti/TUB. M, MassRuler® DNA ladder mix; 350 bp bleomycin primers with: lane 1, 
p2T7Ti/BIP plasmids as a PCR control; lane 2, T. congolense p2T7Ti/TUB genomic DNA; lane 3, T. 
brucei p2T7Ti/OPB clone 1 genomic DNA; lane 4, T. brucei p2T7Ti/OPB clone 2 genomic DNA; lane 5, 
T. congolense p2T7Ti/OPB clone 1 genomic DNA; lane 6, T. congolense p2T7Ti/OPB clone 2 genomic 
DNA. 1000 bp bleomycin primers with: Lane 7, p2T7Ti/BIP plasmid as a PCR control; lane 8, T. 
congolense p2T7Ti/TUB genomic DNA; lane 9, T. brucei p2T7Ti/OPB clone 1 genomic DNA; lane 10, T. 
brucei p2T7Ti/OPB clone 2 genomic DNA; lane 11, T. congolense p2T7Ti/OPB clone 1 genomic DNA; 
lane 12, T. congolense p2T7Ti/OPB clone 2 genomic DNA. Products were separated on a 1% (w/v) 
agarose gel and stained with ethidium bromide (3 µg/ml). B: Western blot analysis of three-day 
RNAi induction of T. congolense p2T7Ti/OPB transformed clones using anti-TcoOPB peptide 
IgY. Lanes 1-3, days 1-3 without induction (-Tet); lanes 4-6, days 1-3 with induction (+Tet). C1: 
Western blot analysis of three-day RNAi induction of T. brucei p2T7Ti/OPB transformed clones 
using anti-TcoOPB peptide IgY. Lanes 1-3, days 1-3 without induction (-Tet); lanes 4-6, days 1-3 
with induction (+Tet). C2: Western blot analysis of 14-day RNAi induction of T. brucei p2T7Ti/OPB 
transformed clones using anti-TcoOPB peptide IgY. Lanes 1-5, days 1, 3, 6, 9 and 14 respectively 
without induction (-Tet); lanes 6-10, days 1, 3, 6, 9 and 14 respectively with induction (+Tet).  
 
A parallel three-day induction experiment with tetracycline to induce RNAi in p2T7Ti/TbOPB 
clones revealed the down-regulation of OPB (Fig. 3.8 C1, lanes 4 - 6) when compared to the 
non-induced culture (Fig. 3.8 C1, lanes 1 - 3). OPB expression was, however, still noticeable 
after 3 days and a longer 14-day tetracycline induction experiment was carried out (Fig. 3.8 
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C2, lanes 6 - 10). OPB expression levels where still detected after 14 days, but at lower 
levels than in the non-induced cultures (Fig. 3.8 C2, lanes 1 - 5). 
 
 In order to observe how efficiently RNAi was functioning, RNA was isolated for RT-PCR 
analysis of p2T7Ti/TbOPB clones grown for three days either in the absence of tetracycline (-
Tet) (Fig. 3.9 A, lanes 7 - 9) or in the presence of tetracycline (+Tet) (Fig. 3.9 A, lanes 10 - 
12). The p2T7Ti/TcoTUB culture was also used for RNA isolation to serve as a positive control 
for RNAi and grown for three days without tetracycline (-Tet) (Fig. 3.9 A, lanes 1 - 3) or 
induced with tetracycline (+Tet) (Fig. 3.9 A, lanes 4 - 6). 
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Figure 3.9 Three-day RNAi induction RT-PCR analysis of T. congolense p2T7Ti/TUB and T. 
brucei p2T7Ti/OPB transformants. A: RNA isolation. T. congolense p2T7Ti/TUB days 1-3: lanes 1-3, 
with no induction (-Tet); lanes 4-6, with induction (+Tet). T. brucei p2T7Ti/OPB days 1-3: lanes 7-9, 
with no induction (-Tet); lanes 10-12, with induction (+Tet). B: RT-PCR analysis of T. congolense 
p2T7Ti/TUB transformants. Days 1-3: lanes 1-3, with no induction (-Tet) and lanes 4-6, with induction 
(+Tet) using 1200 bp tubulin primers; lanes 7-9, with no induction (-Tet) and lanes 10-12, with 
induction (+Tet) using 400 bp actin primers. C: RT-PCR analysis of T. brucei p2T7Ti/OPB 
transformants, days 1-3: lanes 1-3, with no induction (-Tet) and lanes 4-6, T. brucei p2T7Ti/OPB days 
1-3 with induction (+Tet) using 492 bp TbOPB primers; lanes 7-9, with no induction (-Tet) and lanes 
10-12, with induction (+Tet) using 400 bp actin primers.  
 
RT-PCR analysis revealed that RNAi induction in p2T7Ti/TcoTUB control clones over a three-
day period was efficient with a clear reduction in levels of tubulin in cultures induced with 
 91
tetracycline (Fig. 3.9 B, lanes 4 - 6) when compared to non-induced cultures (Fig. 3.9 B, lanes 
1 - 3). Actin primers were used as a loading control for both RNAi induced and non-induced 
cultures (Fig. 3.9 B, lanes 7 - 12). Levels of OPB in T. brucei cultures when RNAi was 
induced with tetracycline for three days were only slightly reduced (Fig. 3.9 C, lanes 4 - 6) 
when compared to non-induced cultures (Fig. 3.9 C, lanes 1 - 3). Actin primers were also 
used as loading controls for both RNAi induced and non-induced cultures (Fig. 3.9 C, lanes 7 
- 12). A repeat of the experiment over a 14-day period using RNA from tetracycline induced 
(Fig. 3.10, A, lanes 6 -10) and non-induced (Fig. 3.10, A, lanes 1 - 5) p2T7Ti/TbOPB cultures 
revealed a steady but incomplete reduction of OPB RNA in tetracycline induced clones (Fig. 
3.10, C, lanes 1 – 5). A reduction was also observed in non-induced cultures over the same 
14-day period (Fig. 3.10, B, 1 - 5). Actin primers were used as loading controls for both 
induced and non-induced p2T7Ti/TbOPB cultures (Fig. 3.10, C, lanes 6 -10 and Fig. 3.10, B, 
lanes 6 -10). The actin loading control in lane 9 of Fig. 3.1 B suggests that less sample was 
loaded affecting the amount of product seen in lane 4 of Fig. 3.1 B. 
 
 
Figure 3.10 RT-PCR analysis of 14-day induction RNAi induction in T. brucei p2T7Ti/OPB 
transformants. A: RNA isolation from T. brucei p2T7Ti/OPB. Lanes 1-5 no induction (-Tet) days 1, 
3, 6, 9 and 14 respectively; lanes 6-10, induction (+Tet) days 1, 3, 6, 9 and 14. B: RT-PCR analysis 
of T. brucei p2T7Ti/OPB transformants with no induction (-Tet). Lanes 1-5, days 1, 3, 6, 9 and 14 
using 492 bp TbOPB primers; lanes 6-10, days 1, 3, 6, 9 and 14 using 400 bp actin primers. C: RT-
PCR analysis of T. brucei p2T7Ti/OPB transformants with induction (+Tet). Lanes 1-5, days 1, 3, 
6, 9 and 14 using 492 bp oligopeptidase B primers; lanes 6-10, days 1, 3, 6, 9 and 14 using 400 bp 
actin primers.  
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In order to quantify the relative amounts of TbOPB that were targeted for RNAi in selected 
clones, RNA was isolated for from clones grown for 14 days either in the absence (-Tet) (Fig. 
3.10 A, lanes 1-5)  or the presence (+Tet) (Fig. 3.10 A, lanes 6-10) of tetracycline. An initial 
experiment that compared the thermo-cycling efficiencies of OPB and actin primers at 
different RNA concentrations was performed as previously described (Livak and Schmittgen, 
2001) (Fig. 3.11 A).  
 
A plot of cDNA dilutions versus cycling efficiencies (∆CT) produced a line with a slope of 
0.0397 meaning that TbOPB primers were operating at a similar efficiency to T. brucei actin 
primers (TbACT). RNA at a concentration of 10 ng was used to calculate the relative 
reduction of TbOPB levels in tetracycline induced cultures compared to non-induced cultures 
over a 10-day period (Fig. 3.11 B). The relative levels of RNA from tetracycline-induced 
cultures were reduced to ca. 50% by day five when compared to day one and this trend in 
reduction was observed until day 14. TbOPB RNA levels at day nine of RNAi induction was 
calculated at ca.13% when compared to day one (Fig. 3.11 B). A reduction in RNA was also 
observed in non-induced cultures with day nine giving the lowest level at ca. 40% of RNA 
when compared to day one (Fig. 3.11 B).  
 
The number of parasites in T. congolense p2T7Ti/TcoOPB, T. congolense p2T7Ti/TcoTUB and 
T. brucei p2T7Ti/TbOPB positive clones and induced for RNAi were counted over the 14 day 
experiment to assess if a growth defect could be detected (Fig. 3.12). Cells were seeded at 1 
x 106 cells/ml of growth medium. All T. brucei parasite clones grew at a higher number of 
cells/ml when compared to all the T. congolense clones. There were no significant differences 
in the proliferation of both tetracycline induced and non-induced T. brucei p2T7Ti/TbOPB 

























Figure 3.11 qPCR analysis of T. brucei p2T7Ti/OPB transformants. A: Validation of the 2-∆∆CT 
method using actin and OPB primers. Serial dilutions of cDNA were generated from total RNA 
ranging from 100-0 ng. Average threshold cycle (∆Ct) was calculated (COPB – CACT) for each cDNA 
dilution. Error bars were calculated [√S.D (OPB) ^2 + S.D (ACT) ^2] with n = 3. B: Relative 
quantification of TbOPB. TbOPB RNA concentration was calculated using actin as a calibrator in T. 
brucei (TbACT) on different days in the presence (+Tet) and absence (-Tet) of tetracycline. TbOPB 
levels relative to TbACT were plotted as a percentage of mean fold change with day one taken at 
100%. Each value is a mean of 3 qPCR reactions. *p< 0.05 and **p<0.001 in comparison to the non-
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Figure 3.12 Growth curves of transformed parasites after induction with 1 µg/ml tetracycline. 
Procyclic cultures (5 x 105) of each clone: T. brucei p2T7Ti/OPB, T. congolense p2T7Ti/OPB and T. 
congolense p2T7Ti/TUB, were seeded in duplicate 10 ml flasks and tetracycline either added to induce 
RNAi (+Tet) or not added in non-induced (-Tet) cultures in a fifteen-day induction experiment. Half the 
medium in all flasks was replaced on day 8. Numbers of parasites were determined as a mean of three 
counts ± SEM.  
 
3.4 DISCUSSION 
Studies on the in vivo function of oligopeptidase B (OPB) in intracellular kinetoplastid 
parasites led to the description of a variety of roles, including the invasion of non-phagocytic 
lymphocytes in T. cruzi (Caler et al., 1998), the invasion of phagocytic lymphocytes in L. 
major (Munday et al., 2011) and a role for immune evasion by depressing a response from 
infected macrophages in L. donovani (Swenerton et al., 2011). A common result for all these 
experiments is that there is no phenotype difference between parasites in vitro in the absence 
of OPB except in assays involving cell invasion. Because all these parasites are intracellular 
kinetoplastids, it was reasoned that OPB may have a different function in T. brucei as it exists 
as an exclusively extracellular parasite (Saravia et al., 2006).  
 
RNAi of TcoOPB was unsuccessful as was observed after assessment with anti-OPB peptide 
antibodies. This failure of RNAi can possibly be attributed to two different factors. More stable 
RNA transcripts that have a longer half-life are more difficult to degrade than mRNA that is 
transcribed at lower levels and is more unstable (Bellofatto and Palenchar, 2008). It is also 
possible for siRNA generated to target genes other than TcoOPB (Qiu et al., 2005). This is 
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especially relevant for the T. congolense genome which has not yet been fully sequenced 
and annotated, leading to a small chance of targeting more than one gene and impaired 
RNAi. In addition, because RNAi requires siRNA base pairing to targeted RNA, natural 
variations that occur between species and different variants can lead to ineffectual 
downregulation of the gene under study (Panjaworayan and Brown, 2011). In chapter 2, the 
failure of knocking down TcoCATL, a multi-copy gene with variations within different catalytic 
domains (Pillay et al., 2010), creates the possibility for the siRNA to target the different 
variants rather than the intented peptidase, in this case TcoCATL. Variations in the success 
of RNAi downregulation of genes can be solved by creating RNAi vectors that target multiple 
sections of one gene, thus increasing the possibility that the intended gene is affected more 
than other variations (Weinberg and Arbuthnot, 2010).  
 
Down-regulation of TbOPB was successfully achieved using RNAi and this was assessed 
with anti-OPB peptide antibodies. TbOPB was still detectable in procyclic lysates 14 days 
after induction using tetracycline, and this could be attributed to TbOPB having a long half-life 
in culture medium due to the absence of natural inhibitors in mammalian host serum used to 
prepare complete medium (Coetzer et al., 2008). To confirm if RNAi in transformed T. brucei 
parasites was functional, it was necessary to ascertain if RNA coding for TbOPB has been 
efficiently degraded as this would provide concrete evidence for the technique (Clayton, 
1999). T. congolense cultures targeted for tubulin (TcoTUB) degradation were used as a 
control for this experiment and RNAi was induced over a period of three and 14 days. RNAi 
targeting tubulin has been used as a control because disrupting the gene leads to a visible 
phenotype where parasites are unable to retain their structure and become “FAT” cells (Inoue 
et al., 2002).  
 
Although RNAi can be observed in trypanosomes several hours after induction (Coustou et 
al., 2010), induction using tetracycline was carried out over a period of fourteen days in the 
present study as this was more effective at reducing levels of TcoOPB when compared to 
TcoTUB. Using qPCR, it was possible to detect a down-regulation of TbOPB to 13% of its 
wild-type level with no observable differences in parasite growth and division. It was 
concluded that reducing the levels of TbOPB has no deleterious effect on the viability of the 
parasites and this correlated well with the experiments performed in related kinetoplastid 
parasites where phenotypes related to the deletion of the OPB gene only became apparent 
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when parasites were evaluated for the invasion of host cells as seen in T. cruzi (Caler et al., 
1998),  L. major (Munday et al., 2011) and L. donovani (Swenerton et al., 2011). 
 
The definitive functions of different peptidases have been described using RNAi. In T. brucei, 
cathepsin L and B (TbCATL and TbCATB) have been shown with in vitro and in vivo studies 
to play a pivotal role in host protein degradation and virulence in mice (Mackey et al., 2004; 
Abdulla et al., 2008). Targeting cathepsin D for RNAi in S. mansoni resulted in the inability of 
parasites to degrade haemoglobin and led to significant growth retardation in vitro and death 
when used for in vivo  studies (Morales et al., 2008). In contrast, not all peptidases targeted 
for RNAi show a phenotype. In contrast to cathepsin D in S. mansoni, targeting cathepsin B 
did not affect the parasites negatively, with results showing the complete degradation of 
mRNA coding for the peptidase (Skelly et al., 2003). From these experiments, it is clear that 
RNAi is a first choice for manipulations that lead to the down-regulation of essential genes. If 
a gene is essential for the survival of an organism, it will be impossible to delete the gene 
coding for its expression and therefore impossible to study function (Motyka and Englund, 
2004; Ullu et al., 2004; Bellofatto and Palenchar, 2008). A major disadvantage of RNAi in 
trypanosomes is apparent when only trace amounts of an enzyme are required for its function 
or in cases where an enzyme has a long half-life (Motyka and Englund, 2004). Depending on 
the organism used for experiments, there is great variability in the length of time it takes for 
the targeted protein to disappear and in addition, different proteins can differ in the extent to 
which they can be knocked down by RNAi (Bonetta, 2004). In cases where a protein has a 
long half-life and is still functional at lower levels of expression, it would be difficult to assign 
function and necessary to consider either increasing the period of RNAi induction or 
designing gene knock-out experiments that delete the gene for the target being investigated.  
 
Because TbOPB activity persists after the death of parasites in the host in vivo due to the 
lack of natural inhibitors (Coetzer et al., 2008), it would be difficult to use an in vivo model as 
any new phenotypes could be attributed to residual amounts of the enzyme present before 
induction. A more attractive model would be the generation of null mutants that would have 
no OPB available as has been carried out for OPB in T. cruzi, L. major and L. donovani 
(Burleigh et al., 1997; Munday et al., 2011; Swenerton et al., 2011). The generation of T. 




GENERATION OF OLIGOPEPTIDASE B NULL MUTANTS IN TRYPANOSOMA 
BRUCEI BRUCEI INCREASES PROLYL OLIGOPEPTIDASE-LIKE ACTIVITY 
 
African trypanosomosis, also referred to as sleeping sickness in humans and nagana in 
cattle, is a parasitic disease caused by protozoan haemoparasites of the genus 
Trypanosoma, with T. congolense, T. vivax and T. brucei brucei causing nagana (Taylor, 
1998). Nagana puts large numbers of cattle in sub-Saharan Africa at risk with an estimated 
revenue loss of up to five billion US $ annually (Swallow, 2000; McDermott and Coleman, 
2001; Antoine-Moussiaux et al., 2009). Symptoms include anaemia, proliferation of lymphoid 
cells, increased permeability of blood vessels, coagulation and immunosuppression 
(Vickerman et al., 1993). Many of these symptoms appear as the invading parasites are 
cleared by the host immune system and most symptoms are attributed to parasite products 
released by dead and dying parasites (Antoine-Moussiaux et al., 2009). These products 
include trypanosome lipids, hemolysins, mitogens, inflammatory factors, hepatotoxins and 
enzymes such as peptidases, phospholipases and acid phosphatises (Tosomba et al., 1996; 
Taylor and Authié, 2004). This observation has led to the idea of developing vaccines and 
chemotherapeutic agents that target pathogenic factors released by the parasite during 
infection, a strategy referred to as an “anti-disease” approach (Authié et al., 2001). Several 
enzymes have been identified as possible pathogenic factors, with oligopeptidase B in T. 
brucei (TbOPB) and prolyl oligopeptidase (TbPOP) implicated in neuroendocrine symptoms 
during T. brucei infection (Knowles et al., 1987; Tetaert et al., 1993; Coetzer et al., 2008; 
Bastos et al., 2010). Both TbPOP and TbOPB belong to the S9 prolyl oligopeptidase family of 
serine proteases but cleave peptides differently with TbPOP hydrolysing substrates at the 
carboxyl end of prolyl and alanyl residues (Bastos et al., 2010). TbOPB on the other hand 
only hydrolyses low molecular mass peptides < 30 amino acids that contain dibasic amino 
acid residues (Arg or Lys) in P1 with a preference for arginine residues in both P1 and P2 
(Coetzer et al., 2008). 
 
In trypanosomes, TbOPB is released as an active parasite peptidase by dead and dying 
parasites during infection (Troeberg et al., 1996a; Morty et al., 2001; Coetzer et al., 2008). 
The peptidase is expressed by several trypanosome species including the haemoflagellates 
T. b. brucei (Troeberg et al., 1996a), T. congolense (Morty et al., 1999a), and T. vivax 
(Coetzer et al., 2008), T. evansi (Morty et al., 2005a) which causes surra and the intracellular 
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T. cruzi (Burleigh et al., 1997) which causes Chagas disease. Due to the restricted size of the 
substrate binding pocket, plasma protease inhibitors such as serpins and α2-macroglobulin 
are not able to inhibit TbOPB in host blood where it remains active (Morty et al., 1999b; Morty 
et al., 2001; Coetzer et al., 2008). In T. evansi, OPB has been implicated in the inactivation of 
host atrial natriuretic factor (ANF), resulting in an increased blood volume which is associated 
with many lesions in the circulatory system of trypanosome infected hosts (Ndung'u et al., 
1992; Morty et al., 2005a). In T. cruzi, an intracellular parasite, OPB is involved in the 
invasion of mammalian host cells by triggering the release of Ca2+ from intracellular stores 
leading to the recruitment and fusion of host cell lysosomes at the invasion site (Burleigh et 
al., 1997; Caler et al., 1998). ∆opb null-mutant T. cruzi parasites were unable to invade host 
cells due to their inability to mobilise Ca2+ (Caler et al., 1998).  
 
Gene knock-out studies in Leishmania major and L. donovani showed that a loss of OPB 
resulted in delayed foot pad lesion formation in mice but no difference was observed in 
virulence during infection (Munday et al., 2011; Swenerton et al., 2011). Knock-out parasites 
were also less able to infect and survive within macrophages in vitro and a large up-
regulation of enzymatically inactive membrane associated enolase was detected in L. 
donovani parasites without OPB (Swenerton et al., 2011). Although T. brucei does not invade 
non-phagocytic and phagocytic cells in the mammalian host bloodstream, there is substantial 
evidence that the parasites leave the blood circulation and invade tissues including crossing 
the blood brain barrier in humans (Grab et al., 2004; Nikolskaia et al., 2006a; Nikolskaia et 
al., 2006b; Grab and Kennedy, 2008; Grab et al., 2009), cattle (Losos and Ikede, 1972; 
Naessens, 2006), mice and rats (Losos and Ikede, 1972; Ojok et al., 2002; Masocha et al., 
2006; Naessens, 2006). The T. b. brucei Lister 427 strain shows a preferential tropism for 
mouse testes (Claes et al., 2009) where parasites are not readily cleared by drugs after 
crossing microvascular endothelial cells into the interstitial tissue between the seminiferous 
tubules.  
Studies into the function of TbOPB during infection have so far been based on experiments 
using inhibitors, trypanocidal agents and neutralising antibodies (Morty et al., 1998; Morty et 
al., 1999a; Morty et al., 2000; Morty et al., 2005a; Morty et al., 2005b). To fully understand 
what role TbOPB plays in parasite physiology and host pathogenesis, oligopeptidase B null 
mutants (∆opb) were generated in a T. b. brucei Lister 427 strain and an attempt was also 
made at knocking out OPB in T. congolense IL3000. TbOPB was found not to be necessary 
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for the survival of trypanosome parasites in vitro and during infection in mice with no 
differences in morphology, rate of parasite division or virulence. Immunohistopathology 
studies of infected mouse testes also showed that TbOPB is not involved in T. b. brucei 
parasites’ ability to cross the blood endothelial barrier. It was, however, observed that 
TbPOP-like activity was significantly increased in ∆opb null mutant parasites with no 
associated increase in TbPOP protein levels. These data may suggest that another POP-like 
peptidase was responsible for the observed increase in activity or that TbOPB is responsible 
for generating an endogenous TbPOP inhibitor. 
 
4.1  MATERIALS AND METHODS 
4.1.2  Materials 
Molecular biology: ApaI, NotI, XbaI, shrimp alkaline phosphatase (SAP), T4 DNA ligase, 10 
mM dNTP mix, X-gal, IPTG, MassRuler™ DNA ladder mix, GeneJET™ plasmid miniprep kit, 
TransformAid™ bacterial transformation kit, shrimp alkaline phosphatase (SAP) and Biotin 
DecaLabel™ DNA labeling kit were obtained from Fermentas (Vilnius, Lithuania). The pGEM-
T® vector was obtained from Promega (Madison, WI, USA), DNA clean and concentrator kit 
from ZymoResearch (Orange, CA, USA), E.Z.N.A® gel extraction kit from PEQlab (Erlangen, 
Germany) and Escherichia coli JM 109 cells were purchased from New England Biolabs 
(Ipswitch, MA, USA). FIREpol® Taq polymerase, 10 x PCR reaction buffer and 25 mM MgCl2 
were acquired from Solis Biodyne (Tartu, Estonia). Hybond™-N DNA binding membrane was 
obtained from Amersham (Buckinghamshire, UK). Molecular biology grade agarose was 
purchased from Conda laboratories (Madrid, Spain), Ampicillin sodium salt from USB 
Corporation (Cleveland, OH, USA), bacteriological agar and tryptone from Merck (Darmstadt, 
Germany). The yeast extract was purchased from Sigma (St. Louis, MO, USA).  
 
Trypanosome culture: Minimum essential medium (MEM), Iscove’s Modified Dulbecco's 
Medium (IMDM), HEPES, sodium pyruvate, thymidine, adenosine, hypoxanthine, thymidine, 
bathocuprone sulfate, glutamine, hemin, proline, cis-aconitate, tetracycline, doxycycline 
hyclate and cyclophosphamide were obtained from Sigma (St. Louis, MO, USA). Heat 
inactivated goat serum and heat inactivated foetal calf serum (FCS) were obtained from 
Gibco (Paisley, UK). 0.2 µm filters were purchased from Pall (Ann Arbor, USA). Culture flasks 
(25 cm2) and 24-well plates were obtained from Corning (NY, USA). Amaxa Nucelofaction® 
transformation system and the Amaxa Basic Parasite Nucleofactor H solution 2 were 
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obtained from Lonza (Levallois-Perret, France). T. congolense TRUM183:29-13 and T. brucei 
T7T-29 RNAi inducible parasite strains and NOD/SCID mice were a gift from Professor Theo 
Baltz (University of Victor-Segalen, Bordeaux 2, France). Balb/C mice were obtained from the 
Bioresources Unit (BRU), Westville campus, University of KwaZulu-Natal (UKZN). Protocols 
using mice were approved by the UKZN animal ethics committee (Reference 036/09/Animal).  
 
Immunofluorescence, western blotting and microscopy: Fluorescein (FITC) conjugated 
donkey anti-mouse IgG, Cy3 (water soluble cyanine fluorescent dye) conjugated donkey anti-
chicken IgG and horseradish peroxidase conjugated horse anti-mouse IgG were obtained 
from Vector labs (Burlingame, USA). Goat anti-rabbit Dylite™ conjugate was purchased from 
Jackson labs (Baltimore, USA). Rabbit anti-VSG serum was a kind gift from Dr Philipe. 
Büscher, Tropical veterinary institute, Antwerp, Belgium. The mouse anti-POP serum for 
TbPOP was from Dr. Aime Santana, Laboratório de Interção Parasito-Hospedeiro, Faculdade 
de Medicina, Universidade Brasília city, Brazil and Dr. Philippe Grellier, Muséum National 
d’Histoire Naturelle, Paris, France. Mouse anti-OPB serum was available from a previous 
study (Bizaaré, 2008). The LSM 710 confocal microscope was purchased from Zeiss, 
Göttingen, Germany.  
 
Peptide substrate: The peptide substrates Benzyloxycarbonyl (Z)-Phe-Arg-7-amino-4-
methylcoumarin (AMC), Z-Arg-Arg-AMC, Z-Gly-Pro-AMC and Z-Arg-Gly-Phe-Phe-Pro-
4MβNA·HCl were obtained from Bachem (Torrance, CA, USA). Activity assays were 




4.2.2.1 Trypanosome culture 
All blood-stream forms of T. b. brucei Lister 427 wild-type and knock-out clones generated 
were cultured in supplemented Iscove’s Modified Dulbecco's Medium (IMDM) as previously 
described (Hirumi and Hirumi, 1989). Briefly, 16.66 g of IMDM was dissolved in 1 litre of 
sterile water containing 3.6 mM NaHCO3, 1 mM hypoxanthine, 1 mM sodium pyruvate, 0.16 
mM thymidine, 0.05 mM bathocuprone, 1.5 mM L-cysteine and 0.2 mM 2-mercaptoethanol. 
The pH was adjusted to between 7.2 and 7.4 and 10% (v/v) heat inactivated foetal calf serum 
added before filtration using a 0.2 µm filter. T. congolense IL3000 procyclic cultures were 
maintained as previously described in Section 2.2.2.2 but without hygromycin or neomycin.  
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4.2.2.2 Generation of heterozygote ∆opb null mutants in T. brucei and T. congolense 
The sequences flanking the OPB gene in T. b. brucei Lister 427 (TbOPB) and T. congolense 
IL3000 (TcoOPB) were identified in the GeneDB database (http://www.genedb.org/tbrucei/, 
and http://www.genedb.org/tcongolense/, accessed 10-10-2007) and used to design primers 
that flank the 3’ and 5’ regions of the OPB gene in T. brucei and T. congolense (Table 4.1). 
Genomic DNA was extracted from in vitro cultures of T. b. brucei Lister 427 and T. 
congolense IL3000 as previously described (Medina-Acosta and Cross, 1993) and used as a 
template for PCR. T-vector cloning and sub-cloning into knock-out vectors was carried out as 
previously described in Section 2.2.2.5, resulting in four recombinant knock-out vectors: 
pGLblaTbOPB and pGLneoTbOPB for T. brucei blasticidin and neomycin resistance plasmids 
respectively, and pGLblaTcoOPB and pGLneoTcoOPB for T. congolense.  
 
T. b. brucei Lister 427 bloodstream parasites and T. congolense IL3000 procyclic parasites 
were transfected with recombinant knock-out constructs using the Amaxa Nucleofector 
system as previously described in Section 2.2.2.2 with appropriate drugs for selection 
(Burkard et al., 2007). Briefly, a pellet of 107 parasites was resuspended in 100 µl Basic 
Parasite Nucleofector H solution 2, mixed with 10 µg of NotI linearised pGLblaTbOPB for T. 
brucei parasites and pGLblaTcoOPB for T. congolense parasites before transfection using 
the X-001 program setting on the Amaxa transfection system (Lonza, Basel, Switzerland) 
(Burkard et al., 2007). Stably transfected trypanosomes were first cultured for 24 h in either 
supplemented IMDM medium (T. brucei) or complete MEM (T. congolense) before selection 
with blasticidin (5 µg/ml). Single knock-out clones, generated by limiting dilution, were 
expanded and taken through a second round of transfection with NotI linearised 
pGLneoTbOPB or pGLblaTcoOPB and selected with neomycin (2.5 µg/ml) and blasticidin (5 
µg/ml) as described above. 
 
4.2.2.3 Confirmation of clones using Southern blot with digoxigenin labelled probes 
To confirm the stable transfection of both plasmids and the deletion of the OPB gene in T. b. 
brucei Lister 427 strain and T. congolense IL3000, a Southern blot was carried out using 
digoxigenin probes according to the manufacturer’s protocol. For T. brucei, two probes that 
spanned the 3’ flanking region of the T. b. brucei OPB gene and either the blasticidin or the 
neomycin coding regions were prepared by PCR incorporating digoxigenin labelled 
nucleotides. A third probe that spanned the T. b. brucei OPB gene was also prepared. For T. 
congolense, a probe that recognised the blasticidin gene was prepared. T. brucei DraI and T. 
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congolense BamHI restricted genomic DNA isolated from the selected clones was separated 
on a 1% (w/v) agarose gel at 110V for 4 h, transferred onto a DNA binding nylon membrane 
using capillary action before probing with the digoxigenin probes prepared as described 
above.  
 
Table 4.1 Sequences of primers designed to amplify the 5’ and 3’ flanking regions of 
oligopeptidase B (OPB) from T. congolense strain IL3000 and T. brucei 427 Lister for cloning 
into the knock-out vectors pGLneo and pGLbla. Each insert primer had either a NotI, XbaI or 
ApaI restriction site (underlined) for incorporation into the pGLneo or pGLbla knock-out plasmids. 
Neomycin and blasticidin resistance gene primers were used to confirm orientation of the 3’ flanking 
regions in the final recombinant plasmids 
Primer name and restriction site Sequence (5’→3’, restriction site underlined) 
OPB T. congolense 3’ flank reverse (ApaI) CGGGGCCCCTTTCACGATCAAAGAAATAAATCT 
OPB T. congolense 3’ flank forward (ApaI) CGGGGCCCGCGCAAGTGGGGGAGGGGCGGTGAGA 
OPB T. congolense 5’ flank reverse (XbaI) CGTCTAGATGTGCGCGTGCGTGTAATAAGCTTCGCCCC 
OPB T. congolense 5’ flank forward (NotI) CGGCGGCCGCCCGACTACTTTCAGCGTCGAAAGCGATTGA 
OPB T. brucei 5’ flank reverse (XbaI) CGTCTAGAGATTGCGATGGAAAGTGCCTCCGAG 
OPB T. brucei 5’ flank forward (NotI) CGGCGGCCGCCCGAATACGTGCAGGTGACAATATA 
OPB T. brucei 3’ flank reverse (ApaI) CGGGGCCCGGTCACTCACATGCAACACGCGGCAA 
OPB T. brucei 3’ flank forward (ApaI) CGGGGCCCGTAGGTAAGGAATAGCTGAAACTTGT 
pGLneo forward primer (Neo Fw) CGTGTTCCGGCTGTCAGCGC 
pGLneo reverse primer (Neo Rv) ACGACGAGATCCTCGCCGTC 
pGLbla forward primer (Bla Fw) TCAACAGCATCCCCATCTCT 
pGLbla reverse primer (Bla Rv) GCAGCAATTCACGAATCCCA 
 
4.2.2.4 Western blot analysis of T. brucei ∆opb clones 
A pellet of 2 x 106 parasites from each culture was washed twice with PBS (pH 7.2) and 
resuspended in 50 µl of lysis buffer [10 mM EDTA, 1% (v/v) Triton X-100, 20 mM Tris-HCl 
buffer, pH 7.2, containing 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride 
(AEBSF) and 10 µM L-trans-epoxysuccinyl-leucylamido (4-guanidino) butane (E64)], an equal 
volume of reducing gel loading buffer was added and samples boiled for 10 min. Lysates 
generated (25 µl) from ~ 5 x 105 parasites were separated per well on a 10% SDS-PAGE gel 
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at 18 mA per gel, blotted onto nitrocellulose (Towbin et al., 1979) and probed with appropriate 
antibodies. The primary antibodies used were polyclonal mouse anti-OPB (1:200) and 
polyclonal chicken anti-immunoglobulin binding protein (BIP) (1:1000) and mouse anti-POP 
serum for TbPOP (1:300). Horseradish peroxidise conjugated horse anti-mouse IgG and 
rabbit anti-chicken IgG secondary antibodies were used at 1:10000. The blot was developed 
using 0.06% (w/v) 4-chloro-1-naphthol, 0.0015% (v/v) H2O2 in Tris buffered saline (20 mM 
Tris-HCl, 200 mM NaCl, pH 7.4). 
 
4.2.2.5 Enzymatic activity analysis of T. b. brucei ∆opb clones 
Parasites (1 x 107), were removed from culture, washed twice in PBS (pH 7.2) and 
resuspended in 900 µl of 0.1% (w/v) Brij-35 containing 10 µg/ml soybean trypsin inhibitor 
(SBTI) to inhibit other parasite serine proteases, 10 µM E-64 and 1 mM EDTA. The lysate 
was incubated for 10 min on ice, 100 µl of 10 x PBS added and centrifuged (10 000 g, 5 min, 
4°C). The protein concentration of the lysate supernatant was determined using the BCA™ 
protein assay. The hydrolysis of Z-Arg-Arg-AMC, Z-Gly-Pro-AMC and Z-Arg-Gly-Phe-Phe-
Pro-4MβNA.HCl by the total parasite protein extract (5 µg) was determined for each clone. 
Briefly, parasite protein extract diluted in 0.1% (w/v) Brij-35 was incubated with assay buffer 
[200 mM Tris-HCl buffer, pH 8, 10 mM DTT and 0.02% (w/v) NaN3] for 10 min at 37°C. 
Aliquots were combined with the appropriate AMC substrate (20 µM) and the fluorescence 
was read (excitation at 360 nm and emission at 460 nm) using a FLUOstar OPTIMA 
fluorescence microplate reader. Lysis buffer [0.1% (w/v) Brij-35, containing 10 µM E-64, 10 
µg/ml SBTI, 1 mM EDTA and 1 x PBS] was used as a negative control. Parallel activity 
assays with inhibitors were carried out with 1 mM AEBSF for TbOPB, and 100 µM Tosyl 
phenylalanyl chloromethyl ketone (TPCK) for TbPOP. When determining cysteine peptidase 
levels in total parasite extract, hydrolysis of Z-Phe-Arg-AMC was carried out using the same 
protocol but with 10 µM E-64 replaced by 1 mM AEBSF and 1 µg/ml of pepstatin A. For 
statistical analyses, values were expressed as means ± standard error of the mean (SEM). 
Significance levels were calculated by unpaired t tests and differences were considered 
significant at a p value <0.001. 
 
4.2.2.6 Detection of enzyme activity in zymograms 
Parasites (2 x 106) were removed from culture, washed twice with PBS (pH 7.2) and 
resuspended in 50 µl of lysis buffer [10 mM EDTA, 1% (v/v) Triton X-100, 20 mM Tris-HCl 
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buffer, pH 7.2]. An equal volume of non-reducing gel loading buffer was added. Lysates 
generated (25 µl) from ~ 5 x 105 parasites were separated per well on a 10% SDS-PAGE gel 
co-polymerised with 1% (w/v) gelatin at 18 mA per gel. After electrophoresis, gels were 
washed twice for 30 min in 2.5% (v/v) Triton X-100 before incubation in 0.1 M Mes buffer pH 
6.0, containing 2 mM EDTA and 1 mM dithiothreitol (DTT) overnight at 37ºC with different 
inhibitors. The following inhibitors and concentrations were used: 10 µM E-64, 10 µM 
pepstatin A, 100 µM TPCK, 100 µg/ml SBTI and 1 mM AEBSF. A control without any inhibitor 
was also incubated overnight. The gels were stained in freshly prepared 0.1% (m/v) amido 
black in methanol/ acetic acid/ water (30:10:60, by vol.) and destained in methanol/ acetic 
acid/ water (30:10:60, by vol.).   
 
4.2.2.7 Immunofluorescence, immuno-histochemistry and microscopy 
For immunofluorescence, ∆opb and wild type T. b. brucei Lister 427 parasites (1 x 106) were 
removed from culture, washed twice in PBS, spread and dried over microscope slides coated 
with 0.01% (w/v) poly-L-lysine before fixing with methanol for 15 min. The fixed parasite 
slides were blocked with 1% (w/v) BSA-PBS  for 1 h before incubation with mouse anti-OPB 
serum (1:500) and chicken anti-BIP IgY (5 µg/ml) in  0.2% (v/v) Triton X-100 in PBS for 1 h. 
All subsequent washes were done in 0.2% (v/v) Triton X-100 in PBS with 5 min for each 
wash. The slides were washed four times and incubated with the secondary fluorescein 
(FITC) conjugated donkey anti-mouse IgG and Cy3 (water soluble cyanine fluorescent dye) 
conjugated donkey anti-chicken IgG both at 1:1000 in 0.2% (v/v) Triton X-100 in PBS for 1 h. 
The slides were washed six times before incubation with Hoechst stain in PBS (2 ng/ml) for 5 
min. The slides were given 5 final washes in PBS, mounted and viewed using a LSM 710 
confocal microscope. To examine the ability of T. b. brucei ∆opb clones to cross endothelial 
barriers, testes from mice infected with 1 x 106 T. b. brucei ∆opb for 5 days were dissected 
and 14 µm thick sections prepared using a cryostat. Sections were mounted, fixed and 
immunostained as previously described (Masocha et al., 2004). Rabbit anti-VSG serum 
(1:1000) was incubated with tissue sections to detect trypanosomes in tissue and goat anti-
rabbit Dylite™ conjugate (1:800) used as a detection antibody. Sections were incubated with 
Hoechst stain in PBS (2 ng/ml) before viewing using a LSM 710 confocal microscope.  
4.2.2.8 Mouse infections 
In order to observe what role TbOPB plays in parasite virulence and infection, groups of 5 
female BALB/c mice were infected by an intraperitoneal injection of 1 x 103 T. b. brucei Lister 
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427 ∆opb parasites per mouse resuspended in 50 µl of phosphate saline glucose (PSG) [57 
mM Na2HPO4, 3 mM NaH2PO4, 42 mM NaCl, 50 mM glucose, 1 mM hypoxanthine, pH 7.4] in 
50% (v/v) glycerol. A control group was also infected with 1 x 103 T. b. brucei Lister 427 wild 
type parasites resuspended in 50 µl of PSG. Parasitaemia was measured daily by bleeding 
from the tail and survival of mice monitored during infection. Infection and care of infected 
mice was carried out using protocols approved by the University of KwaZulu-Natal animal 
ethics committee (Reference 036/09/Animal).  
 
4.3  RESULTS 
4.3.1  Generation of T. b. brucei Lister 427 and T. congolense IL3000 OPB mutants.  
Primers designed were used to amplify the 626 bp 3’ and the 929 bp 5’ regions flanking the T. 
congolense OPB gene (TcoOPB) (Fig.4.1, A1, lane 1 and B1, lane 1). The 626 bp and 929 bp 
PCR products amplified from T. congolense IL3000 genomic DNA were successfully cloned 
into the pTZ57R/T vector (T-vector) (Fig. 4.1, A2, lanes 1-5 and B2, lanes 1-8). 
 






























Figure 4.1 Amplification and T-vector cloning of the 5’ and 3’ regions flanking the T. congolense 
oligopeptidase B gene (TcoOPB). M: Middle Range™ DNA ladder mix. A1: lane 1, 626 bp PCR 
product flanking the 3’ region of the TcoOPB gene (←). A2: lanes 1-5, colony PCR identifying positive 
3’ TcoOPB clones in the T-vector. B1: lane 1, 929 bp PCR product flanking the 5’ region of the 
TcoOPB gene (←). B2: lanes 2-10, colony PCR identifying 5’ TcoOPB positive clones in the T-vector. 
Products were analysed on a 1% (w/v) agarose gel and stained with ethidium bromide (3 µg/ml). 
 
Primers were also used to amplify the 902 bp 5’ and the 601 bp 3’ regions flanking the 
TbOPB gene in T. brucei (Fig. 4.2, A1, lane 1 and B1, lane 1) and subsequently cloned into 
the T-vector (Fig. 4.2, A2, lane 2 and B2, lanes 1-4).     
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Figure 4.2 Amplification and T-vector cloning of the 5’ and 3’ regions flanking the T. brucei 
oligopeptidase B gene (TbOPB). M: Middle Range™ DNA ladder mix. A1: lane 1, 902 bp PCR 
product flanking the 5’ region of the TcoOPB gene. A2: lane 1, colony PCR identifying a 5’ TbOPB 
positive clone positive in the T-vector B1: lane 1, 601 bp PCR product flanking the 3’ region of the 
TcoOPB gene. B2: lanes 1-4, colony PCR identifying 3’ TbOPB positive clones in the T-vector. 
Products were analysed on a 1% (w/v) agarose gel and stained with ethidium bromide (3 µg/ml). 
 
Vectors containing blasticidin resistance (pGLbla) and neomycin resistance (pGLneo) were 
prepared for ligation with 3’- and 5’- TcoOPB, or TbOPB. pGLbla (4566 bp) (Fig. 4.3, A1, lane 
1) and pGLneo (4995 bp) (Fig. 4.3, A1, lane 2) were restricted with either NotI/XbaI or ApaI. 
Recombinant T-vector clones bearing T. congolense sequences were restricted using 
enzymes originally incorporated into the primers (Table 4.1), releasing the 626 bp product 
flanking the 3’ region (Fig. 4.3, A2, lane 1) and the 929 bp product flanking the 5’ region of the 
TcoOPB gene (Fig. 4.3, A3, lane 1). The two restricted products were sub-cloned into 
pGLneo and pGLbla to give pGLneoTcoOPB and pGLblaTcoOPB respectively. Orientation of 
the 3’ insert (due to identical ApaI sites on both ends of the restricted product) in the 
pGLblaTcoOPB and pGLneoTcoOPB recombinant plasmids was confirmed by PCR using 
vector and insert primers resulting in a 1843 bp product for pGLblaTcoOPB (Fig. 4.3, B1, lane 
1) and a 1893 bp product for pGLneoTcoOPB (Fig. 4.3, C, lane 1). The 929 bp 5’  and 626 bp 
3’ inserts in pGLblaTcoOPB (Fig. 4.3, B2, lanes 1 and 2) and in pGLneoTcoOPB (Fig. 4.3 C 
lanes 2 and 3), together with the 314 bp blasticidin (Fig. 4.3, B2, lane 3) and the 435 bp 
neomycin resistance markers (Fig. 4.3, C, lane 4) were also validated using PCR.  
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Figure 4.3 Subcloning of the 5’ and 3’ regions flanking the TcoOPB gene into pGLbla and 
pGLneo knock-out vectors. M: Middle Range™ DNA ladder mix. A1: Vector preparation; lane 1, 
NotI/XbaI or ApaI restricted 4566 bp pGLbla; lane 2, NotI/XbaI or ApaI restricted 4995bp pGLneo. A2: 
lane 1, NotI/XbaI restricted 626 bp product flanking the 3’ region of the TcoOPB gene (←). A3: lane 1, 
ApaI restricted 929 bp product flanking the 5’ region of the TcoOPB gene (←). B1: lane 1, 1843 bp 
product from recombinant pGLbla confirmed with PCR using the blasticidin forward primer with the 
insert 3’ reverse primer. B2: lane 1, 929 bp product from recombinant pGLbla confirmed with PCR 
using 5’ insert primers; lane 2, 626 bp product from recombinant pGLbla confirmed with PCR using 3’ 
insert primers; lane 3, 314 bp product from recombinant pGLbla confirmed using blasticidin forward 
and reverse primers. C: lane 1, 1893 bp product from recombinant pGLneo confirmed with PCR using 
the neomycin forward primer with the insert 3’ reverse primer; lane 2, 626 bp product from recombinant 
pGLneo confirmed with PCR using 3’ insert primers; lane 3, 929 bp product from recombinant pGLneo 
confirmed with PCR using 5’ insert primers; lane 4, 435 bp product from recombinant pGLneo 
confirmed with PCR using neomycin forward and reverse primers. Products were analysed on a 1% 
(w/v) agarose gel and stained with ethidium bromide (3 µg/ml).  
 
Recombinant T. brucei T-vector clones were also restricted releasing the 902 bp 5’ (Fig. 4.4, 
A1, lanes 1 and 2), and the  601 bp 3’ (Fig. 4.4, A2, lanes 1-3) regions flanking the TbOPB 
gene. The two restricted products were sub-cloned into pGLneo and pGLbla (Fig. 4.3, A1, 
lane 1 and 2) to give pGLneoTbOPB and pGLblaTbOPB respectively. Orientation of the 3’ 
insert was confirmed by PCR resulting in a 2007 bp product for pGLneoTbOPB (Fig. 4.4, B, 
lane 3) and a 1868 bp product for pGLblaTbOPB (Fig. 4.4, C1, lane 1). The  601 bp 3’ inserts  
(Fig. 4.4, B, lane 2 and C2, lane 3) and the  902 bp 5’ inserts (Fig. 4.4, B, lane 1 and C2, lane 
1) together with the 435 bp neomycin and 314 bp blasticidin resistance markers (Fig. 4.4, B, 
lane 4 and C2, lane 2) were also validated using PCR.  
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Figure 4.4 Subcloning of the 5’ and 3’ regions flanking the TbOPB gene into pGLbla and 
pGLneo knock-out vectors. M: Middle Range™ DNA ladder mix. A1: lanes 1-2, NotI/XbaI restricted 
902 bp product flanking the 5’ region of the TbOPB gene (←). A2: lanes 1-3, ApaI restricted 601 bp 
product flanking the 3’ region of the TbOPB gene (←). B: lane 1, 902 bp product from recombinant 
pGLneo confirmed with PCR using 5’ insert primers; lane 2, 601 bp product from recombinant pGLneo 
confirmed with PCR using 3’ insert primers; lane 3, 2007 bp product from recombinant pGLneo 
confirmed with PCR using neomycin forward primer with insert 3’ reverse primer; lane 4, 453 bp 
product from recombinant pGLneo confirmed with PCR using neomycin forward and reverse primers. 
C1: lane 1, 1868 bp product from recombinant pGLbla confirmed with PCR using blasticidin forward 
primer with insert 3’ reverse primer. C2: lane 1, 902 bp product from recombinant pGLbla confirmed 
with PCR using 5’ insert primers; lane 2, 314 bp product from recombinant pGLbla confirmed using 
blasticidin forward and reverse primers; lane 3, 626 bp product from recombinant pGLbla confirmed 
with PCR using 3’ insert primers. Products were analysed on a 1% (w/v) agarose gel and stained with 
ethidium bromide (3 µg/ml).  
 
The transfection of wild type bloodstream forms of T. congolense with pGLblaTcoOPB 
produced a distinct heterozygote clone resistant to blasticidin (BLA), T. congolense 
Δopb::BLA/OPB. Several rounds of transfection with pGLneoTcoOPB using the T. 
congolense Δopb::BLA/OPB were not successful (results not shown). The T. congolense 
heterozygote clone was confirmed in a Southern blot using a probe specific to blasticidin (Fig. 
4.5 A). A band at the expected size of 2470 bp was detected in BamHI restricted T. 
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Figure 4.7 Deletion of the OPB gene in T. b. brucei Lister 427. Agarose gel (left hand panels) and 
corresponding Southern blot (right hand panels) of wild type and ∆opb null mutants. M: DNA ladder; 
lane 1, DraI restricted genomic DNA; lane 2, corresponding Southern blot; NEO (neomycin); BLA 
(blasticidin). A: T. brucei 427 Lister wild type genomic DNA incubated with probe 1. B: T. brucei 427 
Lister ∆opb null mutant parasite genomic DNA incubated with probe 1. C: T. brucei 427 Lister ∆opb 
null mutant parasite genomic DNA incubated with probe 2. D: T. brucei 427 Lister ∆opb null mutant 
parasite genomic DNA incubated with probe 3.  
 
4.3.2 ∆opb null mutant clones are unable to hydrolyse Z-Arg-Arg-AMC 
TbOPB was detected in a western blot with anti-OPB antibodies in wild type T. b. brucei 
Lister 427 parasites, (Fig. 4.8 A, left hand panel, lane 2), and at a lower intensity in the 
heterozygote (Fig. 4.8 A, left hand panel, lane 3). No TbOPB was detected in the lane loaded 
with the ∆opb null mutant parasites (Fig. 4.8 A, left hand panel, lane 4). By comparison, 
reprobing the blot with anti-BIP antibodies as a loading control confirmed the presence of 
equal amounts of BIP in all three samples (Fig. 4.8 A, right hand panel). This confirmed that 
TbOPB gene was deleted in ∆opb null mutant parasites. ∆opb null mutant parasites were also 
confirmed in an activity assay using Z-Arg-Arg-AMC (Fig. 4.8, B), the preferred peptide 
substrate for OPB in T. b. brucei (Coetzer et al., 2008). Wild type T. b. brucei parasites were 
able to hydrolyse Z-Arg-Arg-AMC compared to the heterozygote clones ∆opb::BLA/OPB and 
∆opb::NEO/OPB which hydrolysed on average half as much of the substrate relative to the 
wild type parasites (Fig. 4.8 B). The ∆opb null mutants hydrolysed less than 5% of the 
 112
substrate relative to the wild type (Fig. 4.8 B) that is equivalent to the level of activity obtained 
with the no lysate control, which may be ascribed to background hydrolysis of the substrate.   
 







Figure 4.8 Characterisation of ∆opb heterozygote and null mutants. A: Mouse anti-OPB 
antibodies fail to recognise OPB in ∆opb null mutants. Polyclonal mouse anti-OPB was used to detect 
OPB in T. b. brucei wild type, heterozygote and ∆opb null mutants. Polyclonal chicken anti-BIP 
antibodies were used as a loading control. Approximately 5 x 105 parasites were loaded per well. B. 
∆opb null mutants do not hydrolyse Z-Arg-Arg-AMC. Total parasite lysate (5 µg) from each clone was 
resuspended in 0.1% (w/v) Brij-35 containing 10 µg/ml soybean trypsin inhibitor, 10 µM E-64 and 1mM 
EDTA and used to measure the hydrolysis of Z-Arg-Arg-AMC. Fluorescence values obtained relative to 
those with wild type parasites as a percentage. The mean of triplicate experiments ± SEM was plotted 


























4.3.3 T. b. brucei ∆opb null mutant parasites do not display any morphological, 
growth rate or virulence defects 
Fluorescence microscopy of wild type and ∆opb null mutant parasites showed no differences 
in morphology where mouse anti-OPB polyclonal antibodies were able to discriminate 
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Figure 4.9 Δopb null mutant parasites are not recognised by mouse anti-OPB polyclonal 
antibodies and do not display any morphological differences when compared to wild type T. b. 
brucei Lister 427 strain parasites. Trypanosomes from wild type (A) and ∆opb null mutant (B) 
cultures were fixed on slides and probed sequentially with polyclonal mouse anti-OPB serum (1:500) 
and  chicken anti-BIP IgY (5 µg/ml) as a control before viewing under a confocal microscope; panel 1, 
DCI light image; panel 2, Hoestch nuclear staining; panel 3, Cy3 filter for chicken anti-BIP antibodies; 
panel 4, FITC filter for mouse anti-OPB antibodies; panel 5, Combined images.  
 
∆opb null mutant clones were assessed for any differences in the rate of division and growth 
during in vitro culture. No differences were seen in the growth of the parasites when 
compared to the heterozygote or wild type strains (Fig. 4.10 A). The group of mice infected 
with ∆opb null mutant parasites did not survive any longer than the wild type group (Fig. 4.10 
C) and parasitaemia counts were not significantly different between both infected groups (Fig. 





































































Figure 4.10 Infecting mice with ∆opb null mutants had no effect on survival or parasitaemia in vivo. A: The rate of parasite growth in vitro 
was monitored. T. brucei 427 wild type and ∆opb null mutant parasites (1 x 105/ml of each) were diluted to approximately 1 x 105 cells/ml in BSF 
growth medium and grown at 37°C until saturation (106 cells/ml); *p< 0.001 in comparison to the wild type. B: Parasitaemia in mice infected with 
wild type parasites compared to ∆opb null mutant infected mice. Each value is a mean of 5 mice; *p< 0.001 in comparison to the wild type. C: 
Kaplan-Meier survival analysis for mice infected with T. b. brucei wild type parasites compared to ∆opb  null mutant infected mice (n=5 in each 
group).  
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To confirm that TbOPB is not a virulence factor, blood collected from the different infected 
groups was used to measure residual TbOPB activity in vivo (Fig. 4.11). Blood from mice 
infected with ∆opb null mutant parasites was unable to hydrolyze Z-Arg-Arg-AMC when 
compared to blood from mice infected with the wild type strain (Fig. 4.11). The relative value 
of fluorescence using blood from ∆opb null mutant infected mice was comparable to that from 






























Figure 4.11 Blood from mice infected with ∆opb null mutant parasites does not hydrolyse Z-
Arg-Arg-AMC. 25 µl of blood from mice infected with wild type parasites, ∆opb null mutants and non-
infected mice was resuspended in 0.1% (w/v) Brij-35 with 10 µg/ml soybean trypsin inhibitor, 10 µM E-
64 and 1mM EDTA and hydrolysis of Z-Arg-Arg-AMC measured. A mean of triplicate fluorescence 
values were plotted relative to those obtained with the wild type as a percentage for each experiment ± 
SEM; *p< 0.001 in comparison to the wild type. 
 
T. brucei 427 Lister parasites are known to cross endothelial barriers in mouse testes (Claes 
et al., 2009). In order to observe if TbOPB plays a role during crossing, immunofluorescence 
staining of parasites in the testes of mice 5 days after infection with ∆opb null mutant 
parasites showed parasites outside microvascular blood vessels in the interstitial spaces 
between seminiferous tubules (Fig. 4.12). This confirmed that T. b. brucei ∆opb null mutant 





Figure 4.12 ∆opb null mutant parasites localise in intravascular and extravascular areas of the 
mouse testes. Immunofluorescence staining of trypanosomes following incubation with rabbit anti-
VSG antibodies in sections of testes from mice 5 days after infection with 1 x 106 ∆opb null mutant 
parasites revealed parasites (in green) both inside blood vessels and in interstitial spaces between 
seminiferous tubules. IT, intravascular trypanosomes; ET, extravascular trypanosomes; BV, blood 
vessel; ST, seminiferous tubule.     
 
4.3.4 T. b. brucei ∆opb null mutant parasites show significantly elevated levels of 
prolyl oligopeptidase. 
In order to observe how other trypanosomal proteases are affected by knocking out the 
TbOPB gene, proteolytic activity of ∆opb null mutant parasite lysates from in vitro cultures 
was assessed on gelatin containing SDS-PAGE gels (Fig. 4.13 A, lane 1) and compared to T. 
b. brucei wild type parasite lysates (Fig. 4.13 A, lane 2). Two areas of gelatin digestion at 
approximately 200 kDa (Fig. 4.13 A, i) and 150 kDa (Fig. 4.13 A, ii), were more prominent in 
the lanes loaded with ∆opb null mutant parasite lysate than in lanes containing wild type 
parasite lysate. In order to identify the class of peptidases showing elevated activity in ∆opb 
null mutants, lysates were separated on duplicate gelatin containing gels and the gels 
incubated separately with AEBSF (Fig. 4.13 B), pepstatin A (Fig. 4.13 C), E-64 (Fig. 4.13 D), 
SBTI (Fig. 4.13 E) and TPCK (Fig. 4.13 F). The intensity of bands of hydrolysis on gels 
incubated with AEBSF, pepstatin A and SBTI were not significantly different from those on 
the gel incubated in the absence of inhibitors (Fig. 4.13 A). However, in the presence of E-64, 
digestion of gelatin was only observed at approximately 54 kDa (Fig. 4.13 D). The major 
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cysteine protease band at approximately 30 kDa was inhibited by both E64 and TPCK (Fig. 
4.13 D and F). 
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Figure 4.13 T. b. brucei ∆opb null mutant parasites show elevated levels of cysteine peptidase 
activity. Lysates from 5 x 105 parasites were loaded per well on a gelatin gel and incubated in 0.1 Mes 
buffer pH 6 overnight with or without inhibitor. M: marker; lane 1, T. b. brucei ∆opb null mutant parasite 
lysate; lane 2, T. b. brucei wild type parasite lysate. Gels were incubated in 0.1 Mes buffer pH 6 
containing A, No inhibitor; B, 1 mM AEBSF; C, 1 µg/ml pepstatin A ; D, 1 µM E-64 ; E, 100 µg/ml SBTI 
and F, 100 µM TPCK. Gels were stained in freshly prepared 0.1% (m/v) amido black in methanol/acetic 
acid/water (30:10:60, by vol.) and destained in methanol/ acetic acid/ water (30:10:60, by vol.). Areas 
at ~200 kDa (i) and ~150 kDa (ii) at are increased in T. b. brucei ∆opb null mutant parasites. Only 
activity at ~54 kDa (iii) is not actively inhibited by E-64.  
 
An activity assay using Z-Gly-Pro-AMC and Z-Arg-Gly-Phe-Phe-Pro-4MβNA.HCl was carried 
out to observe if the levels of prolyl oligopeptidase in T. brucei (TbPOP) are affected in the 
absence of TbOPB (Fig. 4.14). Z-Phe-Arg-AMC and Z-Arg-Arg-AMC, the preferred substrates 
for trypanosomal cysteine proteases and OPB respectively, were also included. Z-Gly-Pro-
AMC hydrolysis was increased by more than 500% in ∆opb null mutant parasites when 
compared to the wild type (Fig. 4.14). This markedly elevated activity was confirmed by Z-
Arg-Gly-Phe-Phe-Pro-4MβNA.HCl at 200% (Fig. 4.14). Blood from mice infected with ∆opb 
null mutant parasites also displayed increased hydrolysis of Z-Gly-Pro-AMC by 200% when 
compared to blood from mice infected with wild type parasites (Fig. 4.14). Naive blood from 
non-infected mice had the highest activity against Z-Gly-Pro-AMC at almost 300% higher 
than controls due to endogenous prolyl oligopeptidase in the mouse blood (Fig. 4.14). TPCK 
was more effective in inhibiting TbPOP activity in both ∆opb null mutant and wild type 
parasites than AEBSF (Fig. 4.14). A slightly elevated level at approximately 10% of Z-Phe-
Arg-AMC hydrolysis was observed in ∆opb null mutant parasites when compared to the wild 
type confirming the increased cysteine protease activity observed in the zymograms (Fig. 
4.14). E-64 inhibited cysteine protease activity in both ∆opb null mutant and wild type 











Figure 4.14 ∆opb null mutants hydrolyse significantly more Z-Gly-Pro-AMC than wild type parasites. Total parasite lysate from each 
clone (5 µg) or 25 µl of blood from infected mice was resuspended in 0.1% (w/v) Brij-35 with 10 µg/ml SBTI, 1 µg/ml of pepstatin A, and 1 mM 
EDTA and used to measure hydrolysis of either Z-Arg-Arg-AMC specific for TbOPB, Z-Phe-Arg-AMC specific for cysteine peptidases and Z-
Gly-Pro-AMC or Z-Arg-Gly-Phe-Phe-Pro-4MβNA.HCL specific for TbPOP as peptide substrates. A mean of triplicate fluorescence values was 
plotted relative to those obtained with the wild type parasites as a percentage for each experiment ± SEM. *p< 0.05 and **p<0.001 in 
comparison to the wild type parasites. Identical triplicates were incubated with the inhibitors 10 µM E-64, 100 µM TPCK and 1 mM AEBSF to 




To assess if this increase in hydrolysis of substrates containing a prolyl residue in P1 was due 
to an increased level of TbPOP expression in ∆opb null mutant parasites, a western blot 
using anti-POP mouse serum revealed that TbPOP levels remained unchanged in ∆opb null 
mutant parasites compared to wild type parasites (Fig. 4.15, left hand panel). Reprobing the 
blot with anti-BIP antibodies as a loading control confirmed the presence of equal amounts of 
BIP in both parasite lysates (Fig. 4.15, right hand panel). 
97 kDa
66 kDa
Mouse anti-POP Chicken anti-BIP  
Figure 4.15 Measuring protein levels of POP in T. brucei 427 wild type parasites and ∆opb null 
mutants. Mouse anti-POP antibodies recognise POP in ∆opb null mutants at similar levels to POP in 
T. brucei wild type parasites. Polyclonal mouse anti-POP serum was used at a dilution of 1:300. 
Polyclonal chicken anti-BIP antibodies were used as a loading control. Approximately 5 x 105 parasites 
were loaded per well.  
 
4.4 DISCUSSION 
Since TbOPB is expressed as an active cytosolic peptidase at all stages of the T. brucei life 
cycle (Mbawa et al., 1991; Morty et al., 1999b), it is likely to have more than one function 
given the varied environments the parasite endures in different hosts. Obtaining ∆opb null 
mutants in this experiment confirms that TbOPB does not play an essential role in parasite 
survival as has been previously observed in other trypanosomatid parasites such as T. cruzi 
(Caler et al., 1998) and Leishmania spp. (Munday et al., 2011; Swenerton et al., 2011). This 
finding is confirmed by similar growth kinetics in ∆opb null mutants when compared to those 
of the wild type strain even though ∆opb null mutants showed no activity against Z-Arg-Arg-
AMC. Unfortunately, it was only possible to obtain OPB heterozygotes in T. congolense 
IL3000. Previous work has shown that knocking out OPB has a minimal effect on the 
establishment of disease in T. cruzi and Leishmania (Caler et al., 1998; Munday et al., 2011; 
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Swenerton et al., 2011) and this was also observed in the present study with T. brucei ∆opb 
null mutants that were as virulent and pathogenic as the wild type parasites. This result 
correlates well with observations in studies with intracellular trypanosomatids where strong 
phenotypes in the absence of OPB were mostly associated with host cell invasion rather than 
with the establishment of disease in mammalian hosts. 
 
Because T. brucei is an exclusively extracellular parasite it is not surprising that a specific 
phenotype was not observed in infected mice without active TbOPB in the bloodstream. T. 
brucei is an exclusively extracellular parasite that releases OPB after lysis in the host (Morty 
et al., 2001; Coetzer et al., 2008). A mouse infection study was carried out in order to assess 
the possible role that OPB plays in an infection involving extracellular kinetoplastids. There 
were no significant differences in parasitaemia or survival between mice infected with either 
T. brucei Δopb null mutants or wild type parasites. It must be emphasised that although mice 
have been extensively used as a model for trypanosome infections (Antoine-Moussiaux et al., 
2008) and (Magez and Caljon, 2011), extrapolations to the natural infection in cattle should 
be done with caution. T. b. brucei 427 Lister strain infections in mice are used as a model for 
the acute disease in ruminants (Claes et al., 2009), with death occurring within 6–8 days after 
an intraperitoneal injection of 1 × 103 parasites. It would be difficult to evaluate the role of 
TbOPB in mice infected in this manner when compared to a natural infection, where the 
number of parasites infecting the host would be less when delivered by a tsetse bite and the 
resulting infection is chronic (Magez et al., 2010). The in vivo functions of TbOPB can only be 
effectively studied in a ruminant host where a more natural chronic infection is possible, and 
thus, it would be inappropriate to rule out TbOPB as a virulence and pathogenic factor using 
the results observed in this study. 
 
T. brucei parasites are known to cross blood barriers in immuno privileged organs such as 
the brain (Grab et al., 2004; Grab and Kennedy, 2008; Grab et al., 2009) and testes (Claes et 
al., 2009), with cysteine proteases involved in facilitating this process (Nikolskaia et al., 
2006a; Abdulla et al., 2008). It has been previously suggested that TbOPB may have a role to 
play in crossing endothelial barriers in microvascular vessels (Lonsdale-Eccles and Grab, 
2002), and to investigate this thin sections of ∆opb T. brucei infected mouse testes were 
probed with rabbit anti-VSG antibodies. Testes were chosen for sectioning because T. b. 
brucei Lister 427 localises and displays enhanced parasite development in this organ (Claes 
et al., 2009). Parasites were identified outside blood vessels in the interstitial spaces between 
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seminiferous tubules. This confirmed that TbOPB is not involved in assisting parasites in 
crossing endothelial cell blood barriers into tissue.  
 
With no definite phenotype identified for Δopb T. brucei parasites, an investigation of how the 
activity of other T. b. brucei peptidases is affected by the absence of TbOPB was undertaken. 
This would indicate if there are any overlapping functions between TbOPB and other 
proteases within the same serine peptidase family and also across peptidase families. 
Cathepsin L-cysteine peptidases in F. hepatica belong to a large family divided into five 
groups with different substrate specificities that overlap in function (Robinson et al., 2008). 
The expression of these different peptidase classes is tightly regulated according to the life 
cycle stage and environment where F. hepatica is found. Other instances of overlapping 
functions across different peptidase families include plasminogen and different classes of 
matrix metalloproteinases (MMPs) (Lund et al., 1999; Solberg et al., 2003). Using gelatin 
zymograms in the presence and absence of class-specific inhibitors, we were able to identify 
an increase in the levels of cysteine peptidase activity in Δopb T. b. brucei parasites when 
compared to the wild type parasites.  
 
It has been suggested for Leishmania, that up-regulation of other OPB-like genes might 
compensate for the loss of OPB (de Matos Guedes et al., 2008; Munday et al., 2011). 
Because oligopeptidases do not hydrolyse gelatin, peptidolytic activity assays with a proline 
residue in the P1 position (Bastos et al., 2010) was used to assess activity levels of TbPOP, a 
well characterised prolyl oligopeptidase that belongs to the same peptidase family as OPB 
and potentially hydrolyse the same physiological peptide hormone substrates that contain 
both Arg/Lys and Pro residues (Table 4.2). Unlike other serine oligopeptidases, TbPOP is 
poorly inhibited by AEBSF and more effectively inhibited by TPCK (Bastos et al., 2010). 
These unique characteristics of the peptidase were evident in assays using Arg-Gly-Pro-AMC 
where the levels of POP-activity were increased by more than 500% in Δopb null mutants 
compared to wild type parasites and the activity was more effectively inhibited by TPCK than 
by AEBSF. Z-Arg-Gly-Phe-Phe-Pro-4MβNA·HCl was not as effective as the AMC substrate 
because a higher background value was observed in the no lysate control. An accompanying 
increase in TbPOP protein levels in Δopb null mutants was not observed when compared to 
T. brucei wild type lysates, signifying that either another POP-like peptidase was responsible 
for the observed increase in activity, or that TbOPB is able to activate an inhibitor specific for 
TbPOP, thus leading to an increase in TbPOP activity in its absence.  
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Table 4.2 Hydrolysis of peptide hormones by TbOPB and TbPOP 
Peptide TbOPB hydrolysis sites TbPOP hydrolysis sites 
ANF SLR↓ R↓ SSCFGGR↓ IDRIGAQSGLGCNSFR↓ Y a SLRRSSCFGGRIDRIGA↓ QSGLGCNSFRY 
β-endorphin YGGFMTSEK↓ SQTPLVTLFK↓ NAIIK↓  NAYK↓ K↓ GE YGGFMTSEKSQTP↓ LVTLFKNA↓ IIKNAYKKGE b 
Neurotensin pELYENK↓  PR↓  R↓  PYIL-NH2 pELYENKP↓ RRP↓ YIL-NH2 b 
GnRH pEHWSYGLR↓  PG-NH2c pEHWSYGLRP↓ G-NH2  b 
Bradykinin RPPGFSPFR↓  -NH2 RP↓ P↓ GFSP↓ FR-NH2 b 
TRH pEHP-NH2 pEHP↓ -NH2  b 
aMorty et al. (2005a); bBastos et al. (2010); cTetaert et al. (1993). 
 
Previous experiments involving the inhibition of TbOPB by trypanocidal drugs (Morty et al., 
1998) and phosphonate diphenyl esters (Morty et al., 2000) have shown it to be a major 
target of these compounds. Active site labelling identified a band at 80 kDa using fluorescent 
irreversible inhibitors with an arginine residue or arginine analogue in P1 (Morty et al., 2000) 
although native TbPOP is also approximately 80 kDa in size (Bastos et al., 2010), it would not 
have been labelled by the fluorescent inhibitor with this P1 specificity. However, as shown in 
the same study (Morty et al., 2000), these fluorescent irreversible inhibitors also targeted 
other peptidases in T. b. brucei lysates: the peptidyl phosphonate diphenyl ester targeted a 
minor 45 kDa protein, while 120 and 68 kDa proteins were targeted by biotin-Arg-CH2Cl. By 
acting on multiple targets in trypanosomes these inhibitors would therefore be able to kill 
trypanosomes in culture and clear T. brucei parasites in infected mice (Morty et al., 2000), 
whereas specific deletion of this TbOPB gene appears not to be sufficient to affect the 
viability of the Δopb null mutant trypanosomes. Several potential peptide hormone substrates 
all have alanine or proline and arginine or lysine residues that can be cleaved by TbPOP and 
TbOPB, respectively (Table 4.2). This would imply that in the absence of TbOPB, TbPOP or a 
closely related POP-like peptidase would still be capable of hydrolysing these hormones and 
other substrates at a higher turnover. 
 
In conclusion, T. brucei Δopb null mutant parasites were generated with no OPB activity, but 
their TbPOP activity was increased significantly. Since T. brucei serine oligopeptidases have 
the ability to hydrolyse the same peptide hormones, in the absence of one peptidase 
(TbOPB), other peptidases (such as TbPOP) can be up-regulated in activity to take over that 
function. When controlling trypanosomosis, it will be necessary to consider more than one 
target for drug and vaccine development in order to give full protection to the disease. 
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CHAPTER 5  
GENERAL DISCUSSION 
African animal trypanosomosis is a disease in cattle that poses a major impediment to 
agricultural development in sub-Saharan Africa and costs the continent USD $ 1 - 5 billion 
annually in economic losses (Kristjanson et al., 1999; Baral, 2010). Chemotherapy, the main 
mode of treatment available to subsistence farmers in Africa (McDermott and Coleman, 
2001), is fast becoming a non-viable option due to the development of resistance in 
trypanosomes to commonly used drugs in the region (Delespaux and de Koning, 2007). The 
development of a vaccine as an alternative to chemotherapy has been hampered by 
antigenic variation in trypanosomes, which makes it difficult to use a VSG based vaccine 
(McCulloch and Horn, 2009). An alternative that has been suggested is to target pathogenic 
products released during an infection in a strategy referred to as an ‘anti-disease’ approach 
(Authié et al., 1993b; Schofield, 2007; Antoine-Moussiaux et al., 2009). In trypanosomes, 
several toxins that cause harm are released into the host circulatory system. These include 
lipids, hemolysins, mitogens, complement activating and inflammatory factors, hepatotoxins 
and peptidases (Tizard et al., 1978; Antoine-Moussiaux et al., 2009). Phospholipase A1 from 
T. cruzi has been shown to mediate the breakdown of host phosphatidylcholine resulting in 
an increase of free fatty acids levels in circulation that have the potential to disrupt membrane 
phospholipid bilayers (Wainszelbaum et al., 2001). Sialidases released during trypanosome 
infection are responsible for pathogenesis by altering red blood cell surfaces resulting in 
phagocytosis and subsequent anaemia (Nok and Balogun, 2003). Other pathological factors 
released during trypanosome infection include proline racemase that acts as a B cell mitogen 
leading to polyclonal B cell activation thus diverting parasite specific responses in T. cruzi 
infections (Reina-San-Martin et al., 2000). The abnormal activation of host complement is 
caused by trypanosome products such as GP63 surface protease and calreticulin leading to 
tissue degradation and inflammation (Zambrano-Villa et al., 2002; Jameel M, 2004; Ferreira 
et al., 2005). Peptidases that have been implicated in pathogenesis include cathepsin L-like 
peptidases (CATLs) and oligopeptidases (Mottram et al., 1998; Authié et al., 2001; Coetzer et 
al., 2008).  
 
Trypanotolerant cattle, such as the N’dama longhorn, are able to remain productive under 
natural trypanosome challenge by controlling parasitaemia and anaemia, and by producing 
antibodies specific to pathogenic invariant trypanosome antigens (Naessens et al., 2002). 
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Although these antigen-specific antibodies are not responsible for controlling parasite 
numbers during infection, they may be important for neutralising the pathogenic products 
released by infecting trypanosomes. The two peptidases studied in this work, TcoCATL 
(congopain) and OPB (oligopeptidase B), have been implicated in causing pathogenesis 
during natural trypanosome infections. A high IgG response to TcoCATL has been observed 
in trypanotolerant cattle as opposed to trypanosusceptible cattle (Authié et al., 1992; Authié et 
al., 1993a; Authié et al., 1993b), indicating that an immune response against the peptidase is 
necessary to control symptoms associated with the disease. Rats, experimentally infected 
with T. brucei,  have active OPB released into their bloodstream by dead and dying parasites 
which is responsible for catalysing the hydrolysis of peptide hormones leading to homeostatic 
associated pathologies such as hypervolemia and circulatory lesions (Morty et al., 2001; 
Coetzer et al., 2008). The main aim of this study was to investigate the function of two 
trypanosome peptidases that have been identified as pathogenic factors during infection, 
namely TcoCATL and oligopeptidase B in T. brucei and T. congolense, using gene disruption.  
 
TcoCATL is a member of the cathepsin L-like subfamily of the C1 family within clan CA of 
cysteine peptidases (Rawlings et al., 1994; Rawlings et al., 2008). Members of this subfamily 
have the ‘ERFNIN’ conserved motif in their pro-region, substrate specificity defined by the S2 
pocket and like other members of clan CA, are sensitive to inhibition by the cysteine 
peptidase inhibitor E64 (Caffrey and Steverding, 2009). TcoCATL and TcrCATL have broad 
pH profiles that include physiological pH (Mbawa et al., 1992; Chagas et al., 1997; Pillay et 
al., 2010). The ability of parasite CATL-like peptidases to remain active at neutral pH enables 
them to carry out various extra-lysosomal functions necessary for survival in the mammalian 
host. As described in Section 2.3.3 of this work, inducing RNAi against TcoCATL in vivo led 
to a reduction of circulating parasites in mice. It was, however, not possible to induce 
TcoCATL RNAi in procyclics, the only T. congolense life cycle stage that was successfully 
grown in vitro during the course of these experiments. Considering that TcoCATL is only 
expressed maximally during the bloodstream stage of the T. congolense life cycle (Mbawa et 
al., 1991; Mbawa et al., 1992; Pillay, 2011), targeting TcoCATL at the procyclic stage, would 
not have provided any functional information. An attempt to grow the bloodstream form of the 
parasite in vitro was not successful, and modifications such as using fresh goat serum and 
red blood cell lysate were made following a recently described protocol (Coustou et al., 
2010). As an alternative to in vitro studies, it was decided to use transformed procyclic 
parasites that had been differentiated into metacyclics to infect mice and induce RNAi in vivo, 
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similar to a study carried out with TbCATL (Abdulla et al., 2008). Groups of mice infected with 
parasites induced for TcoCATL RNAi displayed a lower parasite burden for an extended 
period of time that could be correlated to reduced TcoCATL activity in blood. This phenotype 
can be attributed to a defect in different mechanisms where CATL peptidases are crucial for 
parasite survival such as nutrition, immunoevasion, virulence and the processing and 
activation of host and parasite proteins (Sajid and McKerrow, 2002). A summary of these 
CATL functions in different kinetoplastid parasites is shown in Table 5.1.  
 
CATL-like peptidases are responsible for the degradation of host proteins that provide 
nutrition in different parasites (Sajid and McKerrow, 2002). In P. falciparum, falcipain-2, a 
CATL-like cysteine peptidase, is responsible for degrading host haemoglobin for nutrition in 
early to mid stage trophozoites (Sijwali and Rosenthal, 2004). This function was described 
after knocking out the gene transcribing falcipain-2, and an accumulation was observed of 
undigested haemoglobin in the parasite food vacuole (Sijwali and Rosenthal, 2004). A similar 
phenotype was also observed in parasites treated with E64 which also resulted in the 
accumulation of undigested haemoglobin (Gamboa de Dominguez and Rosenthal, 1996). 
However, in falcipain-2 null mutants, the phenotype is transient and late trophozoites 
recovered as they developed into the schizont stage. This has been attributed to the 
presence of a second gene coding for falcipain-2 that is transcribed in late stage trophozoites 
(Sijwali and Rosenthal, 2004). The characterisation of recombinant CATL from S. mansoni 
(SmCL1) revealed that the peptidase is also capable of degrading haemoglobin (Brady et al., 
1999). Interestingly, SmCL1 is only able to degrade haemoglobin at pH 4-4.5, indicating that 
it is most active in the schistosome gut where ingested haemoglobin is abundant (Brady et 
al., 1999). In T. brucei, the degradation of transferrin has been attributed to TbCATB rather 
than TbCATL (Mackey et al., 2004). Native TbCATL isolated from infected mice hydrolyses 
fibrinogen, BSA and rabbit IgG at physiological pH in vitro (Troeberg et al., 1996b). However, 
it has also been noted that TbCATL catalytic activity in vivo is inhibited by host cystatins 
(Nwagwu et al., 1988; Troeberg et al., 1996b). T. brucei parasites targeted for CATB knock-
down using RNAi showed an accumulation of FITC-transferrin in RNAi induced parasites 
(Mackey et al., 2004). Bloodstream form parasites acquire iron from the host, and the 
reduced levels of TbCATB led to parasite death in vitro and during infection (Mackey et al., 
2004; Abdulla et al., 2008). TcoCATL may also be responsible for the degradation of host 
proteins due to its in vitro activity on proteins such as BSA, fibrinogen and VSG (Mbawa et 
al., 1992). The role that TcoCATL plays in degrading host proteins may be in conjunction with 
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other peptidases where more than one peptidase can be involved in processing as observed 
in P. falciparum parasites. The degradation of haemoglobin in malaria parasites requires 
plasmepsins that hydrolyse haemoglobin to globin polypeptides (Silva et al., 1996), falcipain-
2 and 3 which hydrolyse the polypeptides to 10-20 residue-long oligopeptides (Sijwali et al., 
2001; Sijwali and Rosenthal, 2004), falcilysin that further catalyse the hydrolysis of 
oligopeptides to 5-10 residue long peptides (Murata and Goldberg, 2003) and finally 
dipeptidyl aminopeptidase 1 that cleaves the short peptides to dipeptides for amino acid 
uptake (Klemba et al., 2004).  
 
Trypanosome CATLs are also involved in protein processing and activation (Caffrey et al., 
2011). Taking into account that T. congolense is an extracellular parasite that is strictly 
confined to the host blood circulation (Ojok et al., 2002), protein processing becomes 
important in relation to evading the host immune response to which the parasite is constantly 
exposed. One method through which trypanosomes are able to escape immune targeting by 
the host is by internalising and degrading trypanosome specific antibodies that are bound to 
surface VSG, as has been observed in T. cruzi  (Teixeira and Santana, 1989). In T. brucei, 
deletion of a gene that codes for the endogenous cysteine peptidase inhibitor (ICP) resulted 
in parasites with a three-fold increase in TbCATL activity, and the degradation of VSG-IgG 
complexes was more efficient when compared to the wild type (Santos et al., 2007). 
Furthermore, the increase in VSG-bound IgG degradation in parasites without ICP was 
specifically inhibited when K11777 and E-64 (both inhibitors of TbCATL) were added to 
parasites labelled with anti-VSG 221 antibodies in vitro (Santos et al., 2007). These 
observations suggest that the increased degradation of VSG-IgG complexes by the parasites 
lacking ICP was due to higher TbCATL activity in the absence of ICP, thus implicating 
TbCATL in the breakdown of VSG-antibody complexes in the lysosome. In T. cruzi, TcrCATL 
hydrolyses high molecular weight kininogen into kinins and this process is enhanced in the 
presence of heparin sulfate (Lima et al., 2002). Kinins released through the action of 
TcrCATL activate local endothelial or smooth muscle cells through kinin receptors, leading to 
inflammatory responses aiding parasite cell invasion and causing symptoms associated with 
heart disease, a hallmark of chagas disease (Scharfstein et al., 2000). The unusual 
processing of the merozoite surface protein-1 (MSP-1) by falcipain seems to occur in P. 
falciparum to facilitate merozoite release from the erythrocyte (Sajid and McKerrow, 2002). 
Falstatin, an endogenous inhibitor for falcipain, regulates falcipain-2 activity in late-stage 
merozoites to modulate the hydrolysis of MSP-1 (Pandey et al., 2006).   




Life stage(s) expressed Sub-cellular distribution Assigned Functions References 
T. congolense TcoCATL1 (CP1) Bloodstream Flagellar pocket,  
Lysosome 




Bloodstream Lysosome Trypanotolerance, degradation of 
endocytosed proteins 





Lysosome Degradation of endocytosed  
proteins 
vi, vii 
vi, viii, ix, x, 
xi, xii 
T. brucei  TbCATL (brucipain, 
trypanopain-Tb) 
Bloodstream Lysosome Degradation of anti-VSG IgG and host 
proteins, crossing blood-brain barrier, 
disease progression in mice, degradation of 
host proteins 
TbCATB (tbcatB) All life stages Lysosome Degradation of transferrin, degradation of 




LmCATL-A All life stages Lysosome Macrophage infection, virulence, potentiates 








Macrophage infection, virulence, lesion 
progression, host immune modulator 
(switches host immune response from Th-1 
to Th-2) 
xvii, xviii, xix, 
xx, xxi 
LmCATL-B3-18 Amastigotes Lysosome Macrophage infection, virulence xxii, xxiii 







Generation of kinins, inflammation, host cell 
signalling, host cell invasion. 
xxiv, xxv, 
xxvi 
TcrCATL2 (cruzipain 1) Trypomastigotes Undetermined Host cell invasion xxvii 
iFish et al. (1995), iiBoulangé et al. (2001), iiiMbawa et al. (1992), ivAuthié (1994), vChagas et al. (1997), viMbawa et al. (1991), viiMendoza-
Palomares et al. (2008), viiiTroeberg et al. (1996b), ixNikolskaia et al. (2006a), xSantos et al. (2007), xiAbdulla et al. (2008), xiiGrab et al. (2009),  
xiiiTazeh et al. (2009), xivMackey et al. (2004), xvO’Brien et al. (2008), xviZhang et al. (2001), xviiOnishi et al. (2004), xviiiMottram et al. (1996), 
xixAlexander  et al. (1998), xxMottram et al. (1998), xxiPollock et al. (2003), xxiiMottram  et al. (2004), xxiiiSaravia et al. (2006), xxivScharfstein et al. 
(2000), xxvLima et al. (2001), xxviLima et al. (2002), xxviiTeixeira and Santana (1989). 
 128
Although a calcium dependent serine peptidase has been implicated in the processing of 
MSP-1 during erythrocyte rupture and invasion (Harris et al., 2005), inhibition of falstatin by 
specific antibodies at the late schizont stage paradoxically blocked erythrocyte invasion 
suggesting that falcipain hydrolyses peptidases necessary for cell invasion (Pandey et al., 
2006). 
 
Kinetoplastid parasites are also able to evade the immune system by modulating the host 
immune system through the action of CATLs (Mottram et al., 1998). In wild type L. mexicana 
infections, parasites modulate the host to produce an IL-4 mediated Th-2 response as 
opposed to an IL-12 mediated Th-1 response (Alexander et al., 1998; Mottram et al., 1998; 
Saravia et al., 2006). CATLs in L. mexicana are encoded for by two different gene loci; 
LmcCATL-A (cpa), a single-copy gene encoding a cathepsin L-like cysteine peptidase 
expressed at lower levels (Mottram et al., 1992); and LmcCATL-B (cpb), a multi-copy gene 
that codes for the major CATL-like cysteine peptidase expressed in high levels during the 
intracellular amastigote stage of the parasite life cycle (Souza et al., 1992). Deleting the 
LmcCATL-A and LmcCATL-B loci that code for both forms of Leishmania cysteine peptidases 
resulted in a shift of the host immune response from a predominantly Th-2 response in mice 
infected with wild type parasites, to a Th-1 response in mice infected with mutant parasites 
lacking both LmcCATL genes (Alexander et al., 1998). An IL-12 mediated Th-1 response in 
mice infected with CATL mutant Leishmania produces IFN-γ, that in turn induces 
macrophages to express nitric oxide which is lethal to infecting parasites (Heinzel et al., 
1993). Hamsters infected with L. mexicana parasites deficient in both forms of LmcCATLs 
displayed a lower parasite burden, had smaller foot pad lesions and a slower progression of 
the disease (Saravia et al., 2006). Interestingly, LmcCATL-B seems to contribute more to 
immunoevasion than LmcCATL-A. Immunising mice with   LmcCATL-B2.8, a product of the 
LmcCATL-B multi-copy gene locus, induced a strong IL-4 mediated Th-2 response, with 
increased IL-4 and IgE production (Pollock et al., 2003). The contribution of LmcCATL-A 
cannot however be discounted as LmcCATL-A/B mutants consistently display lower infectivity 
in vivo and in vitro and induce stronger IL-4 cytokine production than LmcCATL-B mutants 
(Saravia et al., 2006).  
 
The reduction of parasites induced for TcoCATL RNAi in vivo described in Section 2.3.3 of 
this thesis could also be attributed to a loss of virulence, a role that has been described for 
kinetoplastid CATLs [reviewed in Caffrey et al. (2011)]. In Leishmania mexicana, 
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promastigote mutant parasites without the LmcCATL-B gene locus are less able to infect 
macrophages in vitro than wild-type parasites (Frame et al., 2000). In contrast, amastigote 
mutant LmcCATL-B parasites were able to survive in macrophages in vitro pointing to a 
stage-specific difference (Frame et al., 2000). Both life stage mutants were, however, able to 
cause lesions in BALB/c mice but at a much slower rate than wild type parasites. Various 
roles for CATL in trypanosome virulence were also observed in T. brucei. TbCATL is 
necessary for the parasite to traverse the blood-brain barrier (Nikolskaia et al., 2006a; 
Abdulla et al., 2008; Grab and Kennedy, 2008). This is a calcium dependent process that is 
inhibited in an in vitro model by K11777, a specific CATL inhibitor (Nikolskaia et al., 2006a). 
An in vivo model that induces TbCATL RNAi, similar to the methods used in the present work, 
delayed the onset of disease with 50% of the mice used in the study surviving for an extra 60 
days when compared to the wild type infection (Abdulla et al., 2008). Parasites induced for 
TbCATL RNAi in vitro were also significantly slower at crossing a blood-brain barrier model 
(Abdulla et al., 2008). Taken together, these results suggest that TbCATL is assisting the 
parasite in crossing the blood brain barrier via a calcium dependent process (Grab and 
Kennedy, 2008). Inhibitors targeting TbCATL in vivo would be important when formulating 
drugs that can be applicable in late stage cases of the disease when the parasite crosses into 
the brain (Grab and Kennedy, 2008; Grab et al., 2009).  
 
Oligopeptidase B in T. brucei (TbOPB) belongs to the S9 prolyl oligopeptidase family, which 
is grouped in clan SC of serine peptidases in the MEROPS database (Barrett and Rawlings, 
2004; Rawlings et al., 2008). Members of this family differ from classical serine peptidases 
such as trypsin [Clan S (P) A] because they only hydrolyse peptides smaller than ~ 30 amino 
acids in length and hence has no known natural inhibitors (Morty et al., 1999b; Morty et al., 
2001; Morty and Burleigh, 2004; Morty et al., 2005a; Coetzer et al., 2008). The peptidase has 
been studied as a target for diseases such as African trypanosomosis, Chagas disease and 
Leishmaniasis (Caler et al., 1998; Coetzer et al., 2008; Munday et al., 2011). In kinetoplastid 
parasites, OPB is encoded for by a single copy gene and is expressed at all life cycle stages 
(Burleigh et al., 1997; Morty et al., 1999b; de Matos Guedes et al., 2007). In the present study 
it was shown that OPB from T. brucei (TbCATL) was down-regulated using RNAi. Results 
showed that parasites with up to an 87% reduction in expressed OPB were viable and able to 
divide at a rate equal to that of control parasites not induced for RNAi. Tubulin was targeted 
for degradation as a positive control for RNAi where round parasites that have lost their 
morphology (FAT cells) were observed (Inoue et al., 2002; Coustou et al., 2010). Parasites 
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induced for tubulin RNAi (+Tet) divided at a slightly lower rate when compared to parasites 
not targeted for tubulin RNA degradation. Tubulin is an essential structural protein in 
trypanosomes responsible for maintaining their physical morphology and involved in 
cytokenesis during cell division (Ngo et al., 1998; Inoue et al., 2002). The similar rate of 
division in parasites not induced for tubulin RNAi to those induced (Section 3.3.4, Fig 3.12; 
TcoTUB +/-Tet) can be attributed to the leakage of siRNA specific for tubulin that occurs even 
in the absence of tetracycline (Inoue et al., 2002). It must also be taken into account that 
permanently transfected cells have only the two copies of the RNAi plasmid integrated into 
their genome, thus needing a longer period for the RNAi effect to be observed (Inoue et al., 
2002). 
 
When compared to the tubulin control, RNAi targeting OPB in T. congolense was not 
successful (Section 3.3.4). RNAi was used as a tool in this study to assess the importance of 
OPB for parasite survival in vitro. The p2T7Ti RNAi vector used for this study was originally 
constructed for RNAi studies in T. brucei (Wirtz et al., 1999; Inoue et al., 2002). An additional 
tetracycline repressor is required in RNAi inducible T. congolense strains (TRUM183:29-13) 
to control leakage in non-induced (-Tet) controls (Inoue et al., 2002). The hairpin-loop RNAi 
vector (pZJM) developed for T. brucei (Wirtz et al., 1999) has been successfully used for in 
vivo studies and has proven to be stable, inheritable and is tightly regulated using doxycycline 
(Abdulla et al., 2008). The development of a stable hairpin-loop vector for T. congolense 
could alleviate the shortcomings associated with using the p2T7Ti vector. RNAi targeting OPB 
in T. brucei was possible and knockdowns were assessed using western blotting, RT-PCR 
and RT-qPCR (Section 3.3.4). T. brucei parasites induced for OPB RNAi grew at a 
comparable rate to non-induced parasites and following these observations, it was concluded 
that TbOPB is a non-essential peptidase in vitro. This indicated that OPB may have 
overlapping functions with other serine oligopeptidases within the parasite in vitro. It was 
therefore possible to generate TbOPB null mutant parasites as described in Chapter 4.  
 
The observations made on inducing TbOPB RNAi in vitro correlate well with results observed 
when the OPB gene was knocked out in L. major (Munday et al., 2011), L. mexicana (Pollock 
et al., 2003) and T. cruzi (Caler et al., 1998). Leishmania and T. cruzi are both intracellular 
parasites and knocking out the single copy gene encoding for OPB in all three cases does not 
affect parasite differentiation, morphology or motility in vitro and a phenotype is only observed 
during infection studies. T. cruzi ∆opb null mutants used in an in vitro assay to infect non-
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phagocytic cells showed a 75% decline in the ability to infect normal rat kidney fibroblasts and 
L6E9 myoblasts (Caler et al., 1998). Similar results were obtained when OPB was deleted in 
Leishmania where mutant parasites were significantly less able to infect and survive in 
macrophages (Munday et al., 2011). T. brucei is an exclusively extracellular parasite but is 
able to cross endothelial barriers in the mammalian host and access the brain and testes 
(Grab et al., 2004; Grab and Kennedy, 2008; Claes et al., 2009; Grab et al., 2009). The T. 
brucei ∆opb null mutants generated in the present study were able to cross the endothelial 
barrier in mouse testes indicating that this process occurs independent of TbOPB and may 
instead be mediated by CATL peptidases in a calcium dependent reaction as has been 
shown in T. b. gambiense parasites (Nikolskaia et al., 2006a; Nikolskaia et al., 2006b). 
Previous experiments have shown that TbOPB is inhibited by trypanocidal drugs (Morty et al., 
1998) and phosphonate diphenyl esters (Morty et al., 2000). The identification of the 
peptidase irreversibly inhibited by phosphonate diphenyl esters using active site labelling with 
fluorescent inhibitors that have an  Arg or Arg analogue residue in P1, which are specific  for 
TbOPB,  showed a band at 80 kDa, which is the predicted size of TbOPB (Morty et al., 2000). 
However, the fluorescent irreversible inhibitors also targeted other peptidases in T. b. brucei 
lysates, at 45 kDa, 68 kDa and 120 kDa. This would imply that more than one peptidase was 
inhibited leading to a loss of parasite viability and eventual death in vitro and during infection 
in mice. This was confirmed in the present study where T. brucei Δopb null mutants were 
successfully generated and able to infect mice with equal virulence to wild type parasites. 
Kinetoplastid serine peptidases play a variety of functions during infection in the mammalian 
host. Serine peptidase roles involved in host-parasite relationships include invasion of host 
cells, virulence, degradation of host peptides and matrix proteins, and the modulation of host 
immune responses (Coetzer et al., 2008; de Matos Guedes et al., 2010; Alvarez et al., 2011). 
Some of these functions are summarised in Table 5.2 and discussed below.   
 
Oligopeptidase B activity in Leishmania is highest during the amastigote stage in the host and 
is expressed at higher levels when compared to related parasites such as T. cruzi (Pollock et 
al., 2003). In L. donovani Δopb null mutants, there is an accumulation of inactive enolase and 
plasminogen on the parasite cell surface which leads to an increase in macrophage gene 
transcription and up-regulated expression. Infected macrophages are thus activated leading 
to their clearance and ultimately resulting in reduced parasite virulence (Pollock et al., 2003). 
L. donovani and L. major Δopb null mutants were also less able to infect host macrophages in 
vitro, but were as virulent in causing  foot pad lesions in vivo in mice when compared to a wild 
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type infection (Pollock et al., 2003; Munday et al., 2011). It has been suggested that other 
oligopeptidase-B like peptidases might be responsible for compensating for the loss of OPB 
activity in L. major Δopb null mutants (Munday et al., 2011). OPB2 in L. amazonensis is a 
related peptidase with a C-terminal extension that has similar reactive residues to classical 
OPB and could have overlapping roles (de Matos Guedes et al., 2008). In T. cruzi, 
oligopeptidase B is crucial for the invasion of non-phagocytic cells where it activates a 
signalling pathway by mobilising Ca2+ stores in mammalian cells (Burleigh et al., 1997; Caler 
et al., 1998). TcrOPB processes a precursor molecule that generates a Ca2+ agonist that is 
responsible for mobilising Ca2+ in the mammalian cell being invaded. The influx of Ca2+ 
regulates the attachment of host cell lysosomes to the membrane thus enabling parasite 
entry (Caler et al., 1998).  
 
The deletion of TbOPB from T. brucei parasites resulted in a more than 5-fold increase in 
TbPOP-like activity (Chapter 4). In T. brucei and T. cruzi, prolyl oligopeptidase is encoded for 
by a single copy gene with 83% identity in amino acid sequences in the catalytic domain 
between the two parasites (Bastos et al., 2005; Bastos et al., 2010). In T. cruzi, TcrPOP has 
been implicated in assisting parasites gaining entry into murine muscle L-6 cells (Bastos et 
al., 2005). This was observed after parasites, incubated with a specific irreversible 
chloromethane TcrPOP inhibitor showed a dose dependent reduction in the number of 
intracellular parasites (Bastos et al., 2005). However, as with oligopeptidase B, this can only 
be confirmed using TcrPOP null mutant parasites. In T. brucei, POP is capable of  
hydrolysing native collagen and fibronectin which are rich in Gly-Pro residues (Bastos et al., 
2010) and thus could contribute to the presence of T. brucei parasites in the extravascular 
space and their ability to cross endothelial barriers in the brain and testes (Grab and 
Kennedy, 2008; Claes et al., 2009; Bastos et al., 2010).  
 
It has recently been shown that some kinetoplastid serine proteases are also able to 
hydrolyse large substrates such as haemoglobin, BSA and ovalbumin (da Silva-López et al., 
2010). L. chagasi promastigotes were used to generate detergent (LcCSI), aqueous (LcCSII) 
and extracellular (LcCSIII) fractions containing serine peptidase activity that could hydrolyse 
N-ρ-tosyl-L-arginine methyl ester (L-TAME) (da Silva-López et al., 2010). LcCSI and LcCSII 
unlike LcCSIII, are able to hydrolyse haemoglobin, BSA and ovalbumin and display maximal 
activity between pH 7 - 8.5.  







Assigned Functions References 
T. congolense TcoOPB (OP-Tc) 
oligopeptidase B 
 
All Cytoplasm Degradation of host peptides  i, ii 
T. brucei  TbOPB (OP-Tb) 
oligopeptidase B 
All Cytoplasm Degradation of host peptides at Arg 
and Lys residues 






Cytoplasm Degradation of host peptides at Pro 
residues, cleaves collagen I and IV 
vi 
L. major LmOPB  
oligopeptidase B 
All, but highest 
in amastigotes  
Cytoplasm Invasion of host macrophages, 






All, but highest 
in amastigotes  
Cytoplasm Accumulation of enolase on parasite 
cell surface, immune modulation of 










Hydrolysis of haemoglobin, BSA and 
ovalbumin 
ix 




whole cell lysate  
Increase susceptibility to cutaneous 
leishmaniasis, activate IL-4 mediated 
Th2 response, and increase 
cutaneous hypersensitivity.  
x, xi, xii, xiii 
T. cruzi TcrOPB (Tc120) 
oligopeptidase B 
All Cytoplasm  Invasion of host non-phagocytic cells 










Degradation of host peptides at Pro 
residues, cleaves fibronectin, 
collagen I and IV, invasion of host 
non-phagocytic cells, virulence 






Lysosome Processed by TcrCATL  xix 
iMorty et al.(1999a), iiCoetzer et al. (2008), iiiTroeberg et al. (1996b), ivMorty et al. (1999b), vMorty et al. (2001), viBastos et al. (2010), viiMunday 
et al. (2011), viiiSwenerton et al. (2011), ixda Silva-López et al. (2010), xda Silva-López and De Simone (2004), xide Matos Guedes et al. (2007), 
xiiSantana et al. (1997), xiiide Matos Guedes et al. (2008), xivde Matos Guedes et al. (2010), xvBurleigh et al. (1997), xviCaler et al. (1998), 
xviiGrellier et al. (2001), xviiiBastos et al. (2005), xixParussini et al. (2003) 
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A detergent soluble fraction with serine peptidase activity that is able to hydrolyse 
haemoglobin, BSA, ovalbumin and gelatin has also been isolated from L. amazonensis (da 
Silva-López and De Simone, 2004). Inhibition of L. amazonensis with N-tosyl-L-phenylalanine 
chloromethyl ketone (TPCK) and benzamidine serine peptidase inhibitors reduces parasite 
viability and causes lethal morphological alterations (Silva-Lopez et al., 2007). Intradermal 
vaccination of mice with L. amazonensis promastigote antigens (LaAg) increases the 
susceptibility of infected mice to cutaneous leishmaniasis (Velez et al., 2005). This 
susceptibility is reversed when mice are first vaccinated with a parasite extract that has been 
treated with serine peptidase inhibitors (de Matos Guedes et al., 2010). It was observed that 
serine peptidases are responsible for activating an IL-4 mediated Th-2 response that does 
not release IFN-γ. This is similar to the scenario found in L. mexicana infections where 
LmCATL null mutant parasites are unable to switch the host Th-1 response to a Th-2 
response that is not as effective in controlling parasite burden (Alexander et al., 1998).  
 
A T. cruzi serine carboxypeptidase with an unknown function has been recombinantly 
expressed in the baculovirus expression system (Parussini et al., 2003). Processing the 
propeptide of T. cruzi serine carboxypeptidase using TcrCATL resulted in a mature protein 
with three-fold increase in activity, suggesting that some serine peptidases may also be 
substrates for kinetoplastid CATLs (Alvarez et al., 2011). 
 
This study has established through RNAi in vivo that TcoCATLs are important pathogenic 
factors that have an effect on parasite burden during infection in a mouse model. This finding 
is similar to observations on the role of TbCATLs during infection in mice where disease 
progression is reduced when TbCATLs are targeted for RNAi in vivo (Abdulla et al., 2008). 
The development of a drug or vaccine that targets parasite CATLs would assist 
trypanosusceptible breeds of cattle to remain productive with lower parasite burden, reduced 
anaemia and inflammation associated with the disease. This study has also contributing to 
elucidating a role for TbOPB and the overlapping functions it possibly shares with closely 
related TbPOP-like peptidases. When developing a drug targeting oligopeptidase B, it will be 
necessary to consider inhibitors that have an effect on more than one parasite oligopeptidase 
without affecting host peptidase functions. It is therefore important to characterise TbOPB-like 
and TbPOP-like peptidases, and study their roles using RNAi or knock-out techniques. It 
must also be noted that although an overlap in function might occur between TbOPB and 
related enzymes in the acute infection mouse model, a very different scenario may be seen 
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when using a chronic model for infection. Mice infected with T.b. brucei Δopb mutants do not 
survive the first peak of infection before TbOPB is released by dying or dead parasites. Using 
larger mammalian hosts such as goats or cattle, where a natural chronic infection occurs, 
would provide new information on the role of OPB in trypanosomosis. The cyclical killing of 
parasites by the host immune system during the chronic phase of the disease would lead to 
an accumulation of OPB in control livestock infected with wild-type parasites and pathogenic 
effects such as the hydrolysis of host peptides could be compared to a livestock group 
infected with T.b. brucei Δopb parasites. Although this work suggests that TbPOP and 
TbOPB may target the same host peptides, a chronic infection in livestock would elucidate 
the specific functions of each peptidase and identify which serine oligopeptidase is 
predominantly responsible for host peptide hydrolysis and consequent pathologies associated 
with the disease.  
 
In conclusion, kinetoplastid parasite peptidases play various roles important for parasite 
viability within the host. Many of these peptidases seem to possess overlapping functions and 
are able to switch roles depending on the environment the parasite encounters. This has 
enabled trypanosomes to survive in different cells, tissues and hosts due to the function of 
different peptidases expressed at different stages of the life cycle. The loss in function of one 
peptidase can be compensated for by an up-regulation in activity of a closely related 
peptidase that could hydrolyse the same physiological substrate. This study has helped 
describe possible overlapping functions between peptidases involved in pathogenesis during 
trypanosome infection. Future areas of study should include using T.b. brucei Δopb parasites 
to infect ruminants where hormone dysregulation caused by parasite oligopeptidases can be 
adequately studied, and the generation of OPB/POP null mutants that would confirm the 
overlapping functions between these two peptidases. This information can be used when 
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Appendix 2: T. congolense TcoCATL sequence and 5’ region flanking TcoCATL 




contig 0001218  AAGTCGCAAC AGTTGCACGC GGGTGAAGGC CACACAACAG AACAAGAGAG ATCGCTTTCC ACATCCTTCA  7490   
5' overhang     ---------- -----CACGC GGGTGAAGGC CACACAACAG AACAAGAGAG ATCGCTTTCC ACATCCTTCA  55     
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  ACCAAGCTGA AGAAGAACTG GAATGCGTCA TTGAGTGCTC GCTTCATCTA CAACTTCAAG CCTTACTATT  7560   
5' overhang     ACCAAGCTGA AGAAGAACTG GAATGCGTCA TTGAGTGCTC GCTTCATCTA CAACTTCAAG CCTTACTATT  125    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  ATGCACCACA TTGCCCCAAG ACATGGTCCA CGGGTTTGAC ACATGGTACG TGGAAGCAAC ATCAAACATC  7630   
5' overhang     ATGCACCACA TTGCCCCAAG ACATGGTCCA CGGGTTTGAC ACATGGTACG TGGAAGCAAC ATCAAACATC  195    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GTTGATTTAG CACTTGGTGC ACCATGGCCA ATAGTGCGTC ACCTTCGGGC CGTTGGCTTC GCCTTCTGCC  7700   
5' overhang     GTTGATTTAG CACTTGGTGC ACCATGGCCA ATAGTGCGTC ACCTTCGGGC CGTTGGCTTC GCCTTCTGCC  265    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  TGATTCCACC ACACCAACAG CATCAATCAC TCCTCATTGC TGTTGGTCTA TTTGCCACAC TAACACAACG  7770   
5' overhang     TGATTCCACC ACACCAACAG CATCAATCAC TCCTCATTGC TGTTGGTCTA TTTGCCACAC TAACACAACG  335    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 162
contig 0001218  CCAGGAAGAG AAAAACAAGT CACACAAAGC TGGCGCCACA GAAACTAAAG GAGCACTTAA AACCAACATT  7840   
5' overhang     CCAGGAAGAG AAAAACAAGT CACACAAAGC TGGCGCCACA GAAACTAAAG GAGCACTTAA AACCAACATT  405    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
contig 0001218  ATTATAGGCG CAGGATGGTG GGAGATCTTC AAAATATGTG TGCTGCACGA TTCCATTATT CCAGCACAAC  7910   
5' overhang     ATTATAGGCG CAGGATGGTG GGAGATCTTC AAAATATGTG TGCTGCACGA TTCCATTATT CCAGCACAAC  475    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  TGCATAACGA TATATGGCAC CTAGTCGAGC GAAGCGAACG AGCACTTAGA ACAAGTCACT CGATACGCCT  7980   
5' overhang     TGCATAACGA TATATGGCAC CTAGTCGAGC GAAGCGAACG AGCACTTAGA ACAAGTCACT CGATACGCCT  545    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  ACAAAACACA CAAAATAAAA ACAGCAGCAA GGACCACATT GACACACAAC CGAATCAAAA CAAAAACAAC  8050   
5' overhang     ACAAAACACA CAAAATAAAA ACAGCAGCAA GGACCACATT GACACACAAC CGAATCAAAA CAAAAACAAC  615    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CAAATGAAAC CAAGATTACT GTCACTAACA AGTAGAATAA TACACACAAC TAAACACTTA ATAAATAAAA  8120   
5' overhang     CAAATGAAAC CAAGATTACT GTCACTAACA AGTAGAATAA TACCCACAAC TAAACACTTA ATAAATAAAA  685    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CCAGGGAACA ATGGAACGGA AAAAAAGAAG GAAAACAAAA CCCTTTCACA GCAAGGAAAC ATCACACACC  8190   
5' overhang     CCAGGGAACA ATGGAACGGA AAAAAAGAAG GAAAACAAAA CCCTTTCACA GCAAGGAAAC ATCACACACC  755    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
 163
contig 0001218  CTATAAAATA ATCAGCAAAA AAAACAAACC AACATCATCT CTACAAAAGA AAAAAATAGC ACTATGGTGG  8260   
5' overhang     CTATAAAATA ATCAGCAAAA AAAACAAACC AACATCATCT CTACAAAAGA AAAAAATAGC ACTATGGTGG  825    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  AAAATAGAAA TTAACCGACC ACAATAAAAG AAACAAATAA AAAACAAAGA ACAGCAACAG TAAC-AAAAA  8329   
5' overhang     AAAATAGAAA TTAACCGACC ACCATAAAAG AATCCAATAA AAAACAAACC ACAGCCACAG TAACAAAAAA  895    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  AACATTACTT ACATTCTAAC ACCAGCAACC ATCTCTCCCT GTATGTCACA CCGTACGTTG GCGCAGTGTA  8399   
5' overhang     AACATGACTT ACATTCTAAC ACCAGCAACA ATCTCTCCCT GTATGTCACA CCGTACGTTG GCGCAGTGTA  965    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             ---------- ---------- ---------- ---------- ---------- ---------- -----GTGTA  5      
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  TCCTGCACTC ACGAACGAGC TAAAAATAAG AATCAAAAAA GGGAGAACGA TAGAGCAGCG ACAACCCGAG  8469   
5' overhang     TCCTGCACTC ACGAACGAGC TAAAAATAAG AATA------ ---------- ---------- ----------  999    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             TCCTGCACTC ACGAACGAGC TAAAAATAAG AATCAAAAAA GGGAGAACGA TAGAGCAGCG ACAACCCGAG  75     
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  AAGGTAAGAG GCTTTTCTTC TTTCTTTTCC TTTATTGTAC GATGCCACGA TCAGAAATGA CACGCACCCT  8539   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             AAGGTAAGAG GCTTTTCTTC TTTCTTTTCC TTTATTGTAC GATGCCACGA TCAGAAATGA CACGCACCCT  145    
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GCGCTTCTCC GTGGGCCTGC TCGCCGTTGC GGCGTGCTTT GTTCCCGTGG CGTTGGGAGT GCTTCACGCA  8609   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             GCGCTTCTCC GTGGGCCTGC TCGCCGTTGC GGCGTGCTTT GTTCCCGTGG CGTTGGGAGT GCTTCACGCA  215    
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
 164
contig 0001218  GAGCAATCGT TGCAGCAGCA ATTCGCCGCA TTCAAGCAAA AGTACAGCAG GTCGTACAAG GACGCCACGG  8679   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             GAGCAATCGT TGCAGCAGCA ATTCGCCGCA TTCAAGCAAA AGTACAGCAG GTCGTACAAG GACGCCACGG  285    
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  AGGAGGCATT CCGTTTCCGC GTCTTCAAGC AGAACATGGA GCGTGCAAAG GAGGAGGCCG CTGCGAACCC  8749   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             AGGAGGCATT CCGTTTCCGC GTCTTCAAGC AGAACATGGA GCGTGCAAAG GAGGAGGCCG CTGCGAACCC  355    
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CTATGCGACG TTTGGTGTGA CGCGGTTCTC CGATATGTCA CCCGAGGAGT TCAGGGCGAC CTACCACAAC  8819   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             CTATGCGACG TTTGGTGTGA CGCGGTTCTC CGATATGTCA CCCGAGGAGT TCAGGGCGAC CTACCACAAC  425    
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GGGGCGGAGT ACTACGCTGC GGCGCTGAAG CGACCACGCA AGGTGGTGAA TGTGTCCACT GGGAAGGCAC  8889   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP7             GGGGCGGAGT ACTACGCTGC GGCGCTGAAG CGACCACGCA AGGTGGTGAA TGTGTCCACT GGGAAGGCAC  495    
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CTGAGGCAGT TGACTGGCGC AAGAAGGGCG CGGTGACACC CGTGAAGGAC CAGGGGAAAT GCGACTCTTC  8959   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ---------- ---------- ---------- ---------- -----CGGAC CAGGGGCAAT GCGACTCTTC  25     
CP7             CTGAGGCAGT TGACTGGCGC AAGAAGGGCG CGGTGACACC CGTGAAGGAC CAGGGGAAAT GCGACTCTTC  565    
CP5             ---------- ---------- ---------- ---------- ------GGAC CAGGGGCAAT GCGACTCTTC  24     
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GTGGGCATTC ACTGTCATAG GGAACATAGA GGGCCAGTGG AAGATTGCGG GCCATGAGCT GACGTCTCTG  9029   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GTGGGCATTC ACTGTCACGG GGAACATAGA GGGCCAGTGG AAGATTGCGG GCCATGAGCT GACGTCTCTG  95     
CP7             GTGGGCATTC ACTGTCATAG GGAACATAGA GGGCCAGTGG AAGATTGCGG GCCATGAGCT GACGTCTCTG  635    
CP5             GTGGGCATTC ACTGTCACGG GGAACATAGA GGGCCAGTGG AAGATTGCGG GCCATGAGCT GACGTCTCTG  94     
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
 165
contig 0001218  TCGGAGCAGA TGCTCGTGTC ATGTGACACT AATGACCTTG GCTGCCGAGC TGGCTTCATG GACACCGCGT  9099   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TCGGAGCAGA TGCTCGTGTC ATGTGACACT AATGACCTTG GCTGCCGAGC TGGCTTCATG GACACCGCGT  165    
CP7             TCGGAGCAGA TGCTCGTGTC ATGTGACACT AATGACCTTG GCTGCCGAGC TGGCTTCATG GACACCGCGT  705    
CP5             TCGGAGCAGA TGCTCGTGTC ATGTGACACT AATGACCTTG GCTGCCGAGC TGGCTTCATG GACACCGCGT  164    
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  TCAAATGGAT TGTGTCGTCG AATAATGGCA ATGTGTTCAC GGAGCAAAGT TACCCGTACG CATCAGGAGG  9169   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TCAAATGGAT TGTGTCGTCG AATAATGGCA ATGTGTTCAC GGAGCAAAGT TACCCGTACG CATCAGGAGG  235    
CP7             TCAAATGGAT TGTGTCGTCG AATAATGGCA ATGTGTTCAC GGAGCAAAGT TACCCGTACG CATCAGGAGG  775    
CP5             TCAAATGGAT TGTGTCGTCG AATAATGGCA ATGTGTTCAC GGAGCAAAGT TACCCGTACG CATCAGGAGG  234    
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GGGGAACGTG CCGACGTGCA ACAAGAGCGG CAAGGTCGTT GGTGCGAACA TCGACGACCA CGTTCACATT  9239   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GGGGAACGTG CCGACGTGCA ACAAGAGCGG CAAGGTCGTT GGTGCGAACA TCGACGACCA CGTTCACATT  305    
CP7             GGGGAACGTG CCGACGTGCA ACAAGAGCGG CAAGGTCGTT GGTGCGAACA TCGACGACCA CGTTCACATT  845    
CP5             GGGGAACGTG CCGACGTGCA ACAAGAGCGG CAAGGTCGTT GGTGCGAACA TCGACGACCA CGTTCACATT  304    
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CCGGAGGACG AAAACGCAAT AGCCGAGTGG CTGGCAAAAA AAGGGCCCGT CGCGATTGCC GTGGACGCCA  9309   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CTAGACAACG AAAACGCAAT AGCCGAGTGG CTGGCAAAGA AAGGGCCCGT CGCGATTGCC GTTGACGCCA  375    
CP7             CCGGAGGACG AAAACGCAAT AGCCGAGTGG CTGGCAAAAA AAGGGCCCGT CGCGATTGCC GTGGACGCCA  915    
CP5             CTAGACAACG AAAACGCAAT AGCCGAGTGG CTGGCAAAGA AAGGGCCCGT CGCGATTGCC GTTGACGCCA  374    
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CCAGTTTCCA GAGCTACACG GGCGGAGTGT TGACATCATG CATCTCTAAG GAAGTGAACT CTGCTGCGCT  9379   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CCAGTTTCCA GAGCTACAC- GGCGGAGTGT TGACATCATG CATCTCCGAG CATCTGGACC ATGGTGTGCT  444    
CP7             CCAGTTTCCA GAGCTACACG GGCGGAGTGT TGACATCATG CATCTCTAAG GAAGTGAACT CTGCTGCGCT  985    
CP5             CCAGTTTCCA GAGCTACAC- GGCGGAGTGT TGACATCATG CATCTCCGAG CATCTGGACC ATGGTGTGCT  443    
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CCTCGTGGGG TATGACGACA CAAGCAAGCC ACCATACTGG ATTATCAAGA ACTCATGGAG CAAGGGATGG  9449   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CCTCGTGGGG TATGACGACA CAAGCAAGCC ACCATACTGG ATTATCAAGA ACTCATGGAG CAAGGGATGG  514    
CP7             CCTCGTGGGG TATGACGACA CAAGCAAGCC ACCATACTGG ATTATCAAGA ACTCATGGAG CAAGGGATGG  1055   
CP5             CCTCGTGGGG TATGACGACA CAAGCAAGCC ACCATACTGG ATTATCAAGA ACTCATGGAG CAAGGGATGG  513    
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
 166
contig 0001218  GGCGAGGAGG GTTACATCCG CATTGAGAAG GGCACAAACC AATGTCGTAT GAAAGAATAC GTGAGCTCCG  9519   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GGCGAGGAGG GTTACATCCG CATTGAGAAG GGCACAAACC AATGTCTTAT GAAAAATCTC CCAAGCTCCG  584    
CP7             GGCGAGGAGG GTTACATCCG CATTGAGAAG GGCACAAACC AATGTCGTAT GAAAGAATAC GTGAGCTCCG  1125   
CP5             GGCGAGGAGG GTTACATCCG CATTGAGAAG GGCACAAACC AATGTCTTAT GAAAAATCTC CCAAGCTCCG  583    
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CCGTTGTCAG CGGCCCTCCG CCTCCG---C ---CCCCGAC TCCGACCTTC ACGCAGGAGT TGTGCGAGGG  9583   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CCGTTGTCAG CGTCCCTCCG CCTCCGCCTC CACCCCCGAC TCCGACCTTC ACGCAGTCGT TCTGCCCCAA  654    
CP7             CCGTTGTCAG CGGCCCTCCG CCTCCG---C ---CCCCGAC TCCGACCTTC ACGCAGGAGT TGTGCGAGGG  1189   
CP5             CCGTTGTCAG CGTCCCTCCG CCTCCGCCTC CACCCCCGAC TCCGACCTTC ACGCAGTCGT TCTGCCCCAA  653    
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  TGCCGAATGC CAGAGTAAGT GCACCAAAGC CACATTCCCA ACGGGCAAGT GCGTGCAGCT CAGCGGCGCC  9653   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CGCAAAATGC CAGAGTAGGT GCACCAAAGC CACATTCCCA ACGGGCAAGT GCGTGCAGCT CAGCGACACC  724    
CP7             TGCCGAATGC CAGAGTAAGT GCACCAAAGC CACATTCCCA ACGGGCAAGT GCGTGCAGCT CAGCGGCGCC  1259   
CP5             CGCAAAATGC CAGAGTAGGT GCACCAAAGC CACATTCCCA ACGGGCAAGT GCGTGCAGCT CAGCGACACC  723    
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GGTTCTGTCA TCGCCTCGTG CGGCTCCAAT AACCTCACGC AGATCGTCTA CCCGTTGAGC AGCTCCTGCA  9723   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GGCTCTGCCA TCGCCTCGTG CGGCTCCAAT AACCTCACGC AGATCGTCTA CCCGTTGAGC AGCTCCTGCA  794    
CP7             GGTTCTGTCA TCGCCTCGTG CGGCTCCAAT AACCTCACGC AGATCGTCTA CCCGTTGAGC AGCTCCTGCA  1329   
CP5             GGCTCTGCCA TCGCCTCGTG CGGCTCCAAT AACCTCACGC AGATCGTCTA CCCGTTGAGC AGCTCCTGCA  793    
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GCGGCTTCTC CGTTCCGTTG ACTGTGCCAC TGGACAAGTG CCTGCCCATT GTGATTGGAT CCGTGGCTTA  9793   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GCGGCTACTC CGTTCCGTTG ACTGTGCCAC TGGACAAGTG CCTGCCCATT GTGATTGGAT CCATGATGTA  864    
CP7             GCGGCTTCTC CGTTCCGTTG ACTGTGCCAC TGGACAAGTG CCTGCCCATT GTGATTGGAT CCGTGGCTTA  1399   
CP5             GCGGCTACTC CGTTCCGTTG ACTGTGCCAC TGGACAAGTG CCTGCCCATT GTGATTGGAT CCATGATGTA  863    
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  TGAGTGCTCT GACAAGGCTC CTACGGAGTC CGCCCGGCTC GTGCGGCACG AGTGAGGCTG CTGGCGGCGA  9863   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CAAGTGCTCT GACAAGGCTC CTACGGAGTC CGCCCGGCTC GTGCGGCACG AGTGAGGCTG CTGGCGGCGA  934    
CP7             TGAGTGCTCT GACAAGGCTC CTACGGAGTC CGCCCGGCTC GTGCGGCACG AGTGAGGCTG CTGGCGGCGA  1469   
CP5             CAAGTGCTCT GACAAGGCTC CTACGGAGTC CGCCCGGCTC GTGCGGCACG AGTGAGGCTG CTGGCGGCGA  933    
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
 167
contig 0001218  CTGCTTGCCG GCTTCACGTA CCTCTCCCGA AACTCCAATT CTGTTTTGCT TTCATGCACT GTTCCAGTGT  9933   
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CTGCTTGCCG GCTTCACGTA CCTCTCCCAA AACTCCAATT CTGTTTTGCT TTCATGCACT GTTCCAGTGT  1004   
CP7             CTGCTTGCCG GCTTCACGTA CCTCTCCCGA AACTCCAATT CTGTTTTGCT TTCATGCACT GTTCCAGTGT  1539   
CP5             CTGCTTGCCG GCTTCACGTA CCTCTCCCAA AACTCCAATT CTGTTTTGCT TTCATGCACT GTTCCAGTGT  1003   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  ATTTGCTTTC TTGGTGTGCG GCCACACGAT GCGGCTCTGA GGCGAGTGCG AGGGACACCG CGCCGCTCTG  10003  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ATTTGCTTTC TTGGTGTGCG GCCACACGAT GCGGCTCTGA GGCGAGTGCG AGGGACACCG CGCCGCTCTG  1074   
CP7             ATTTGCTTTC TTGGTGTGCG GCCACACGAT GCGGCTCTGA GGCGAGTGCG AGGGACACCG CGCCGCTCTG  1609   
CP5             ATTTGCTTTC TTGGTGTGCG GCCACACGAT GCGGCTCTGA GGCGAGTGCG AGGGACACCG CGCCGCTCTG  1073   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CCTCTCAGCA CTTGCGGAGT GTGAGAAAGC TGCCCCAACC ACGCGTGTGT CTTTCTATGC TTTTGCTTGT  10073  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CCTCTCAGCA CTTGCGGAGT GTGAGAAAGC TGCCCCAACC ACGCGTGTGT CTTTCTATGC TTTTGCTTGT  1144   
CP7             CCTCTCAGCA CTTGCGGAGT GTGAGAAAGC TGCCCCAACC ACGCGTGTGT CTTTCTATGC TTTTGCTTGT  1679   
CP5             CCTCTCAGCA CTTGCGGAGT GTGAGAAAGC TGCCCCAACC ACGCGTGTGT CTTTCTATGC TTTTGCTTGT  1143   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CCTTTTTCTC CATTACTTTT ACTGGCTCAC TGACCACGGC AACAGTCGCT GCTGCCACTG ACCCGCGAGG  10143  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CCTTTTTCTC CATTACTTTT ACTGGCTCAC TGACCACGGC AACAGTCGCT GCTGCCACTG ACCCGCGAGG  1214   
CP7             CCTTTTTCTC ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             CCTTTTTCTC ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  AGCGTCGCAC CCCGTTGGCC TTGTCTTTGT TGTTTTTGCG CCCACACTTG CTCCCAATAC GCTTCGCTTG  10213  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  AGCGTCGCAC CCCGTTGGCC TTGTCTTT-T TATTTTTGCG CCCACACTTG CTCCCAATAC GCTTCGCTTG  1283   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CCTGATTGCG CTTCTTCCTT TGCCTCCCGT CTCTCCCTGT ATGTCACACC GTACGT-TGG CGCAGTGTAT  10282  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CCTGATTGCG CTTCTTCCTT TGCCTCCCGT CTCTCCCTGT ATGTCACACC GTACGT-TGG CGCAGTGTAT  1352   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ------CAGT TTCTGTACTA TATTGTGTAT  24     
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----GTGTAT  6      
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----GTGTAT  6      
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----GTGTAT  6      
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
 168
contig 0001218  CCTGCACTCA CGAACGAGCT AAAAATAAGA ATCAAAAAAG GGAGGACG-A TAGAGCAGCG ACAACCCGAG  10351  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CCTGCACTCA CGAACGAGCT AAAAATAAGA ATCAAAAAAG GGAGGACG-A TAGAGCAGCG ACAACCCGAG  1421   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             CCTGCACTCA CGAACGAGCT AAAAATAAGA ATCAAAAAAG GGAGAACGAA TAGAGCAGCG ACAACCCGAG  94     
CP4             CCTGCACTCA CGAACGAGCT AAAAATAAGA ATCAAAAAAG GGAGAAC-AA TAGAGCAGCG ACAACCCGAG  75     
CP3             CCTGCACTCA CGAACGAGCT AAAAATAAGA ATCAAAAAAG GGAGGACG-A TAGAGCAGCG ACAACCCGAG  75     
CP8             CCTGCACTCA CGAACGAGCT AAAAATAAGA ATCAAAAAAG GGAGGACG-A TAGAGCAGCG ACAACCCGAG  75     
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  AAGGTAAGAG GCTTTTCTTC TTTCTTTTCC TTTATTGTAC GATGCCACGA TCAGAAATGA CACGCACCCT  10421  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  AAGGTAAGAG GCTTTTCTTC TTTCTTTTCC TTTATTGTAC GATGCCACGA TCAGAAATGA CACGCACCCT  1491   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             AAGGTAAGAG GCTTTTCTTC TTTCTTTTCC TTTATTGTAC GATGCCACGA TCAGAAATGA CACGCACCCT  164    
CP4             AGCGTAAGAG GCTTTTCTTC TTTCTTTTCC TTTATTGTAC GATGCCACGA TCAGAAATGA CACGCACCCT  145    
CP3             AAGGTAAGAG GCTTTTCTTC TTTCTTTTCC TTTATTGTAC GATGCCACGA TCAGAAATGA CACGCACCCT  145    
CP8             AAGGTAAGAG GCTTTTCTTC TTTCTTTTCC TTTATTGTAC GATGCCACGA TCAGAAATGA CACGCACCCT  145    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GCGCTTCTCC GTGGGCCTGC TCGCTGTTGC GGCGTGCTTT GTTCCCGTGG CGTTGGGAGT GCTTCACGCA  10491  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GCGCTTCTCC GTGGGCCTGC TCGCTGTTGC GGCGTGCTTT GTTCCCGTGG CGTTGGGAGT GCTTCACGCA  1561   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             GCGCTTCTCC GTGGGCCTGC TCGCCGTTGC GGCGTGCTTT GTTCCCGTGG CGTTGGGAGT GCTTCACGCA  234    
CP4             GCGCTTCTCC GTGGGCCTGC TCGCCGTTGC GGCGTGCTTT GTTCCCGTGG CGTTGGGAGT GCTTCACGCA  215    
CP3             GCGCTTCTCC GTGGGCCTGC TCGCTGTTGC GGCGTGCTTT GTTCCCGTGG CGTTGGGAGT GCTTCACGCA  215    
CP8             GCGCTTCTCC GTGGGCCTGC TCGCTGTTGC GGCGTGCTTT GTTCCCGTGG CGTTGGGAGT GCTTCACGCA  215    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GAGCAATCGT TGCAGCAGCA ATTCGCCGCA TTCAAGCAAA AGTTCAGCAG GTCGTACAAG GACGCCACGG  10561  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GAGCAATCGT TGCAGCAGCA ATTCGCCGCA TTCAAGCAAA AGTACAGCAG GTCGTACAAG GACGCCACGG  1631   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             GAGCAATCGT TGCAGCAGCA ATTCGCCGCA TTCAAGCAAA AGTACAGCAG GTCGTACAAG GACGCCACGG  304    
CP4             GAGCAATCGT TGCAGCAGCA ATTCGCCGCA TTCAAGCAAA AGTACAGCAG GTCGTACAAG GACGCCACGG  285    
CP3             GAGCAATCGT TGCAGCAGCA ATTCGCCGCA TTCAAGCAAA AGTACAGCAG GTCGTACAAG GACGCCACGG  285    
CP8             GAGCAATCGT TGCAGCAGCA ATTCGCCGCA TTCAAGCAAA AGTTCAGCAG GTCGTACAAG GACGCCACGG  285    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  AGGAGGCATT CCGTTTCCGT GTCTTCAAGC AAAACATGGA GCGTGCAAAG GAGGAGGCCG CTGCGAACCC  10631  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  AGGAGGCATT CCGTTTCCGC GTCTTCAAGC AGAACATGGA GCGTGCAAAG GAGGAGGCCG CTGCGAACCC  1701   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             AGGAGGCATT CCGTTTCCGT GTCTTCAAGC AGAACATGGA GCGTGCAAAG GAGGAGGCCG CTGCGAACCC  374    
CP4             AGGAGGCATT CCGTTTCCGC GTCTTCAAGC AGAACATGGA GCGTGCAAA- GAGGAGGCCG CTGCGAACCC  354    
CP3             AGGAGGCATT CCGTTTCCGC GTCTTCAAGC AGAACATGGA GCGTGCAAAG GAGGAGGCCG CTGCGAACCC  355    
CP8             AGGAGGCATT CCGTTTCCGT GTCTTCAAGC AAAACATGGA GCGTGCAAAG GAGGAGGCCG CTGCGAACCC  355    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CTATGCGACG TTTGGTGTGA CGCGGTTCTC CGATATGTCA CCCGAGGAGT TCAGGGCGAC CTACCACAAC  10701  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CTATGCGACG TTTGGTGTGA CGCGGTTCTC CGATATGTCA CCCGAGGAGT TCAGGGCGAC CTACCACAAC  1771   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             CTATGCGACG TTTGGTGTGA CGCGGTTCTC CGATATGTCA CCCGAGGAGT TCAGGGCGAC CTACCACAAC  444    
CP4             CTATGCGACG TTTGGTGTGA CGCGGTTTTC CGATATGTCA CCCGAGGAGT TCAGGGCGAC CTACCACAAC  424    
CP3             CTATGCGACG TTTGGTGTGA CGCGGTTCTC CGATATGTCA CCCGAGGAGT TCAGGGCGAC CTACCACAAC  425    
CP8             CTATGCGACG TTTGGTGTGA CGCGGTTCTC CGATATGTCA CCCGAGGAGT TCAGGGCGAC CTACCACAAC  425    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
 169
contig 0001218  GGGGCGGAGT ACTACGCTGC GGCGCTGAAG CGACCACGCA AGGTGGTGAA TGTGTCCACT GGGAGGCCAC  10771  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GGGGCGGAGT ACTACGCTGC GGCGCTGAAG CGACCACGCA AGGTGGTGAA TGTGTCCACT GGGAAGGCAC  1841   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             GGGGCGGAGT ACTACGCTGC GGCGCTGAAG CGACCACGCA AGGTGGTGAA TGTGTCCACT GGGAAGGCAC  514    
CP4             GGGGCGGAGT ACTACGCTGC GGCGCTGAAG CGACCACGCA AGGTGGTGAC TGTGTCCACT GGGAAGGCAC  494    
CP3             GGGGCGGAGT ACTACGCTGC GGCGCTGAAG CGACCACGCA AGGTGGTGAA TGTGTCCACT GGGAAGGCAC  495    
CP8             GGGGCGGAGT ACTACGCTGC GGCGCTGAAG CGACCACGCA AGGTGGTGAA TGTGTCCACT GGGAGGCCAC  495    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CGAT-GACGG TTGACTGGCG CAAGAAGGGC GCGGTGACAC CCGTGAAGGA CCAGGGGAAA TGCGACTCTT  10840  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CTGA-GGCAG TTGACTGGCG CAAGAAGGGC GCGGTGACAC CCGTGAAGGA CCAGGGGCAA TGCGGTTCTT  1910   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             CTGA-GGCAG TTGACTGGCG CAAGAAGGGC GCGGTGACAC CCGTGAAGGA CCAGGGGCAA TGCGGCTCTT  583    
CP4             CTGA-GGCAG TTGACTGGCG CAAGAAGGGC GCGGTGACAC CCGTGAAGGA CCAGGGACAA TGCGGTTCTT  563    
CP3             CTGA-GGCAG TTGACTGGCG CAAGAAGGGC GCGGTGACAC CCGTGAAGGA CCAGGGGCAA TGCGGTTCTT  564    
CP8             C-GATGACGG TTGACTGGCG CAAGAAGGGC GCGGTGACAC CCGTGAAGGA CCAGGGGAAA TGCGACTCTT  564    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CGTGGGCATT CTCTGCCATA GGGAACATAG AGGGCCAGTG GAAGATTGCG GGCCATGAGC TGACGTCTTT  10910  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GCTGGGCATT CTCTGCCATA GGGAACATAG AGGGCCAGTG GAAGATTGCG GGCCATGAGC TGACGTCTCT  1980   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             GCTGGGCATT CTCTGCCATA GGGAACATAG AGGGCCAGTG GAAGGTTGCA GGCCATGAGC TGACGTCTTT  653    
CP4             GCTGGGCATT CTCTGCCATA GGGAACATAG AGGGCCAGTG GAAGGTTACG GGCCATAATC TGACGTCTCT  633    
CP3             GCTGGGCATT CTCTGCCATA GGGAACATAG AGGGCCAGTG GAAGATTGCG GGCCATGAGC TGACGTCTCT  634    
CP8             CGTGGGCATT CTCTGCCATA GGGAACATAG AGGGCCAGTG GAAGATTGCG GGCCATGAGC TGACGTCTTT  634    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GTCGGAGCAA ATGCTCGTGT CATGTGACAC TAATGACCTT GGCTGCGAAC TTGGTCTCAA GGACCCCGCG  10980  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GTCGGAGCAG ATGCTCGTGT CATGTGACAC TAATGACTTT GGCTGCGGAG GTGGTCTCAT GGACGACGCG  2050   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             GTCGGAGCAG ATGCTCGTGT CATGTGACAC TAATGACTTT GGCTGCGAAG GTGGTCTCAT GGACGACGCG  723    
CP4             GTCGGAGCAG ATGCTCGTGT CATGTGACAC TGAGGACCTT GGTTGCGCAG GTGGTCTCAT GGATAACGCG  703    
CP3             GTCGGAGCAG ATGCTCGTGT CATGTGACAC TAATGACTTT GGCTGCGGAG GTGGTCTCAT GGACGACGCG  704    
CP8             GTCGGAGCAA ATGCTCGTGT CATGTGACAC TAATGACCTT GGCTGCGAAC TTGGTCTCAA GGACCCCGCG  704    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  TTCCAATGGA TTTTATGGTC GAATAAGGGC AATGTGTTCA CGGAGCAAAG TTACCCGTAC GCATCAGGAG  11050  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TTCAAATGGA TTGTGTCGTC GAATAAGGGC AATGTGTTCA CGGAGCAAAG TTACCCGTAC GCATCAGGAG  2120   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             TTCAAATGGA TTGTGTCGTC GAATAAGGGC AATGTGTTCA CGGAGCAAAG TTACCCGTAC GCATCAGGAG  793    
CP4             TTCAAATGGA TTGTGTCGTC GAATAAGCAC AATGTGTTCA CGGAGGAAAG TTACCCGTAC GCCTCAAAAG  773    
CP3             TTCAAATGGA TTGTGTCGTC GAATAAGGGC AATGTGTTCA CGGAGCAAAG TTACCCGTAC GCATCAGGAG  774    
CP8             TTCCAATGGA TTTTATGGTC GAATAAGGGC AATGTGTTCA CGGAGCAAAG TTACCCGTAC GCATCAGGAG  774    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GGGGGAACGT GCCGACGTGC GACATGAGCG GCAAGGTCGT TGGTGCGAAG ATCAGTAACA TGCGCT-ACC  11119  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GGGGGAACGT GCCGGCGTGC GACATGAGCG GCAAGGTCGT TGGTGCGAAG ATCAGAGAC- CACGTTGACC  2189   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             GGGGGAACGT GCCGACGTGC GACAAGAGCG GCAAGGTCGT TGGTGCGAAG ATCAGAGAC- CACGTTGACC  862    
CP4             GGGGGAACGT GCCGCCTTGC CGCATGAGCG GCAAAGTCGT TGGTGCGAAG ATCAGAGAC- CATGTTGACC  842    
CP3             GGGGGAACGT GCCGGCGTGC GACATGAGCG GCAAGGTCGT TGGTGCGAAG ATCAGAGAC- CACGTTGACC  843    
CP8             GGGGGAACGT GCCGACGTGC GACATGAGCG GCAAGGTCGT TGGTGCGAAG ATCAGTAACA TGCGCT-ACC  843    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
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contig 0001218  TACCACTAGA CGAAGACACA ATAGCCGAGT GGCTGGCAAG GAAAGGGCCC GTCGCGATTG CCGTTGACGC  11189  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TTCCGGAGGA CGAAAACGCA ATAGCCGAGT GGCTGGCAAA GAAAGGGCCC GTCGCGATTG CCGTTGACGC  2259   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             TTCCGGAGGA CGAAAACGCA ATAGCCGAGT GGCTGGCAAA GAACGGGCCC GTCGCGATTG CCGTTGACGC  932    
CP4             TTCCGAAGGA CGAAAACGCA ATAGCCGAGT GGCTGGCAAA GAACGGGCCC GTCGCGATTG CCGTTGACGC  912    
CP3             TTCCGGAGGA CGAAAACGCA ATAGCCGAGT GGCTGGCAAA GAAAGGGCCC GTCGCGATTG CCGTTGACGC  913    
CP8             TACCACTAGA CGAAGACACA ATAGCCGAGT GGCTGGCAAG GAAAGGGCCC GTCGCGATTG CCGTTGACGC  913    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CACCAGTTTC CAGAGGTACA CGGGCGGAGT GTTGACATCA TGCATCTCTC GA-CGACTCA ACTACGGTGC  11258  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CACCAGTTTC CAGAGCTACA CGGGCGGAGT GTTGACATCA TGCATCTC-C GAGCATCTGG ACCATGGTGT  2328   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             CACCAGTTTC CAGAGCTACA CGGGCGGAGT GTTGACATCA TGCATCTC-C GAGCATCTGG ACCATGGTGT  1001   
CP4             CACCAGTTTC CAGGACTACA CGGGCGGAGT GCTGACATCA TGCATCTC-T AAGCAACTGG ACCATGGTGT  981    
CP3             CACCAGTTTC CAGAGCTACA CGGGCGGAGT GTTGACATCA TGCATCTC-C GAGCATCTGG ACCATGGTGT  982    
CP8             CACCAGTTTC CAGAGGTACA CGGGCGGAGT GTTGACATCA TGCATCTCTC GA-CGACTCA ACTACGGTGC  982    
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GCTCCTCGTG GGGTATGACG ACACAAGCAA GCCACCATAC TGGATTATCA AGAACTCATG GGGCAAGGGA  11328  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GCTCCTCGTG GGGTATGACG ACACAAGCAA GCCACCATAC TGGATTATCA AGAACTCATG GAGCAAGGGA  2398   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             GCTCCTCGTG GGGTATGACG ACACAAGCAA GCCACCATAC TGGATTATCA AGAACTCATG GAGCAAGGGA  1071   
CP4             GCTCCTCGTT GGGTATGACG ACACGAGCAA GCCACCATAC TGGATTATCA AGAACTCATG GAGCGAGAAA  1051   
CP3             GCTCCTCGTG GGGTATGACG ACACAAGCAA GCCACCATAC TGGATTATCA AGAACTCATG GAGCAAGGGA  1052   
CP8             GCTCCTCGTG GGGTATGACG ACACAAGCAA GCCACCATAC TGGATTATCA AGAACTCATG GGGCAAGGGA  1052   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  TGGGGCGAGG AGGGTTACAT CCGCATTGAG AAGGGCACAA ACCAATGTCT TGTGAAAAAT CTCCCAAGCT  11398  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TGGGGCGAGG AGGGTTACAT CCGCATTGAG AAGGGCACAA ACCAATGTCT TATGAAAAAT CTCCCAAGCT  2468   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             TGGGGCGAGG AGGGTTAC-T CCGCATTGAG AA-GGCAC-A ACCAATGTCT TATGAAAAAT CTCCCAAGCT  1138   
CP4             TGGGGCGAGG AGGGTTACAT CCGCATTGAG AAGGGCACAA ACCAATGTCT TATGAAAAAT TACGCGACCT  1121   
CP3             TGGGGCGAGG AGGGTTACAT CCGCATTGAG AAGGGCACAA ACCAATGTCT TATGAAAAAT CTCCCAAGCT  1122   
CP8             TGGGGCGAGG AGGGTTACAT CCGCATTGAG AAGGGCACAA ACCAATGTCT TGTGAAAAAT CTCCCAAGCT  1122   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CCGCCGTTGT CAGCGTCCCT CCGCCTCCAC CCCCGGCTCC GACCTTCACG CAGGAGTTGT GCGAGGGTGC  11468  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CCGCCGTTGT CAGCGGCCCT CCGCCTCCGC CCCCGACTCC GACCTTCACG CAGGAGTTGT GCGAGGGTGC  2538   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             CCGCCGTTGT CAGCGGCCCT CCGCCTCCAC CCCCGACTCC GACCTTCACG CAGGAGTTGT GCGAGGGTGC  1208   
CP4             CCGCCGTTGT CCACCGCCCC GTCCCTCCGC CTCCACCCCC GGCGTCGACG ---------- ----------  1171   
CP3             CCGCCGTTGT CAGCGGCCCT CCGCCTCCGC CCCCGACTCC GACCTTCACG CAGGAGTTGT GCGAGGGTGC  1192   
CP8             CCGCCGTTGT CAGCGTCCCT CCGCCTCCAC CCCCGGCTCC GACCTTCACG CAGGAGTTGT GCGAGGGTGC  1192   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CGAATGCTAG AGTAAGTGCA CCAAAGCCAC ATTCCCAACG GGCAAGTGCG TGCAGCTCAG CGGCGCCGGT  11538  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CGAATGCCAG AGTAAGTGCA CCAAAGCCAC ATTCCCAACG GGCAAGTGCG TGCAGCTCAG CGGCGCCGGT  2608   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             CGAATGCCAG AGTAAGTGCA CCAAAGCCAC ATTCCCAACG GGCAAGTGCG TGCAGCTCAG CGGCGCCGGT  1278   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             CGAATGCCAG AGTAAGTGCA CCAAAGCCAC ATTCCCAACG GGCAAGTGCG TGCAGCTCAG CGGCGCCGGT  1262   
CP8             CGAATGCTAG AGTAAGTGCA CCAAAGCCAC ATTCCCAACG GGCAAGTGCG TGCAGCTCAG CGGCGCCGGT  1262   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
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contig 0001218  TCTGTCATCG CCTCGTGCGG CTCCAATAAC CTCACGCAGA TCGTCTACCC GTTGAGCAGC TCCTGCAGCG  11608  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TCTGTCATCG CCTCGTGCGG CTCCAATAAC CTCACGCAGA TCGTCTACCC GTTGAGCAGC TCCTGCAGCG  2678   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             TCTGTCATCG CCTCGTGCGG CTCCAATAAC CTCACGCAGA TCGTCTACCC GTTGAGCAGC TCCTGCAGCG  1348   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             TCTGTCATCG CCTCGTGCGG CTCCAATAAC CTCACGCAGA TCGTCTACCC GTTGAGCAGC TCCTGCAGCG  1332   
CP8             TCTGTCATCG CCTCGTGCGG CTCCAATAAC CTCACGCAGA TCGTCTACCC GTTGAGCAGC TCCTGCAGCG  1332   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GCTTCTCCGT TCCGTTGACT GTGCCACTGG ACAAGTGCCT GCCCATTGTG ATTGGATCCG TGATGTATGA  11678  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GCTACTCCGT TCCGTTGACT GTGCCACTGG ACAAGTGCCT GCCCATCGTG ATTGGATCCG TGATGTATGA  2748   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             GCTTCTCCGT TCCGTTGACT GTGCCACTGG ACAAGTGCCT GCCCATTGTG ATTGGATCCG TGATGTATGA  1418   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             GCTACTCCGT TCCGTTGACT GTGCCACTGG ACAAGTGCCT GCCCATCGTG ATTGGATCCG TGATGTATGA  1402   
CP8             GCTTCTCCGT TCCGTTGACT GTGCCACTGG ACAAGTGCCT GCCCATTGTG ATTGGATCCG TGATGTATGA  1402   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
 
contig 0001218  GTGCTCTGAC AAGGCTCCTA CGGAATCCGC CCGGCTCGTG CGGCACGAGT GAGGCTGCTG GCGGCGACTG  11748  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GTGCTCTGGC AAGGCTCCTA CGGAATCCGC CCGGCTCGTG CGGCACGAGT GAGGCTGCTG GCGGCGACTG  2818   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             GTGCTCTGAC AAGGCTCCTA CGGAATCCGC CCGGCTCGTG CGGCACGAGT GAGGCTGCTG GCGGCGACTG  1488   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             GTGCTCTGGC AAGGCTCCTA CGGAATCCGC CCGGCTCGTG CGGCACGAGT GAGGCTGCTG GCGGCGACTG  1472   
CP8             GTGCTCTGAC AAGGCTCCTA CGGAATCCGC CCGGCTCGTG CGGCACGAGT GAGGCTGCTG GCGGCGACTG  1472   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CTTGCCGGCT TCACGTACCT CTCCCGAAAC TCCAATTCTG TTTTGCTTTC ATGCACTGTT CCAGTGTATT  11818  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CTTGCCGGCT TCACGTACCT CCCCCAAAAC TCCAATTCTG TTTTGCTTTC ATGCACTGTT CCAGTGTATT  2888   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             CTTGCCGGCT TCACGTACCT CTCCCGAAAC TCCAATTCTG TTTTGCTTTC ATGCACTGTT CCAGTGTATT  1558   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             CTTGCCGGCT TCACGTACCT CCCCCAAAAC TCCAATTCTG TTTTGCTTTC ATGCACTGTT CCAGTGTATT  1542   
CP8             CTTGCCGGCT TCACGTACCT CTCCCGAAAC TCCAATTCTG TTTTGCTTTC ATGCACTGTT CCAGTGTATT  1542   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  TGCTTTCTTG GTGTGCGGCC ACACAATGCG GCTCTGAGGC GAGTGCGAGG GACACCGCGC CGCTCTGCCT  11888  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TGCTTTCTTG GTGTGCGGCC ACACGATGCG GCTCTGAGGC GAGTGCGAGG GACACCGCGC CGCTCTGCCT  2958   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             TGCTTTCTTG GTGTGCGGCC ACACAATGCG GCTCTGAGGC GAGTGCGA-G GACA-CGCGC CGCTCTGCCT  1626   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             TGCTTTCTTG GTGTGCGGCC ACACGATGCG GCTCTGAGGC GAGTGCGAGG GACACCGCGC CGCTCTGCCT  1612   
CP8             TGCTTTCTTG GTGTGCGGCC ACACAATGCG GCTCTGAGGC GAGTGCGAGG GACACCGCGC CGCTCTGCCT  1612   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CTCAGCACTT GCGGAGTGTG AGAAAGCTGC CCCAACCACG CGTGTGTCTT TCTATGCTTT TGCTTGTCCT  11958  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CTCAGCACTT GCGGAGTGTG AGAAAGCTGC CCCAACCACG CGTGTGTCTT TCTATGCTTT TGCTTGTCCT  3028   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             CTCAGCACTT GCGGAGTGTG AGAAAGCTGC CCCAACCACG CGTGTGTCTT TCTATGCTTT TGCTTGTCCT  1696   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             CTCAGCACTT GCGGAGTGTG AGAAAGCTGC CCCAACCACG CGTGTGTCTT TCTATGCTTT TGCTTGTCCT  1682   
CP8             CTCAGCACTT GCGGAGTGTG AGAAAGCTGC CCCAACCACG CGTGTGTCTT TCTATGCTTT TGCTTGTCCT  1682   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
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contig 0001218  TTTTCTCCAT TACTTTTACT GGCTCACTGG CCACGGCAAC AGTCGCTGCT GCCACTGACC CGCGAGGAGC  12028  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TTTTCTCCAT TACTTTTACT GGCTCACTGA CCACGGCAAC AGTCGCTGCT GCCACTGACC CGCGAGGAGT  3098   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             TTTTCTCG-- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             TTTTCTC--- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             TTTTCTC--- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GTCGCACCCC GTTGGCCTTG TCTTT-TTAT TTTTGCACCC ACACTTGCTC CCAATACGCT TCGCTTGCCT  12097  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GTCGCACCCC GTTGGCCTTG TTTTTGTTAT TTTTGCACCC ACACTTGCTC CCAATACGCT TCGTTTGCCT  3168   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GATTACGCTC CCTCCTTTGC CTCCCGTCTC TCCCTGTATG TCACACCGTA CGTTGGCGCA GTGTATCCTG  12167  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GATTGCGCTT CTTCCTTTGC CTCCCGTCTC TCCCTGTATG CCACACCGTA CGTTGGCGCA GTGTATCCTG  3238   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CACTCACGAA CGAGCTAAAA ATAAGAATCA AAAAAGGGAG AACAATAGAG CAGCGACAAC CCGAGAAGGT  12237  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CACTCACGAA CGAGCTAAAA ATAAGAATCA AAAAAGGGAG AACAATAGAG CAGCGACAAC CCGAGAGCGT  3308   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------A AAAAAGGGAG AACAATAAAG TAGCGACAAC CAGAGAAGGT  41     
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  AAGAGGCTTT TCTTCTTTCT TTTCCTTTAT TGTACGATGC CACGATCAGA AATGACACGC ACCCTGCGCT  12307  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  AAGAGGCTTT TCTTCTTTCT TTTCCTTTAT TGTACGATGC CACGATCAGA AATGACACGC ACCCTGCGCT  3378   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             GAGAGGCCTT TCTTCTTTCT TTTCCTTTAT TGTACGATGC CACGATCAGA AATGACACGC ACCCTGCGCT  111    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  TCTCCGTGGG CCTGCTCGCT GTTGCGGCGT GCTTTGTTCC CGTGGCGTTG GGAGTGCTTC ACGCAGAGCA  12377  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TCTCCGTGGG CCTGCTCGCC GTTGCGGCGT GCTTTGTTCC CGTGGCGTTG GGAGTGCTTC ACGCAGAGCA  3448   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             TCTCCGTGGG CCTGCTCGCC GTCGCGGCGT GCTTTGTTCC CGTGGCGTTG GGAGTGCTTC ACGCAGAGCA  181    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
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contig 0001218  ATCGTTGCAG CAGCAATTCG CCGCATTCAA GCAAAAGTAC AGCAGGTCGT ACAAGGACGC CACGGAGGAG  12447  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ATCGTTGCAG CAGCAATTCG CCGCATTCAA GCAAAAGTAC AGCAGGTCGT ACAAGGACGC CACGGAGGAG  3518   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ATCGTTGCAG CAGCAATTCG CCGCATTCAA GCAAAAGTAC AGCAGGTCGT ACAAGGACGC CACGGAGGAG  251    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  GCATTCCGTT TCCGTGTCTT CAAGCAGAAC ATGGAGCGTG CAAAGGAGGA GGCCGCTGCG AACCCCTATG  12517  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GCATTCCGTT TCCGCGTCTT CAAGCAGAAC ATGGAGCGTG CAAA-GAGGA GGCCGCTGCG AACCCCTATG  3587   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             GCATTCCGTT TCCGCGTCTT CAAGCAGAAC ATGGAGCGTG CAAAGGAGGA GGCCGCTGCG AACCCCTATG  321    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  CG-------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CGACGTTTGG TGTGACGCGG TTTTCCGATA TGTCACCCGA GGAGTTCAGG GCGACCTACC ACAACGGGGC  3657   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             CGACGTTTGG TGTGACGCGG TTCTCCGATA TGTCACCCGA GGAGTTCAGG GCGACCTACC ACAACGGGGC  391    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GGAGTACTAC GCTGCGGCGC TGAAGCGACC ACGCAAGGTG GTGACTGTGT CCACTGGGAA GGCACCTGAG  3727   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             GGAGTACTAC GCTGCGGCGC TGAAGCGGCC ACGCAAGGTG GTGAATGTGT CCACTGGGAA GGCACCACCG  461    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GCAGTTGACT GGCGCAAGAA GGGCGCGGTG ACACCCGTGA AGGACCAGGG ACAATGCGGT TCTTGCTGGG  3797   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             GCAGTTGACT GGCGCAAGAA GGGCGCAGTG ACACCCGTGA AGGACCAGGG GGCATGCGGT TCTTGCTGGG  531    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CATTCTCTGC CATAGGGAAC ATAGAGGGCC AGTGGAAGGT TACGGGCCAT AATCTGACGT CTCTGTCGGA  3867   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             CGTTCTCTGC CATAGGGAAC ATAGAGGGCC AGTGGAAGGT TGCGGGCCAT GAGCTGACGT CTCTGTCGGA  601    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
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contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GCAGATGCTC GTGTCATGTG ACACTGAGGA CCTTGGTTGC GCAGGTGGTC TCATGGATAA CGCGTTCAAA  3937   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             GCAAATGCTC GTGTCATGTG ACACTACGGA CTATGGCTGC CGAGGAGGCC TCATGGACAA ATCGCTTCAA  671    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TGGATTGTGT CGTCGAATAA GCACAATGTG TTCACGGAGG AAAGTTACCC GTACGCCTCA AAAGGGGGGA  4007   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             TGGATTGTGT CGTCGAATAA GGGCAATGTG TTCACGGCGC AAAGTTACCC GTACGCATCA GGAGGGGGGA  741    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ACGTGCCGCC TTGCCGCATG AGCGGCAAAG TCGTTGGTGC GAAGATCAGA GACCATGTTG ACCTTCCGAA  4077   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             AGATGCCGCC TTGTAACAAG AGCGGCAAAG TCGTTGGTGC AAAGATCAGT GGCCACATTA ACCTTCCGAA  811    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GGACGAAAAC GCAATAGCCG AGTGGCTGGC AAAGAACGGG CCCGTCGCGA TTGCCGTTGA CGCCACCAGT  4147   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             GGACGAAAAC GCAATAGCGG AGTGGCTGGC AAAGAACGGG CCCGTCGCGA TTGCCGTTGA CGCCACCAGT  881    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TTCCAGGACT ACACGGGCGG AGTGCTGACA TCATGCATCT CTAAGCAACT GGACCATGGT GTGCTCCTCG  4217   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             TTCCTGGGCT ACAAAGGCGG AGTGTTGACA TCATGCATCT CTAAGGGACT GGATCATGAT GTGCTCCTCG  951    
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1      
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TTGGGTATGA CGACACGAGC AAGCCACCAT ACTGGATTAT CAAGAACTCA TGGAGCGAGA AATGGGGCGA  4287   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             TGGGGTATGA CGACACGAGC AAGCCACCAT ATTGGATTAT CAAGAACTCA TGGAGCAAGG GATGGGGCGA  1021   
CP6             ---------- ---------- ---------- ---------- ---------- ------GAGA AATGGGGCGA  14     
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contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GGAGGGTTAC ATCCGCATTG AGAAGGGCAC AAACCAATGT CTTATGAAAA ATTACGCGAC CTCCGCCGTT  4357   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             GGAGGGTTAC ATCCGCATTG AGAAGGGCAC AAACCAATGT CTCATGAAAA ATTACGCGAG GTCAGCCGTT  1091   
CP6             GGAGGGTTAC ATCCGCATTG AGAAGGGCAC AAACCAATGT CTTATGAAAA ATTACGCGAC CTCCGCCGTT  84     
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GTCCACCGCC CCGTC-CCTC CGCCTCCACC CCCGGCGTCG ACGTTCACGC AGGAGTTCTG CGAGGGTGCC  4426   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             GT-CAGCGGC CCTCCGCCTC CGCCTCCACC CCCGGCGTCG ACCTTCACGC AGGAGTTCTG CGAGGGTGCA  1160   
CP6             GTCCACCGCC CCGTC-CCTC CGCCTCCACC CCCGGCGTCG ACGTTCACGC AGGAGTTCTG CGAGGGTGCC  153    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GAATGCCAGA GTGGCTGCAC CAAAGCCACA TTCCCAACGG GCAAGTGCGT GCAGCTCAGC GGCGCCGGTT  4496   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             GAGTGCCAGA GTGGTTGCAC CAAAGCCACA TTCCCAACGG GCAAGTGCGT GCAGTTCGGC GGCGCCGGTT  1230   
CP6             GAATGCCAGA GTGGCTGCAC CAAAGCCACA TTCCCAACGG GCAAGTGCGT GCAGCTCAGC GGCGCCGGTT  223    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CTGTCATCGC CTCGTGCGGC TCCAATAACC TCACACAGAT CGTCTACCCG TTGAGCAGCT CCTGCAGCGG  4566   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             CTGTCATCGC CTCGTGCGGC TCCAATAACC TCACACAGAT CGTCTACCCG TTGAGCAGCT CCTGCAGCGG  1300   
CP6             CTGTCATCGC CTCGTGCGGC TCCAATAACC TCACACAGAT CGTCTACCCG TTGAGCAGCT CCTGCAGCGG  293    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CTACTCCGTT CCGTTGACTG TGCCACTGGA CAAGTGCCTG CCCATCGTGA TTGGATCCGT GATGTATGAG  4636   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             CTTCTCCATT CCGTTGACTG TGCCACTGGA CAAGTGCCTG CCCATCGTGG TTGGATCCGT GATGTATGAG  1370   
CP6             CTACTCCGTT CCGTTGACTG TGCCACTGGA CAAGTGCCTG CCCATCGTGA TTGGATCCGT GATGTATGAG  363    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TGCTCTGGCA ATGCTCCTAC GGAATCCGCC CGGCTCGTGC GACACGAGTG AGGCTGCTGG CGGCGACTGC  4706   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             TGCTCTGGCA AGGCTCCTAC GGAATCCGCC CGGCTCGTGC GGCACGAGTG AGGCTGCTGG CGGCGACTGC  1440   
CP6             TGCTCTGGCA ATGCTCCTAC GGAATCCGCC CGGCTCGTGC GACACGAGTG AGGCTGCTGG CGGCGACTGC  433    
 
 176
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TTGCCGGCTT CACGTACCTC TCCCAAAACT CCAATTCTGT TTTACTTTCA TGCATTGTTC CAGTGTATTT  4776   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             TTGCCGGCTT CACGTACCTC TCCCAAAACT CCAATTCTGT TTTGCTTTCA TGCACTGTTC CAGTGTATTT  1510   
CP6             TTGCCGGCTT CACGTACCTC TCCCAAAACT CCAATTCTGT TTTACTTTCA TGCATTGTTC CAGTGTATTT  503    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  GCTTTCTTGG TGTGCGGCCA CACGATGCGG CTCTGAGGCG AGTGCGAGGG ACACCGCGCC GCTCTGCCTC  4846   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             GCTTTCTCGG TGTGCGGCCA CACAATGCGG CTCTGAGGCG AGTGCGAGGG ACA-CGCGCC GCTCTGCCTC  1579   
CP6             GCTTTCTTGG TGTGCGGCCA CACGATGCGG CTCTGAGGCG AGTGCGAGGG ACACCGCGCC GCTCTGCCTC  573    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TCAGCACTTG CGGAGTGTGA GAAAGCTGCC CCAACCACGC GTGTGTCTTT CTATGCTTTT GCTTGTCCTT  4916   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             TCAGCACTTG CGGAGTGTGA GAAAGCTGCC CCAACCACGC GTGTGTCTTT CTATGCTTTT GCTTGTCCTT  1649   
CP6             TCAGCACTTG CGGAGTGTGA GAAAGCTGCC CCAACCACGC GTGTGTCTTT CTATGCTTTT GCTTGTCCTT  643    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TTTCTCCATT ACTTTTACTG GCTCACTGGC CACGACAACA GTTGGTGCTG CCACTGACCC GCGAGTGGTG  4986   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             TTTCACCATT ACTTTTATTG GCTCACTGGC CACGGCCACA GTCGCTGCTG CCACTGACCC GCGAGGGGCG  1719   
CP6             TTTCTC---- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TCGCACCCCG TTGGCCTTGT TTTTTATTTT GTGAAAGCGT CTGGTATAAA TGTTTTAGGA CTTGCCCTCT  5056   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             TCACACCCCG TCGGCCTTGT TTTTTG---- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CGTGACAAAT GTCTGTTATT CTCTTTCAGC TATTTGGAAA ACGTGTGCGT TTTTGAAATG CAGGTTTATC  5126   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
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contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TAAACAGAGT TTATGATATC TACACGGCCG TCCCTCCCTC AGGTGGAATG GGCAACGAGT TCCATGGCAT  5196   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TTTTGGATTA CTTTCGCTGA TGTTAAGGAA CTTCCTTTTT GTCGTGCTTT CGACCGGCAG AGGACCTGAG  5266   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  AGTCACGTAT CATGTGGACG GGCTTCTAAC GATTGAGGAT GGAAATGTCA TGCTTTACTT TGAGCGCGGA  5336   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CATAAAATGG ATTTCGTATC ATTAAGGCAG TGGATGGTAC GTTTTACGCT GCCCAGAATC TCAGATTTTC  5406   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TTTGAGTGTT TGAAGAGGCG AGAGAATCAC TCCGTGCGTA ATGGACGACT GTAGAAGCCA CGGAATCTGC  5476   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ACTCCATAAT CAATATGAGA GTGCTTGCGC GCAGCTCCCT GACGAGAGCT TCCACGTGCA GCAAAATGCG  5546   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
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contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  AATGAGCGGT TGGGCGGGAT GCAGCAACAG CTTGAACATC TGCAAGGAAT TATTGCACAA CAAGCAGCAC  5616   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  AGTTAGAAGA ATATGTCCGA ACGGATGCTA CGTTACGGCA ACAATTGACT GGTCAAGGTG TAGGCGTTCA  5686   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CACAGAGGAG GGTGAAAGGC ACCATGGAAA GCAGGACACG GGTAATGTAA AACGTATGGA TGAATACGCT  5756   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TGGAAAGGGT TCCCACCGCA CGCGCCTCGA CCTTCATCAG GCGGTGTTGG CATCCGGGGA ATAAAGGAGT  5826   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TACAGGGGAA CTCCTGGATG TCAGGAGTGA GACCCGAATA TAAATATTCG TACATTAGTG AGTGCGATGG  5896   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  AGTATCTTGA GGACAGAAAT CCGGAACAAC TGATCGCGGC GTATCAGTAC ATGTCTCCGA CAGCGGCAAC  5966   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
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contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ACCGGGACCG GCTTATACGG AGGCTTGGAA AAACTTCGTA TCGTGGGCAT TGGGGTTGCG CTCGGAGGGC  6036   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ATATCGGAGG GGCACCTCCA ATTGGGGAGG CAGTTGTATA ACCAACTGCG GACAATACAG ACAGTTAAAG  6106   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ATCACCCAGG TGTGAAGATT GAGGACATAA GAGAGTCAGT TGAGTACCCT CATAGAAAGG ATGATGTTTT  6176   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CATTCAAGCG GCTCTGAAGG CAAAAAGGCA TCAAACCGCG ATCCCTCCAG GTCGGGCGCA GTGTTTCACA  6246   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  TGCGGTCGCG TGGTGCACTA CAGCAGCTCG TGTCGTGTAT CCAAGAAGAA ACCAGAGAGT CACCCAACAA  6316   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  ACGGTTTCAG GCCCCGGAGG CAATGACTTC GGGGGCCTTT AATACCTTTT CCCATACCAC ACAGGGGAAG  6386   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
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contig 0001218  ---------- ---------- ---------- ---------- ---------- ---------- ----------  12519  
5' overhang     ---------- ---------- ---------- ---------- ---------- ---------- ----------  999    
contig 0002521  CAGAAAAGAG GGTGTCATGT GGTGCAATAT TTCTCGTGTT CGGGCGAGTC CCCCGACACA GACGGGGAGA  6456   
CP7             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP5             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1153   
CP2             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1704   
CP4             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1171   
CP3             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP8             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1689   
CP1             ---------- ---------- ---------- ---------- ---------- ---------- ----------  1745   
CP6             ---------- ---------- ---------- ---------- ---------- ---------- ----------  649    
 
contig 0001218  ---------- ---------- ---------- ---------- - 12519  
5' overhang     ---------- ---------- ---------- ---------- - 999    
contig 0002521  GTGTGGCCGT TACGGATAGC AAAGTCAGCA GCTGCTCAAT G 6497   
CP7             ---------- ---------- ---------- ---------- - 1689   
CP5             ---------- ---------- ---------- ---------- - 1153   
CP2             ---------- ---------- ---------- ---------- - 1704   
CP4             ---------- ---------- ---------- ---------- - 1171   
CP3             ---------- ---------- ---------- ---------- - 1689   
CP8             ---------- ---------- ---------- ---------- - 1689   
CP1             ---------- ---------- ---------- ---------- - 1745   




Appendix 3: Multiple sequence alignment of the Oligopeptidase B gene in different 
trypanosome species. Residues in colour were used to design primers in TbOPB and 
TcoOPB for RNAi.  
Key: (* = identical), (. = very similar), (: = similar).  
 
 
T. brucei         MQTERGPIAAHRPHEVVFGKVEGEDRGANPMDPPRRRVDPLFWLRDDNRADPEVLAHLHL 60 
T. evansi         MQTERGPIAAHRPHEVVFGKVEGLDRGANPMDPPRRRVDPLFWLRDDNRADPEVLAHLHL 60 
T. congolense     MTSDRGPIAAHKPYEVVFGKVEGEDRGPNPMDPPRRRVDPLFWLRDDSRTNPDVLAHLHL 60 
T. vivax          MPAPCGPVAEQQDHEVIFGKVEGEDRGPNPMDPPLRRNDPLFWLRDDNRTNPKVLAHLHL 60 
T. cruzi          --MKCGPIATPKDHEVVFGYVEGENRGNNAMNPPRRRNDPLFWLRDDSRKNPEVIAHLKL 58 
                       **:*  : :**:** *** :** *.*:** ** *********.* :*.*:***:* 
 
T. brucei         EKDYYEKRAVDIKDLAETIYQEHISHIEETDMSAPYVYDRFLYYTRDVKGLSYKLHCRVP 120 
T. evansi         EKDYYEKRAVDIKDLAETIYQEHISHIEETDMSAPYVYDRFLYYTRDVKGLSYKLHCRVP 120 
T. congolense     ERDYFEKRTGDIKDLAETIYQEHISHIEETDMSPPYTYNRFVYYTRRVKGLSYKIHCRVP 120 
T. vivax          EKAYFEECTVDLKDLSETVYQEHLSHIQETDMSAPYVHDNYMYYKREVKGLSYKIHCRVP 120 
T. cruzi          EQAYFEERTADIKDFSETIFKEYFSHIKETDISAPYRYDGYTYYTREVEGLSYKIHCRVP 118 
                  *: *:*: : *:**::**:::*::***:***:*.** :: : **.* *:*****:***** 
 
T. brucei         AGKTPGEGEDEEIVLDENKLAEGKSFCVVGCVAPAPPEHALVAYSVDYCGDEVYSIRFVR 180 
T. evansi         AGKTPGEGEDEEIVLDENKLAEGKSFCVVGCVAPAPPEHALVAYSVDYCGDEVYSIRFVR 180 
T. congolense     LGKVPGEGPDEEIVLDENKLAEGKAFCDVRSVAPAPPEHMLVAYSVDHLGDELYSIQFVG 180 
T. vivax          LGKTPG-SSDEQVVLDENKLAEGKAFCHVRQVEPAPPKHSLVAYSVDYTGNEVYTIRFVG 179 
T. cruzi          LGMTPGKSEDEQVILDENKLAEGKSFCMVHEVKPAPPDHNLVAYSVDYVGNEMYTIRFTD 178 
                   * .**.. **:::**********:** *  * ****.* *******: *:*:*:*:*.  
 
T. brucei         DVVADKVEGTNGSVVWGPNAECFFYITKDASKRDNKVWRHIIGQPQSEDVCLYTDDDPLF 240 
T. evansi         DVVADKVEGTNGSVVWGPNAECFFYITKDASKRDNKVWRHIIGQPQSEDVCLYTDDDPLF 240 
T. congolense     DASPDKLEGTTGSIIWGTNAECFFYVTPDSTKRSNKVWRHIIGQSQSEDVCLYTDDDPLF 240 
T. vivax          DDVPDVVEGTNGHIVWGPDGGCFFYTTKDAAQRDYKVWRHVIGQQQSEDVCLYTEVDAVF 239 
T. cruzi          NAVTDVVEGTNGQILWGPNASCFFYITKDAAERNYKIWRHIIGRPQSEDVCLYTENDLLF 238 
                  :  .* :***.* ::**.:. **** * *:::*. *:***:**: *********: * :* 
 
T. brucei         SVGVGRSGDGKTLIICSMSSETSESHLLDLRKGVKHNTLEMVRPREKGVRYTVEMHGTDT 300 
T. evansi         SVGVGRSGDGKTLIICSMSSETSESHLLDLRKGVKHNTLEMVRPREKGVRYTVEMHGTDT 300 
T. congolense     SVAASKSGDGHTLLISSSSSETTELHLLDLRKGLNNTTLEVVRKREKNVRYEVEMHGTET 300 
T. vivax          SACMSKSGDGNTLLITSSSSETTEVHLLDLRGGVAHNELETVRPREKGVRYDVALHGTDT 299 
T. cruzi          STAMAISGDGNTLIIGSGSFETTESHLLDLRKGNGHTTLEMVRPRERGVRYDVELHGTET 298 
                  *.  . ****:**:* * * **:* ****** *  :. ** ** **:.*** * :***:* 
 
T. brucei         LIVLTNKDKCVNGKVVLTKRSAPTDWGTVLIPHDDKVTIDDVAVFAKFAVLSGRRDGLTR 360 
T. evansi         LIVLTNKDKCVNGKVVLTKRSAPTDWGTVLIPHDDKVTIDDVVVFAKFAVLSGRRDGLTR 360 
T. congolense     LVILTNKDKCINGKVVLAKRASPSEWTNVLVPHDDKVFIDDIAVFAKFAVLSGRRDGLTR 360 
T. vivax          LLVLTNKDKCINGQVLIVQRSAPSDWTRVLVPHSEEVFIEEIAVFSTFAVLAGRRAGLSR 359 
T. cruzi          LLILTNKDNCMNGKVVSATRNTPSDWENVIVPHSEDVFIGEIGVFAKFVVLSGRRGGITR 358 
                  *::*****:*:**:*: . * :*::*  *::**.:.* * :: **:.*.**:*** *::* 
 
T. brucei         VWTVRLGPDNLFSS-ATLKELHFDEPVFTAHVVCSQMKTYDASLLRLRYSSMTTPTVWYD 419 
T. evansi         VWTVRLGPDNLFSS-ATLKELHFDEPVFTAHVVCSQMKTYDASLLRLRYSSMTTPTVWYD 419 
T. congolense     VWTVQVGPDNCFSA-GTLRELQFDEPVFTAHVITSQMKTYDTSSLRLEYSSMTTPTTWFD 419 
T. vivax          IWTMQVGPDNTFSN-SLVNELQFDEPVFTTHVVLSQMHMYNTATLRLTYSSMTTPTTWYD 418 
T. cruzi          VWAMPVGSDGLFRSGAFVQEVSFDEPVFTAFPVFSHMKMYDTETLRVSYTSMSTPTTWFD 418 
                  :*:: :*.*. *   . :.*: *******:. : *:*: *::  **: *:**:***.*:* 
 
T. brucei         EDVLSGERKVVKARKVGGGFESKNYVCRRELATAPDGTKVPISLVYDTSIDLKKPNPTML 479 
T. evansi         EDVLSGERKVVKARKVGGGFESKNYVCRRELATAPDGTKVPISLVYDTSIDLKKPNPTML 479 
T. congolense     EDLASGKRTVVKVSKVGGGFDSKNYVCQRRLATAPDGTTIPLSILYDVSLDMKKPHPTML 479 
T. vivax          VHVAEGGRTPVKIREVGGGFNPAHYVSKRLLATAPDGTKIPISLVYDAALDLTKPHPTML 478 
T. cruzi          LHVVNGTRTIVKVREVLGNFDAKNYTCRRLFATAPDRTKIPLSIVHDVSLDMSKPHPTVL 478 




T. brucei         YGYGSYGICIEPEFNSRFLPYVDRGMIYAIAHVRGGGEMGRTWYEVGGKYLTKRNTFMDF 539 
T. evansi         YGYGSYGICIEPEFNSRFLPYVDRGMIYAIAHVRGGGEMGRTWYEVGGKYLTKRNTFMDF 539 
T. congolense     YGYGSYGICVEPQFDIRCLPYVDRGVI WYEIGGKYLTKRNTFMDF 539 
T. vivax          YGYGSYGICVEPEFNIQYLPYVDRGVIFAIAHVRGGGEMGRAWYELGAKYLTKRNTFMDF 538 
T. cruzi          YAYGSYGACVEPEFSVKYLPYLDRGVIYVIAHVRGGGEMGRAWYEVGAKYLTKRNTFSDF 538 
                  *.***** *:**:*. : ***:***:*:.************:***:*.********* ** 
 
T. brucei         IACAEHLISSGLTTPAQLSCEGRSAGGLLVGAVLNMRPDLFHVALAGVPFVDVMTTMCDP 599 
T. evansi         IACAEHLISSGLTTPAQLSCEGRSAGGLLVGAVLNMRPDLFHVALAGVPFVDVMTTMCDP 599 
T. congolense     ISCAEHLISSGVTTPPQLACEGRSAGGLLVGAVLNMRPDLFRVAVAGVPFVDVMTTMCDP 599 
T. vivax          IACAEHLISSGLTTPNQLACEGRSAGGLLIGAVLNMRPDLFHVALAGVPFVDVMTTMCDP 598 
T. cruzi          IACAEYLIEIGLTTPSQLACEGRSAGGLLIGAVLNMRPDLFRVALAGVPFVDVMTTMCDP 598 
                  *:***:**. *:*** **:**********:***********:**:*************** 
 
T. brucei         SIPLTTGEWEEWGNPNEYKFFDYMNSYSPIDNVRAQDYPHLMIQAGLHDPRVAYWEPAKW 659 
T. evansi         SIPLTTGEWEEWGNPNEYKFFDYMNSYSPIDNARAQDYPHLMIQAGLHDPRVAYWEPAKW 659 
T. congolense     SIPLTTGEWEEWGNPNEYKFFDYMNSYSPIDNVRPQDYPNLIIQAGLHDPRVAYWEPAKW 659 
T. vivax          TIPLTTFEWEEWGNPNEYKYFDYMNSYSPIDNVRAQAYPHLMIQAGLHDPRVAYWEPVKW 658 
T. cruzi          SIPLTTGEWEEWGNPNEYKFFDYMNSYSPVDNVRAQDYPHLMIQAGLHDPRVAYWEPAKW 658 
                  :***** ************:*********:**.*.* **:*:***************.** 
 
YAIAHVRGGGEMGRA
T. brucei         ASKL LKMDLESGHFSASDRYKYLRENAIQQAFVLKHLNVRQLLRK 715 
T. evansi         ASKLRELKTDSNEVLLKMDLESGHFSASDRYKYLRENAIQQAFVLKHLNVRQLLRK 715 
RELKTDSNEVL
T. congolense     AS LKMDLDSGHFSASDRYKYLREHAIQQAFVLKHLGVRRLLRH 715 
T. vivax          ASRLRQLKTDGNEVLVKMDLDSGHFSSADRYKYWREMAIQQAFVLKHLNVRCLLRR 714 
T. cruzi          ASKLRALKTDSNEVLLKMDLESGHFSPSDRYRYWREMSFPQAFVLKHLNARTLLRR 714 
                  **:** ****.****:****:*****.:***:* ** :: ********..* ***: 
 
KLRELKTDNNEVL
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